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ABSTRACT 
Acute myeloid leukaemia (AML) is a heterogeneous disease with numerous 
recurrent cytogenetic and molecular abnormalities. This heterogeneity is 
reflected in the variation in clinical outcome seen in patients. This disparity in 
outcome is also seen within groups of patients who have the same mutation or 
no known molecular abnormalities.   
To investigate whether the DNA methylation profile of samples can provide 
prognostic information, the methylome of forty cytogenetically normal AML 
samples that were wild-type for NPM1 and FLT3 was analysed, 20 were from 
patients with chemosensitive disease and 20 with chemoresistant disease. 
Unsupervised cluster analysis revealed the DNA methylation profile to be most 
associated with underlying CEBPA genotype hence a CEBPA signature was 
created using the 25 CpG sites that differed the most between wild-type (n=30) 
and classic CEBPADM (double mutant) samples (n=10). Two follow-up cohorts 
were analysed, validating the initial signature in differentiating classic CEBPADM 
samples from wild-type. CEBPASM (single mutant) samples had profiles more 
similar to the CEBPAWT (wild-type) signature.  Non-classic CEBPADM samples 
with at least one mutation leading to loss of function of the C terminal were 
associated with a CEBPA mutant methylation profile. Methylation of the CEBPA 
promoter was not associated with a classic CEBPADM methylation profile in 
eight of the nine cases exhibiting hypermethylation. 
The ASXL1 gene, known to have a role in histone regulation, was screened in 
371 patients using denaturing HPLC. The overall mutation rate was 9%. Overall 
survival was significantly lower in patients with an ASXL1 mutation, however the 
mutation was associated with secondary disease and older age, and thus in 
multivariate analysis mutations in ASX L1 lost significance.   
These studies indicate that epigenetic factors are closely linked to other 
prognostic traits such as age or underlying molecular status of the AML. Given 
this association, DNA methylation could play an important role in assessing the 
significance of different types of mutations. 
4 
 
ACKNOWLEDGEMENTS 
 
I would like to thank Professor Rosemary Gale for her help and support 
throughout the PhD, I have learnt so much from her methodical approach to 
research and meticulousness in scientific writing. I am incredibly grateful to 
Professor David Linch who gave me the opportunity to undertake this PhD. He 
gave me very useful advice and guidance, and helped me understand the 
importance of asking the right question. I would also like to thank Dr Duncan 
Sproul for the bioinformatic analysis of the array data. Thanks to everyone in lab 
305, who taught me a great deal and helped make the PhD so enjoyable. This 
work would not have been possible without the patients and clinical 
investigators involved in the trials. 
Thank you to mum, dad, Lamah and Reem for their continuous love, 
encouragement and enthusiasm in trying to understand my research. Finally, 
thank you to my team, Trevor, Sammy and Tamara.
5 
 
TABLE OF CONTENTS 
TITLE PAGE ................................................................................... 1 
DECLARATION .............................................................................. 2 
ABSTRACT .................................................................................... 3 
ACKNOWLEDGEMENTS ............................................................... 4 
TABLE OF CONTENTS .................................................................. 5 
TABLE OF FIGURES ................................................................... 10 
LIST OF TABLES ......................................................................... 13 
COMMONLY USED ABBREVIATIONS ........................................ 14 
CHAPTER 1: INTRODUCTION ..................................................... 16 
1.1 Haematopoiesis ........................................................................................ 16 
1.2 AML ............................................................................................................ 16 
1.2.1 Diagnosis and Classification of AML .................................................... 18 
1.2.2 Prognostic Factors in AML ................................................................... 18 
1.2.2.1 Patient-related factors .................................................................... 18 
1.2.2.2 Disease-related factors .................................................................. 20 
1.2.2.3 Response to therapy ...................................................................... 29 
1.2.3 Treatment of AML ................................................................................. 29 
1.3 Epigenetics ................................................................................................ 31 
6 
 
1.3.1 DNA methylation .................................................................................. 32 
1.3.1.1 CpG dinucleotides.......................................................................... 32 
1.3.1.2 Distribution of methylation of CpG sites ......................................... 33 
1.3.1.3 Regulation of DNA methylation ...................................................... 34 
1.3.2 The significance of DNA methylation .................................................... 35 
1.3.3 Techniques for analysis of DNA methylation ........................................ 36 
1.3.4 Histone modification ............................................................................. 39 
1.3.4.1 Lysine methylation by Polycomb proteins as an example of histone 
modifications .............................................................................................. 40 
1.3.5 Interaction of histone modification and DNA methylation ..................... 41 
1.3.6 Epigenetic changes in cancer ............................................................... 42 
1.3.6.1 The cancer methylome .................................................................. 42 
1.3.6.2 Interaction of epigenetic and genetic factors in cancer .................. 43 
1.4 Aims of this thesis .................................................................................... 44 
CHAPTER 2: MATERIALS AND METHODS ................................ 46 
2.1 Molecular Biology ..................................................................................... 46 
2.1.1 Reagents .............................................................................................. 46 
2.1.2 Polymerase Chain Reaction (PCR) ...................................................... 47 
2.1.3 Agarose gel electrophoresis ................................................................. 48 
2.1.4 Screening for mutations using dHPLC ................................................. 49 
2.1.5 Restriction Enzyme Digestion ............................................................... 50 
2.1.6 DNA sequencing .................................................................................. 51 
2.1.7 Fragment analysis of PCR and restriction enzyme digestion products . 51 
2.1.8 LB Broth and agar plates ...................................................................... 52 
2.1.9 TOPO® TA cloning of PCR products ................................................... 52 
2.2 Analysis of DNA methylation ................................................................... 53 
2.2.1 Reagents .............................................................................................. 53 
2.2.2 Bisulfite conversion of DNA .................................................................. 53 
2.2.3 Methylation-Specific PCR to check conversion efficiency .................... 54 
2.2.4 Pyrosequencing .................................................................................... 55 
7 
 
CHAPTER 3: ASSOCIATION OF CEBPA GENOTYPE WITH 
METHYLATION PATTERNS IN AML ........................................... 58 
3.1 Introduction ............................................................................................... 58 
3.1.1 CEBPA structure and function .............................................................. 58 
3.1.2 CEBPA mutations in AML ..................................................................... 60 
3.1.3 Types of CEBPA mutations .................................................................. 64 
3.1.4 DNA methylation in AML ...................................................................... 66 
3.1.5 Significance of aberrant DNA methylation in AML ................................ 69 
3.2 Patients, Materials and Methods ............................................................. 71 
3.2.1 Sample selection .................................................................................. 72 
3.2.2 Sample analysis on the Illumina Infinium Methylation Arrays ............... 72 
3.2.3 Methylation quantification using pyrosequencing ................................. 75 
3.3 Results ....................................................................................................... 76 
3.3.1 Validation of array results using pyrosequencing ................................. 76 
3.3.2 Cluster analysis of samples based on methylation array results .......... 84 
3.3.3 Creation of CEBPA methylation signatures .......................................... 88 
3.3.4 Validation of results in two further cohorts of samples ......................... 95 
3.3.5 Definition of criteria for a classic CEBPADM methylation profile .......... 100 
3.3.6 Correlation of methylation array results with other mutations ............. 104 
3.3.7 Assessment of other samples within the good-risk prognostic category
 .................................................................................................................... 104 
3.4 Discussion ............................................................................................... 110 
CHAPTER 4: INVESTIGATION OF NON-CLASSIC CEBPADM AND 
CEBPASM SAMPLES AND METHYLATION OF THE CEBPA 
PROMOTER ............................................................................... 115 
4.1 Introduction ............................................................................................. 115 
4.1.1 Allelic status of CEBPADM and CEBPA mutant level .......................... 116 
4.1.2 Promoter hypermethylation in AML .................................................... 117 
4.1.3 Promoter hypermethylation of CEBPA ............................................... 117 
8 
 
4.2 Materials and Methods ........................................................................... 121 
4.2.1 Allelic status of CEBPADM samples .................................................... 121 
4.2.2 Quantification of CEBPA mutant level ................................................ 123 
4.2.3 Analysis of CEBPA promoter methylation .......................................... 123 
4.3 Results ..................................................................................................... 124 
4.3.1 Further investigation of the CEBPADM samples .................................. 124 
4.3.1.1 Allelic status of the CEBPADM samples ........................................ 124 
4.3.1.2 Mutant level in CEBPADM samples ............................................... 126 
4.3.2 Methylation profile of non-classic CEBPADM cases ............................ 127 
4.3.3 Analysis of CEBPASM samples in the validation cohort ...................... 129 
4.3.4 Methylation of the CEBPA promoter ................................................... 129 
4.3.4.1 Data from the arrays .................................................................... 129 
4.3.4.2 Analysis of the CEBPA promoter by bisulfite sequencing ............ 134 
4.4 Discussion ............................................................................................... 146 
CHAPTER 5: DETECTION OF ASXL1 MUTATIONS IN AML AND 
THEIR PROGNOSTIC IMPACT .................................................. 151 
5.1 Introduction ............................................................................................. 151 
5.1.1 Structure and function of ASXL1 ........................................................ 152 
5.1.2 Mutations in the ASXL1 gene ............................................................. 155 
5.1.3 Functional consequences of ASXL1 mutations .................................. 160 
5.1.4 Incidence and characteristics of AML patients with ASXL1 mutations 162 
5.1.5 Impact of ASXL1 mutations on outcome in AML patients ................... 163 
5.2 Patients, Materials and Methods ........................................................... 163 
5.2.1 Patients .............................................................................................. 163 
5.2.2 Screening for ASXL1 exon 12 mutations by dHPLC .......................... 164 
5.2.3 Investigation of abnormal WAVE chromatograms .............................. 164 
5.2.4 Therapy .............................................................................................. 168 
5.2.5 End points .......................................................................................... 170 
5.2.6 Statistical methods ............................................................................. 170 
9 
 
5.3 Results ..................................................................................................... 171 
5.3.1 Detection of sequence alterations by WAVE analysis ........................ 171 
5.3.2 Patient characteristics according to ASXL1 genotype ........................ 177 
5.3.3 Clinical outcome according to ASXL1 genotype ................................. 177 
5.4 Discussion ............................................................................................... 184 
CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS ..... 187 
6.1 Future directions ..................................................................................... 190 
6.2 Conclusions ............................................................................................ 191 
REFERENCES ............................................................................ 192 
APPENDIX .................................................................................. 234 
10 
 
TABLE OF FIGURES 
Figure 1.1 Summary of haematopoiesis ........................................................... 17 
Figure 2.1 Chemical effect of bisulfite treatment on cytosine and 5’ 
methylcytosine. ................................................................................................. 54 
Figure 3.1 Structure and functional domains of C/EBPα ................................... 59 
Figure 3.2 Unsupervised components analysis of gene expression data from 38 
CEBPAMUT samples. ......................................................................................... 67 
Figure 3.3 Illumina Infinium I assay. .................................................................. 74 
Figure 3.4 Pyrosequencing assay design and representative pyrograms for the 
SOCS2 probe. ................................................................................................... 78 
Figure 3.5 Titration curves for the percentage methylation obtained using 
standards in the pyrosequencing assays. ......................................................... 79 
Figure 3.6 Pyrosequencing results for the patient samples as analysed at the 
selected CpG sites. ........................................................................................... 80 
Figure 3.7 Comparison of the methylation values obtained by pyrosequencing 
with beta values from the methylation array. ..................................................... 81 
Figure 3.8 Bland-Altman plots to compare the pyrosequencing and methylation 
array quantification results. ............................................................................... 83 
Figure 3.9 Unsupervised cluster analysis based on the most differentially 
methylated CpG sites. ....................................................................................... 85 
Figure 3.10 Boxplot showing the mean CpG Island methylation level in classic 
CEBPADM.and CEBPAWT samples. ................................................................... 87 
Figure 3.11 Comparison of the classic CEBPADM and CEBPAWT methylation 
signatures to the methylation levels at these 25 CpG sites in normal bone 
marrow and blood cells. .................................................................................... 93 
Figure 3.12 Heatmap showing methylation values for each sample at the 25 
CpG sites in the CEBPA methylation signature. ............................................... 94 
Figure 3.13 Distance from the classic CEBPADM and CEBPAWT signatures for 
the cohort 1 samples. ........................................................................................ 96 
Figure 3.14 β values from patients studied in cohorts 2 and 3 with the 450K 
array at four of the sites in the CEBPA methylation signature. ......................... 98 
Figure 3.15 Methylation levels at all the CpG sites investigated on the 450K 
arrays that relate to 4 specific genes in the methylation signature. ................... 99 
11 
 
Figure 3.16 Unsupervised cluster analysis of cohorts 2 and 3. ....................... 101 
Figure 3.17 Heatmap showing methylation values for the CEBPA signature loci 
in the 95 patients analysed in the follow-up cohorts. ....................................... 102 
Figure 3.18 Comparison of the distance from the CEBPAMUT signature with the 
difference in the distance from each of the signatures in classic CEBPADM 
cases. ............................................................................................................. 103 
Figure 3.19 Titration curves for the percentage methylation obtained using 
standards in the pyrosequencing assays. ....................................................... 106 
Figure 3.20 Comparison of the pyrosequencing results and array beta values for 
patient samples. .............................................................................................. 107 
Figure 3.21 Pyrosequencing results of samples from good-risk prognostic 
patients at three of the 25 CpG sites in the CEBPAMUT signature. .................. 108 
Figure 3.22 Euclidian distance of samples from patients in the good risk 
prognostic groups from the median profile of CEBPADM. ................................ 109 
Figure 4.1 Distance scores for all CEBPADM and CEBPAWT samples in the 
validation cohorts. ........................................................................................... 125 
Figure 4.2 Distance scores for the non-classic CEBPADM and the CEBPASM 
cases. ............................................................................................................. 128 
Figure 4.3 Location of probes on the Illumina methylation arrays that are 
associated with the CEBPA gene. .................................................................. 130 
Figure 4.4 Heatmap showing the methylation values for probes closest to the 
CEBPA gene in the 95 patients in the follow-up cohorts, as analysed on the 
450K Illumina Methylation Array. .................................................................... 132 
Figure 4.5 β values at probe 2, CG21715751 for the 95 samples in the follow-up 
cohorts, arranged according to CEBPA genotype. .......................................... 133 
Figure 4.6 Location of the three PCRs designed to investigate methylation in the 
CEBPA promoter. ........................................................................................... 135 
Figure 4.7 Bisulfite sequence of part of the CEBPA distal promoter region in 
control samples with known methylation levels. .............................................. 137 
Figure 4.8 Estimated methylation levels at individual CpG sites examined by 
bisulfite sequencing of control samples. ......................................................... 138 
12 
 
Figure 4.9 Comparison of methylation levels from the 450K array beta values 
with estimated levels from bisulfite sequencing in the distal CEBPA promoter 
region. ............................................................................................................. 140 
Figure 4.10 Comparison of the median methylation level in the forward and 
reverse strands at four CpG sites in the CEBPA distal promoter region ......... 141 
Figure 4.11 Median methylation levels in the distal CEBPA promoter region for 
AML samples according to their CEBPA genotype. ........................................ 143 
Figure 4.12 Number of samples with evidence of methylation at individual CpG 
sites in the CEBPA distal promoter region. ..................................................... 144 
Figure 4.13 Distance scores for cases with hypermethylation in the distal 
CEBPA promoter region. ................................................................................ 145 
Figure 5.1 Representation of ASXL1 locus and PCR fragments used for 
detection of ASXL1 mutations by WAVE® analysis. ........................................ 153 
Figure 5.2 Proposed function of ASXL1 and the polycomb complexes. .......... 154 
Figure 5.3 Representative amplicon melting curve profiles for WAVE® analysis.
 ........................................................................................................................ 165 
Figure 5.4 Identification and confirmation of the common synonymous SNP, 
c.3759T>C. ..................................................................................................... 167 
Figure 5.5 Outline of the relevant treatment protocols for patients in Medical 
Research Council trials AML10, AML11 and AML12. ..................................... 169 
Figure 5.6 Representative analysis of two ASXL1 mutations. ......................... 172 
Figure 5.7 Distribution, incidence and type of truncating ASXL1 exon 12 
mutations detected in the 4 patient groups ..................................................... 176 
Figure 5.8 Outcome according to ASXL1 mutant status in the total cohort. .... 182 
Figure 5.9 Overall survival in the different patient groups. .............................. 183 
13 
 
LIST OF TABLES 
Table 1.1 WHO classification of AML ................................................................ 19 
Table 1.2 Cytogenetic risk group classification ................................................. 21 
Table 1.3 Recurrent mutations seen in AML ..................................................... 22 
Table 1.4 Main methods of analysing DNA methylation .................................... 38 
Table 3.1 Published studies investigating incidence and impact of CEBPA 
mutations in patients with AML. ........................................................................ 61 
Table 3.2 Published studies that list type of CEBPADM mutations in AML ........ 65 
Table 3.3 CEBPA genotype of samples investigated using methylation arrays 86 
Table 3.4 List of the genes or regions associated with the 25 differentially 
methylated CpG sites in the CEBPA methylation signature. ............................. 89 
Table 3.5 Published associations between genes in the CEBPA signature and 
leukaemia. ........................................................................................................ 91 
Table 4.1 Frequency of CEBPA promoter methylation reported in diagnostic 
AML samples .................................................................................................. 119 
Table 4.2 Methods used to differentiate between WT and mutant alleles in 
CEBPA mutation quantification and clone characterisation ............................ 122 
Table 4.3 Mutation screening of full length clones from CEBPADM samples ... 126 
Table 4.4 Mutant levels of compound heterozygous CEBPADM samples ........ 127 
Table 5.1 Mutation rate of ASXL1 in myeloid malignancies ............................ 156 
Table 5.2 ASXL1 missense mutations considered to be SNPs ....................... 174 
Table 5.3 Frameshift and nonsense mutations detected in ASXL1 exon 12 ... 175 
Table 5.4 Patient demographics according to ASXL1 mutant status .............. 178 
Table 5.5 Correlation of ASXL1 mutation status with other mutations ............ 179 
Table 5.6 Outcome of patients with and without a mutation in ASXL1 exon 12.
 ........................................................................................................................ 180 
 
Appendix Table 1 Primer sequences, annealing temperatures and WAVE 
analysis temperatures if appropriate ............................................................... 234 
Appendix Table 2 List of samples with CEBPA mutations in all cohorts and 
classification of samples ................................................................................. 238 
 
14 
 
COMMONLY USED ABBREVIATIONS 
 
AA Amino acid 
AML Acute Myeloid Leukaemia 
APL Acute Promyelocytic Leukaemia 
aCGH Array comparative genomic hybridisation 
Asx Additional sex combs 
ASXL1 Additional sex comb like 1 gene 
ATRA All-trans-retinoic acid 
BM Bone Marrow 
bp Base pairs 
CBF Core Binding Factor 
cDNA Complementary DNA 
CEBPA CCAAT-enhancer binding protein α 
CGI CpG Island 
ChIP Chromatin Immunoprecipitation 
CI Confidence intervals 
CIR Cumulative Incidence of Relapse 
CLP Common Lymphoid Progenitor 
CMP Common Myeloid Progenitor 
CpG Cytosine (phosphate) Guanine dinucleotide 
CR Complete Remission  
DBD DNA-binding domain 
dHPLC Denaturing high performance liquid chromatography 
DNA Deoxyribonucleic acid 
DNMT DNA methyltransferase 
DNMT3A DNA methyltransferase 3A 
FAB French-American-British 
FLT3 Fms-like tyrosine kinase-3 
gDNA Genomic DNA 
GMP  Granulocyte/macrophage progenitor 
GVL Graft-versus-leukaemia 
15 
 
HELP HpaII tiny fragment Enrichment by Ligation-mediated PCR 
HLA Human Leukocyte Antigen 
HR Hazard Ratio 
ID Induction death 
IDH Isocitrate Dehydrogenase 
IK Intermediate Karyotype 
ITD Internal Tandem Duplication 
LIC Leukaemia initiating cell 
LZD Leucine zipper domain 
MDS  Myelodysplasia 
MeDIP Methylated DNA immunoprecipitation 
MEP Megakaryocyte/erythroid progenitors 
MHC Major histocompatibility complex 
MRC   Medical Research Council  
NGS Next Generation Sequencing 
NK Normal Karyotype 
NPM1 Nucleophosmin 1 
nt  Nucleotide 
OR   Odds Ratio  
OS   Overall Survival  
PCR Polymerase chain reaction 
PRC2 Polycomb Repressive Complex 2 
RD Resistant Disease 
RED Restriction Enzyme Digest 
RNA Ribonucleic acid 
SCT Stem Cell Transplantation 
SNP Single Nucleotide Polymorphism 
TA Transactivation activity 
TAD Transactivation Domain 
TKD Tyrosine Kinase Domain 
TSS Transcription start site 
WHO World Health Organization 
WT Wild-type 
16 
 
CHAPTER 1:INTRODUCTION 
Acute myeloid leukaemia (AML) is a heterogeneous malignancy characterised 
by an accumulation of myeloid precursors. Part of the heterogeneity is 
explained by the different chromosomal changes and mutations seen in this 
disease. However, these underlying genetic changes do not account for the full 
diversity seen, both clinically and biologically, and recent studies have 
demonstrated the important role of epigenetic factors in contributing to its 
pathogenesis. This thesis presents studies exploring epigenetic differences 
identified in AML and mutations in a gene coding for an epigenetic modifier, with 
a view to determining whether they can aid stratification of patients into 
prognostic groups. 
1.1 Haematopoiesis 
Mature blood cells have a life span ranging from a few days to a few months 
and thus are continually replenished throughout life. This continual source of 
blood cells is maintained by a few haematopoietic stem cells which have the 
ability to self-renew and also differentiate further into more committed progenitor 
cells, culminating in terminally differentiated mature blood cells (Orkin & Zon, 
2008). This hierarchical process is summarised in Figure 1.1. Haematopoiesis 
is a co-ordinated process regulated by specific growth factors and transcription 
factors. It occurs in waves at different sites that alter during development; in 
adults the location of haematopoiesis is predominantly in the bone marrow of 
the central skeleton and proximal parts of the femurs and humeri.  
1.2 AML 
AML is a relatively uncommon malignancy of haematopoietic cells of the 
myeloid lineage; the incidence is 2-3 cases per 100,000 individuals per year in 
the population less than 60 years of age, but it increases to 13-15 in the 
population over 60 years of age (Lowenberg et al, 1999). Patients present with 
symptoms of pancytopenia such as fatigue, breathlessness, bleeding, bruising 
and recurrent infections; leukaemic infiltration which can affect anywhere but 
particularly the spleen, liver, gums, skin and nervous system; or leukostasis
17 
 
(COPYRIGHT PROTECTED IMAGE REMOVED)  
Figure 1.1 Summary of haematopoiesis. The stages at which haematopoietic 
development is blocked in the absence of a given transcription factor are 
indicated by red bars.  
Abbreviations: CMP, common myeloid progenitor; CLP, common lymphoid progenitor; 
MEP, megakaryocyte/erythroid progenitor; GMP, granulocyte/macrophage progenitor; 
RBCs, red blood cells. 
 
Taken from Orkin and Zon (2008). 
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which can lead to neurological or pulmonary complications. Usually symptoms 
develop rapidly, over days to weeks. Although there are no known causes of 
AML, there are several factors that increase the risk of developing it, and this is 
reflected in the classification of the disease. 
1.2.1 Diagnosis and Classification of AML 
A diagnosis of AML is made if 20% or more of nucleated blood cells in the bone 
marrow are myeloid blasts, although cases with fewer than 20% blasts that also 
have an underlying cytogenetic rearrangement such as inv(16), t(8;21) or 
t(15;17) are also diagnosed as AML. The current classification is based on the 
World Health Organisation (WHO) proposal (Swerdlow et al, 2008) which is 
summarised in Table 1.1. This incorporates the previous French-American-
British classification, which was based only on morphological features and 
cytochemistry, but has been extended to include subtypes related to 
predisposing clinical or underlying genetic factors. The main subtypes are AML 
with recurrent genetic abnormalities; AML with myelodysplasia-related changes; 
therapy-related myeloid neoplasms; myeloid proliferations related to Down 
syndrome; AML, not otherwise specified.  
1.2.2 Prognostic Factors in AML  
Prognostic factors can be grouped into patient-related, disease-related and 
response to therapy. 
1.2.2.1 Patient-related factors 
Studies have shown that a higher WHO performance score or the presence of 
co-morbidities at diagnosis are independent risk factors associated with a 
poorer outcome (Döhner et al, 2010; Giles et al, 2007). However, age at 
diagnosis is the strongest patient-related factor, with the prognosis gradually 
getting worse with increasing age. The 5-year overall survival rate of patients 
diagnosed below the age of 14 years is 63%, compared to 35% for those aged 
45-59 years and only 14% for those over 60 years (Smith et al, 2011). The 
reason for this is multi-factorial; older patients are more likely to have underlying 
co-morbidities and worse performance score, as well as differences in ability to 
tolerate chemotherapy and the complications of chemotherapy. Furthermore,
19 
 
 Table 1.1 WHO classification of AML 
 
 Acute myeloid leukaemia with recurrent genetic abnormalities 
AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
APL with t(15;17)(q22;q12); PML-RARA 
AML with t(9;11)(p22;q23); MLLT3-MLL 
AML with t(6;9)(p23;q34); DEK-NUP214 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA 
Acute myeloid leukaemia with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
Acute myeloid leukaemia, not otherwise specified 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic/monocytic leukaemia 
Acute erythroid leukaemia 
Pure erythroid leukaemia 
Erythroleukemia, erythroid/myeloid 
Acute megakaryoblastic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down syndrome 
Transient abnormal myelopoiesis 
Myeloid leukaemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
20 
 
the disease biology itself is different in the older age group, with a higher 
frequency of adverse cytogenetics and higher incidence of secondary AML. 
However, even when all these factors are taken into account, age is still an 
independent prognostic variable (Liersch et al, 2014).    
1.2.2.2 Disease-related factors 
Certain factors such as previous chemotherapy or myelodysplastic changes not 
only increase the risk of developing AML (secondary AML), but are also 
associated with a worse prognosis when compared to AML arising de novo 
(Arber et al, 2003), hence patients in these categories are considered 
separately in the classification system.  
The majority of patients develop AML de novo. Approximately 60% of these 
have recurrent cytogenetic alterations, many of which are of major prognostic 
importance and have been used as the basis of risk-stratified treatment for over 
20 years. A recent cytogenetic analysis of 5876 patients aged between 15 and 
59 years treated in UK MRC trials found that approximately one-quarter of 
patients had either t(15;17), inv(16) or t(16;16), or t(8;21) and were in a 
favourable prognostic group (Table 1.2) (Grimwade et al, 2010). The latter two 
translocations lead to CBFB-MYH11 and RUNX1-RUNXT1 fusion proteins 
respectively and are termed core-binding factor leukaemias; patients with these 
changes had a 10-year overall survival of approximately 60%. The 17% of 
patients with poor prognostic changes, as specified in Table 1.2, had a 10-year 
survival of 12%. The remaining 58% of patients either had no karyotypic change 
or changes with no known prognostic impact, and this group had a 10-year 
overall survival of approximately 35%.  
However, an increasing number of recurrent mutations has now been found in 
AML, some of which have prognostic impact (Table 1.3). The list given is not 
exhaustive and many new less common mutations have been identified, 
particularly with the increase in availability of whole genome sequencing (2013). 
One of the most commonly found mutations in AML is an internal tandem 
duplication in the FMS-like tyrosine kinase 3 gene (FLT3/ITD). FLT3 encodes a 
receptor tyrosine kinase that is expressed in early haematopoietic cells.
21 
 
  
Table 1.2 Cytogenetic risk group classification  based on analysis of 
young adult patients with AML treated on UK MRC protocols 
Risk Group 
 
10-year 
OS2
 
Proportion 
of patients2
 
Original MRC1
 
Refined MRC2
 
Favourable 69% 
7% t(8;21) t(8;21) 
13% t(15;17) t(15;17) 
5% inv(16) or t(16;16) inv(16) or t(16;16) 
Intermediate 
38% 41% Normal karyotype Normal karyotype 
33% 17% Other non-complex Other non-complex 
Adverse 12% 17% 
abn(3q) abn(3q) excluding 
t(3;5) 
 Inv(3) or t(3;3) 
-5 or del(5q) add(5q), del(5q) or -5 
-7 -7, add(7q) or del(7q) 
 t(6;11) 
 t(10;11) 
 t(9;22) 
 t(11q23) excluding 
t(9;11) and t(11;19) 
 -17 or abn(17p) 
Complex ≥5 
unrelated abn, 
excluding those 
with favourable 
changes 
Complex ≥4 unrelated 
abn, excluding those 
with favourable 
changes 
 
1(Grimwade et al, 1998) 2(Grimwade et al, 2010) 
Abbreviations: OS, overall survival; MRC, Medical Research Council; abn, 
abnormality; del, deletion; add, addition; t, translocation. 
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Table 1.3 Recurrent mutations seen in AML 
Table 1.3 continued 
Gene Chr Proposed Function 
Reported 
Incidence 
Type of mutations 
commonly 
detected 
Overall impact 
on outcome 
Associations References 
ASXL1 20q11 
Additional sex comb like 1 
- Stablilises PRC2 which 
catalyses repressive 
histone trimethylation mark 
H3K27Me3  
3-19% 
Frameshift  
Nonsense 
Adverse 
Older adults 
Secondary disease 
 
Inv. with NPM1
MUT
 
Chou et al (2010b) 
Paschka et al (2011) 
Pratcorona et al (2012) 
Schnittger et al (2013) 
El-Sharkawi et al (2013) 
BCOR Xp11.4 BCL-6 co-repressor 
4% (NK-
AML) 
Frameshift 
Nonsense 
Splice site 
Adverse 
NK-AML 
DNMT3A
MUT
 
Inv. with NPM1
MUT
 
Grossmann et al 
(2011b) 
BCORL1 
Xq25-
26.1 
Transcriptional co-
repressor 
6% 
Frameshift 
Nonsense 
Missense 
Splice site 
N/A  Li et al (2011) 
CBL 11q23.3 
Casitas B cell lymphoma 
gene- involved in the 
degradation of tyrosine 
kinases 
1-3% Missense N/A CBF-leukaemia 
Bacher et al (2010) 
Allen et al (2011) 
Ibanez et al (2012) 
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Table 1.3 continued 
Gene Chr Proposed Function 
Reported 
Incidence 
Type of mutations 
commonly 
detected 
Overall impact 
on outcome 
Associations References 
CEBPA 19q13.1 
Transcription factor 
promoting cell 
differentiation 
6% 
Frameshift or 
nonsense at N 
terminus 
In-frame insertion or 
deletion at C 
terminus 
Often biallelic  
Favourable 
(CEBPA
DM 
only) 
NK-AML 
Hou et al (2009) 
Wouters et al (2009) 
Dufour et al (2010) 
Green et al (2010b) 
Taskesen et al (2011) 
c-KIT 4q12 Tyrosine kinase receptor 2-3% 
MIssense (D816 or 
N822) 
Inframe indel in 
extracellular domain 
Adverse CBF-leukaemia 
Care et al (2003) 
Boissel et al (2006) 
Cairoli et al (2006) 
Paschka et al (2006) 
Schnittger et al (2006) 
Allen et al (2011) 
Chen et al (2016) 
DNMT3A 2p23 
DNA methyltransferase 3A: 
catalyses de novo 
methylation of CpG 
dinucleotides 
15-25% 
Missense 
(predominantly 
R882) 
Nonsense 
Frameshift 
Splice site 
Adverse 
FAB M4/ M5 
IR-AML/ NK-AML 
NPM1
MUT
 
 
Ley et al (2010) 
Thol et al (2011a) 
Yan et al (2011) 
Marcucci et al (2012) 
Renneville et al (2012) 
Ribeiro et al (2012) 
Gale et al (2015) 
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Table 1.3 continued 
Gene Chr Proposed Function 
Reported 
Incidence 
Type of mutations 
commonly 
detected 
Overall impact 
on outcome 
Associations References 
EZH2 
7q35-
q36 
Histone lysine N-
methyltransferase- member 
of the polycomb protein 
family involved in histone 
methylation and chromatin 
silencing 
1-3% 
Nonsense 
Frameshift 
Missense 
N/A Del7q Wang et al (2013b) 
FLT3 13q12 Tyrosine kinase receptor 
25% 
7% 
FLT3/ITD 
FLT3/TKD 
(Missense) 
Adverse 
No impact 
NPM1
 MUT
 
NK-AML 
Kottaridis et al (2001) 
Thiede et al (2002) 
Mead et al (2007) 
Gale et al (2008) 
GATA2 3q21.3 
Transcription factor 
involved in haematopoiesis 
3% in 
CEBPA
WT
  
18-27% in 
CEBPA
DM
 
Missense 
Unclear: 
Favourable/ No 
impact 
CEBPA double 
mutant AML 
Fasan et al (2013b) 
Green et al (2013) 
Grossmann et al (2013) 
Pasquet et al (2013) 
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Table 1.3 continued 
Gene Chr Proposed Function 
Reported 
Incidence 
Type of mutations 
commonly 
detected 
Overall impact 
on outcome 
Associations References 
IDH1 2q33.3 
Isocitrate Dehydrogenase 
1: Cytosolic metabolic 
enzyme catalyses the 
conversion of isocitrate to α 
ketoglutarate 
7-16% Missense at R132 
Unclear: 
Adverse/No 
impact/ 
Favourable in 
FLT3/ITD 
positive 
subgroup 
NK-AML 
NPM1
 MUT
 
inv. with CEBPA
MUT
, 
TET2
 MUT 
and 
WT1
MUT 
Abbas et al (2010) 
Boissel et al (2010) 
Chou et al (2010a) 
Green et al (2010a) 
Marcucci et al (2010) 
Paschka et al (2010) 
Wagner et al (2010) 
Nomdedeu et al (2012) 
IDH2 15q26.1 
Isocitrate Dehydrogenase 
2: Mitochondrial metabolic 
enzyme catalyses the 
conversion of isocitrate to α 
ketoglutarate 
8-15% 
Missense at R140 
or R172 
Unclear: 
Adverse/No 
impact/ 
Favourable 
NPM1
 MUT
 
Inv. with TET2
 MUT 
and WT1
MUT 
Abbas et al (2010) 
Boissel et al (2010) 
Chou et al (2011b) 
Green et al (2011) 
Paschka et al (2010) 
JAK2 9p24 
Janus Kinase 2: implicated 
in cell signalling 
1% V617F Adverse CBF-leukaemia 
Fröhling et al (2006) 
Illmer et al (2007) 
KRAS 12p12.1 GTPase 5-20% Missense No impact Inv(16) 
Bowen et al (2005) 
Rocquain et al (2010) 
MLL 11q23 
Histone methyltransferase: 
mediates H3K4me, active 
transctiptional mark 
5-10% PTD Adverse NK-AML 
Schnittger et al (2000) 
Dohner et al (2002) 
Steudel et al (2003) 
  
 
2
6
 
Table 1.3 continued 
Gene Chr Proposed Function 
Reported 
Incidence 
Type of mutations 
commonly 
detected 
Overall impact 
on outcome 
Associations References 
NPM1 5q35.1 Nucleolar protein 20-35% Frameshift Favourable 
FLT3 
 
 
Dohner et al (2005) 
Schnittger et al (2005) 
Verhaak et al (2005) 
Thiede et al (2006) 
NRAS 1p13.2 GTPase 5-20% Missense No impact  
Bacher et al (2006) 
Bowen et al (2005) 
PHF6 Xq26.3 
Plant Homeodomain finger 
6:X linked transcriptional 
regulator 
2-4% 
Nonsense 
Frameshift 
Adverse Male sex 
Van Vlierberghe et al 
(2011) 
PTPN11 12q24 
Encodes SHP2, a non-
tyrosine phosphatase 
signalling molecule 
3% Missense N/A Paediatric AML 
Loh et al (2004) 
Hugues et al (2005) 
RUNX1 21q22.3 
Runt related transcription 
factor 1: transcription factor 
required for 
haematopoiesis 
10-15% 
Frameshift 
Nonsense 
Missense 
 
Adverse 
CN-AML 
MLL
MUT
 
Inv. with CEBPA
MUT
 
and NPM1
MUT
 
Tang et al (2009) 
Gaidzik et al (2011) 
Mendler et al (2012) 
TET2 4q24 
Catalyses conversion of 
methylcytosine to 
hydroxymethylcytosine 
8-12% 
Frameshift 
Nonsense 
Missense 
Adverse 
NK AML 
Inv. with IDH1
MUT
, 
IDH2
MUT
 and 
WT1
MUT
 
Chou et al (2011a) 
Metzeler et al (2011b) 
Gaidzik et al (2012) 
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Table 1.3 continued 
Gene Chr Proposed Function 
Reported 
Incidence 
Type of mutations 
commonly 
detected 
Overall impact 
on outcome 
Associations References 
TP53 17p13.1 Tumour suppressor 2-5% 
Frameshift 
Nonsense 
Missense 
Adverse 
Complex karyotype 
Secondary AML 
Bowen et al (2009) 
Rucker et al (2012)  
Wong et al (2015) 
WT1 11p13 
Transcription factor that 
acts as a tumour 
suppressor 
Recruits and aids TET2 
10-15% 
Frameshift 
Missense 
Nonsense 
Unclear: 
adverse/ no 
impact 
FLT3/ITD  
CEBPA
MUT
 
Inv. with IDH1
MUT
, 
IDH2
MUT
 and 
TET2
MUT
 
Paschka et al (2008) 
Virappane et al (2008) 
Gaidzik et al (2009) 
Rampal et al (2014) 
Abbreviations: CBF, core binding factor; CEBPA
DM
, Double mutation in CEBPA; Chr, chromosome; Inv., inversion; Inv. with, inverse association with; IR-
AML, intermediate risk AML; ITD, internal tandem duplication; MUT, mutation; N/A, data not available; NK-AML, normal karyotype AML; PTD, partial 
tandem duplication; TKD, tyrosine kinase domain; WT, wild type. 
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A FLT3/ITD, seen in approximately 25% of AML patients, leads to a 
constitutively active receptor and is associated with a poor prognosis (Kottaridis 
et al, 2001; Thiede et al, 2002). A second type of mutation within this gene, 
either a missense mutation or small in-frame size change within the tyrosine 
kinase domain (FLT3/TKD), is less frequent and its impact on prognosis is not 
as clear (Mead et al, 2007; Thiede et al, 2002; Whitman et al, 2008). Another 
gene frequently mutated in patients with AML is nucleophosmin (NPM1), which 
encodes a nucleolar transporter protein. Mutations in NPM1 are found in 
approximately 20-35% of cases, and in the absence of a FLT3/ITD are 
associated with a good prognosis (Gale et al, 2008; Schnittger et al, 2005; Shen 
et al, 2011; Thiede et al, 2006). Mutations in the CCAAT/ enhancer-binding 
protein alpha gene, CEBPA, are found in approximately 10% of patients, the 
majority of whom have an intermediate karyotype (IK) and are wild-type (WT) 
for NPM1, and are associated with a good prognosis. They are discussed 
further in Chapter 3. 
More recent studies have identified recurrent mutations in genes that encode 
proteins involved with maintaining the “epigenetic equilibrium”. These mutations 
in epigenetic modifiers are thought to exert their effects via changes in histone 
structure, e.g. methylation, ubiquitination, phosphorylation and DNA 
methylation, which in turn are thought to lead to global alterations in gene 
expression. Examples include the DNA methyltransferase 3A (DNMT3A), Ten 
Eleven Translocation methylcytosine dioxygenase 2 (TET2), Isocitrate 
Dehydrogenase 1 and 2 (IDH1, IDH2), Additional sex comb like 1 (ASXL1) and 
EZH2 genes. The significance of changes in methylation in cancer is further 
discussed in section 1.3.6, and of these mutations in chapter 5. 
It should be noted that as more is discovered about the underlying cytogenetic 
and molecular mutations that occur recurrently in AML, the factors that are 
considered to be associated with good or poor prognosis are constantly coming 
under review. As more mutations are identified, assessing their impact on 
prognosis is becoming more complex due to their co-incidence, particularly 
where factors associated with both good and poor prognosis are both present, 
for example FLT3/ITDs and NPM1 mutations. Furthermore, as new therapies 
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are introduced, particularly targeted therapies, this may change how prognostic 
factors are interpreted.  
1.2.2.3 Response to therapy 
Patients who are in complete remission following the first cycle of induction 
chemotherapy have a better prognosis than those who still have detectable 
disease (Wheatley et al, 1999). The likelihood of achieving a complete 
remission is dictated in part by the risk factors discussed above, for example 
age. The length of remission has also been associated with outcome; those 
patients who relapse within 6 months of induction therapy have a worse 
outcome compared to those who relapse after 6 months (Döhner et al, 2010). 
These studies define remission morphologically. However, with the identification 
of recurrent mutations, use of more sensitive molecular methods to assess 
minimal residual disease are becoming increasingly more common, and a 
recent study has shown that patients with persistent subclinical disease do 
worse than those who are in molecular remission as defined by these methods 
(Ivey et al, 2016).  
1.2.3 Treatment of AML 
The mainstay of treatment of AML is chemotherapy using protocols that have 
not changed dramatically over the past few decades. There are two phases of 
chemotherapy; the first is remission induction and the second is consolidation. 
Standard remission induction for non-acute promyelocytic leukaemia (APL), in 
patients who can tolerate intensive chemotherapy, consists of a nucleoside 
analogue, usually cytarabine, in combination with an anthracycline such as 
daunorubicin. Several studies have looked at different chemotherapeutic 
agents, dosing schedules or additional drugs, but to date these changes have 
not led to a significant survival advantage. The aim of this phase of 
chemotherapy is to induce a remission, CR, defined as less than 5% blasts in 
the bone marrow, detected morphologically, with recovery of blood counts. For 
patients less than 60 years of age, approximately 80% will achieve CR, 10-20% 
will have persistent disease and approximately 5% will die as a result of 
complications of the disease and/or treatment (Burnett, 2013).  
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Once in remission, the aim of the second phase of chemotherapy is to prevent 
relapse by eliminating residual subclinical disease. The most common agent 
given for this, outside of a trial setting, is high-dose cytarabine. However, again, 
the number of cycles to give and alternative combination chemotherapies are 
under investigation. Stem cell transplants (SCT) are an important tool in 
preventing relapse, however this comes at a cost as they are associated with an 
increased risk of treatment-related morbidity and mortality. There is no current 
evidence that autologous SCT are superior to chemotherapy alone in outcome, 
and so these are not standard practice (Burnett et al, 2011). Several factors are 
involved in deciding whether an allogeneic SCT should be performed in first 
remission, the first of which is donor availability, either a well-matched sibling or 
unrelated donor. A second consideration is whether the patient is fit enough to 
tolerate the procedure. The introduction of reduced intensity allografts, which 
use less myeloablative chemotherapeutic regimes and rely more on the graft-
versus-leukaemia effect, has meant that this option can be used in older less fit 
patients than previously. Thirdly, the choice is based on risk stratifying the 
disease, which in practice is predominantly done using cytogenetics. Generally, 
if the risk of relapse is greater than 35% at 4 years post-remission, then it is 
considered high enough to outweigh the risks of the transplant itself 
(Cornelissen et al, 2007). Standard current practice in the UK is that patients 
with adverse risk cytogenetics are recommended for a SCT in first remission, 
whereas those with favourable risk cytogenetics or who have a mutation in 
NPM1 in the absence of FLT3/ITD are not. Other patients within the 
intermediate risk category are usually considered for a SCT, but there is no 
clear consensus whether this is the best option, perhaps reflecting the 
heterogeneity of this group (Burnett & Hills, 2011).  
The overall survival (OS) rate in younger patients treated with standard therapy 
has steadily improved over the past few decades from a 5-year survival rate of 
25% to 40% (Burnett, 2013). This improvement is primarily due to decreased 
treatment-related mortality because of better supportive care and treatment of 
complications rather than due to changes in the chemotherapy itself. 
Unfortunately, this improvement has not been replicated in the older age group, 
as survival rate in patients over 60 years of age still remains at approximately 
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20% at 5 years (Burnett, 2013). Even those patients who are considered fit 
enough to receive the same intensive chemotherapy as younger patients have 
worse outcomes when compared to the younger patients undergoing the same 
therapy.  
Research into new chemotherapy drugs is ongoing, however currently most 
clinical trials assessing new agents have adopted a more targeted approach to 
treatment. Examples include antibody-drug conjugates such as gemtuzumab 
ozogamicin, which targets CD33 found on leukaemic blasts, and drugs that 
target particular mutations, for example FLT3 inhibitors such as lestaurtinib 
(Stein & Tallman, 2016). Drugs aimed at epigenetic targets are also of particular 
interest given that epigenetic dysregulation is a feature of AML (see Chapter 3), 
and the potential reversibility of this dysregulation. The most widely used drugs 
for AML in this category are the pyrimidine analogues 5-azacytidine 
(azacitidine) and 5-aza-2’deoxycytidine (decitabine). These function as 
inhibitors of DNA methyltransferases by being incorporated into the DNA as 
cytosine analogues, leading to hypomethylation at lower doses and preventing 
cell proliferation at higher doses (Leone et al, 2002). There is some evidence 
that these drugs are effective, especially in the older age group when compared 
to current conventional care. One study showed an improvement in overall 
survival in patients taking azacitidine compared to those who did not,10.4 
months and 6.5 months respectively, p = 0.10 (Dombret et al, 2015). However, 
there is little evidence that these agents lead to a reversal of aberrant 
methylation and restoration of the expression of critical tumour suppressor 
genes (Voso et al, 2014). There are also several drugs in clinical phase trials 
that act on enzymes affecting histone modifications, such as histone 
deacetylase inhibitors, and on proteins that “read” acetyl marks, such as BET 
inhibitors (Wouters & Delwel, 2016).  
 
1.3 Epigenetics 
Epigenetics is defined as heritable changes in gene expression that are not due 
to alterations in the DNA sequence itself (Holliday, 1987). More recently it has 
been suggested that this should encompass “the structural adaptation of 
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chromosomal regions so as to register, signal or perpetuate altered activity 
states” (Bird, 2007). This subtle change allows for the inclusion of chromatin 
marks that may alter gene expression but are transient. As all cells have the 
same DNA, the epigenome dictates which genes are active and therefore why 
gene expression is so varied in different cell types. There are currently three 
systems that are known to have an effect on gene expression and thus are 
considered “epigenetic”, namely DNA methylation, histone modifications, and 
RNA-associated silencing (which will not be discussed).  
1.3.1 DNA methylation 
The most studied epigenetic marker is DNA methylation. In 1975, two papers 
were independently published detailing methylation of cytosines, which involves 
the addition of a methyl group to the 5’ carbon of the cytosine bases in the 
context of CpG dinucleotides. They proposed it could lead to gene silencing and 
thus play a role in the development of organisms by regulating gene expression 
(Holliday & Pugh, 1975; Riggs, 1975). There is evidence of methylation of 
cytosine bases in non-CpG contexts but this is far less frequent and its role is 
currently not clear, although studies have demonstrated that it may have an 
important function in embryonic stem cells and brain tissue (Guo et al, 2014; 
Ramsahoye et al, 2000; Ziller et al, 2011). 
1.3.1.1 CpG dinucleotides 
As methylation was found predominantly in the cytosines of CpG dinucleotides, 
this led to an interest in the distribution of CpGs within the genome. Although 
there are approximately 28 million CpG sites in the human genome, based on 
the total GC content, there are fewer CpG sites than would be expected by 
chance alone (Russell et al, 1976). Moreover, the distribution of CpG 
dinucleotides is not random. Most of the genome is deplete of CpG 
dinucleotides, however there are CpG-rich regions (termed CpG islands, CGIs) 
that are mainly concentrated around the promoter region and first exon of 60-
70% of genes in the human genome (Saxonov et al, 2006). A formal definition 
of a CGI is that it is a sequence of at least 200 bases with a GC content greater 
than 50%, and the observed to expected ratio of CpG sites is greater than 60% 
(Gardiner-Garden & Frommer, 1987). Given the strong link between CGIs and 
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promoter regions, CGIs are sometimes used to elucidate promoters and genes 
that are hitherto unknown (Illingworth et al, 2010; Larsen et al, 1992). For 
example, Macleod et al (1998) discovered a novel intronic promoter within the 
MHC class II-I Aβ gene in mice which, when deleted, led to decreased 
transcription of the gene. 
Differences have been observed between genes that have CGIs within their 
promoters and those that do not. All constitutively expressed genes have a CGI 
located around the transcription start site, and approximately 40% of genes that 
show differential expression across tissue types have an associated CGI, 
although the location of the CGI in these cases is more variable (Larsen et al, 
1992; Zhu et al, 2008). Furthermore, CGI promoters are able to initiate 
transcription from multiple positions, whereas non-CGI promoters are generally 
associated with a single initiation site (Sandelin et al, 2007). 
1.3.1.2 Distribution of methylation of CpG sites 
In normal human cells, the CpGs within islands are often unmethylated whereas 
CpG sites outside the CGIs are generally methylated (Weber et al, 2007). 
Although the density of CpGs is less outside CGIs, given the size of the 
genome this still amounts to approximately 70% of the total CpGs being 
methylated (Ehrlich et al, 1982). The relative paucity of CpG sites throughout 
the genome is thought to be due to spontaneous deamination of methylated 
cytosines to form thymine (Holliday & Grigg, 1993); conversely CGIs are 
thought to be “protected” as they usually remain unmethylated (Smallwood et al, 
2011). 
Although most CGIs associated with genes remain unmethylated, there are a 
subset that are methylated, and this can be tissue specific (Shen et al, 2007). 
For example, analysis of chromosomes 6, 20 and 22 identified 11 CGIs out of 
2279 which were differentially methylated in eight different tissue types 
(Eckhardt et al, 2006). Investigation of the methylation status of CGIs on 
chromosome 21q revealed 31 out of 149 CGIs (21%) detected were fully 
methylated in normal peripheral blood cells (Yamada et al, 2004). Interestingly, 
the most variation in methylation levels seen across tissue types is in areas of 
intermediate rather than high CpG density. Irizarry et al (2009) found that most 
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variation occurred in regions up to 2 kilobases away from the CGIs, which they 
named CpG shores. These tissue-specific differentially methylated regions were 
not only conserved between different individuals analysed, but also could be 
extrapolated to mouse tissues, indicating remarkable conservation of the 
methylation pattern across species.  
1.3.1.3 Regulation of DNA methylation 
Given the stability of the methylation distribution across the genome, many 
studies have investigated how DNA methylation is initiated and maintained. The 
addition of methyl groups to cytosine is catalysed by the DNA methyltransferase 
(DNMT) family of enzymes, of which DNMT1, DNMT3A and DNMT3B are 
considered the most important (Bestor, 1988). Traditionally, DNMT3A and 
DNMT3B were thought of as de novo methyltransferases and the function of 
DNMT1 was to maintain methylation patterns due to its affinity for 
hemimethylated DNA and its ability to target foci of DNA replication (Bestor & 
Ingram, 1983; Leonhardt et al, 1992). However, all three are necessary for 
embryonic development (Chen et al, 2003; Li et al, 1992; Okano et al, 1999) 
and maintenance of methylation pattern (Jones & Liang, 2009).  
During early embryonic development, there is an initial loss of methylation 
followed by a period of global de novo methylation, to which CGIs remain 
immune (Monk et al, 1987). The mechanism by which CGIs remain 
unmethylated is unknown. Evidence exists that this may be due to bound 
transcription factors at the CGIs that preclude the methylation of the underlying 
island. For example, ablation of the binding site for the transcription factor Sp1 
facilitates de novo methylation of the APRT promoter CGI (Brandeis et al, 
1994). Another hypothesis is that the methyl marks are removed from CGIs by 
active demethylation (Frank et al, 1991). 
The process of demethylation is not as well understood. Although none have 
been identified, demethylases that can actively remove the methyl group from 
DNA are thought to exist (Ooi & Bestor, 2008). Many papers have looked at 
other mechanisms by which methyl groups are removed, for example, the TET 
proteins catalyse the oxidation of 5-methylcytosine to 5-hydroxymethylcytosine, 
which is thought to be an intermediate in the subsequent demethylation of the 
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cytosine base (Tahiliani et al, 2009). TET proteins can also cause further 
oxidation to produce 5-formylcytosine and 5-carboxylcytosine (Ito et al, 2011). 
Absence of TET3 in mice led to a failure of demethylation of CpG sites in key 
genes such as Nanog involved with embryogenesis, leading to a delay in 
development (Gu et al, 2011). Furthermore, during embryonic stem cell 
differentiation, the levels of TET1 and TET2 proteins decrease with a 
concomitant decrease in 5-hydoxycytosine and increase in 5-methylcytosine. 
Knockdown of TET1 and TET2 leads to downregulation of genes, including 
those associated with pluripotency, and an increase in methylation at the 
promoters of these genes (Ficz et al, 2011). However, TET proteins have also 
been implicated in repression of genes through interactions with other proteins 
such as the SIN3A co-repressor complex (Williams et al, 2011). 
1.3.2 The significance of DNA methylation 
Methylation is essential for viability of somatic cells, as cultured fibroblasts with 
Cre-mediated deletion of DNMT1 underwent apoptosis (Jackson-Grusby et al, 
2001), however there are many questions as to its exact function. Most work to 
investigate the role of DNA methylation has concentrated on investigation of 
CGIs within promoter regions of genes. The initial reports that described DNA 
methylation postulated its role was to silence gene expression (Holliday & Pugh, 
1975; Riggs, 1975). Indeed, in vitro experiments showed that methylation of the 
adenine phosphoribosyltransferase gene inhibited its expression when 
transduced into mouse L cells (Stein et al, 1982). Since then methylation of 
CGIs has been linked with X chromosome inactivation in females, gene 
imprinting, and tissue-specific gene expression/repression (Illingworth et al, 
2008; Li et al, 1993; Venolia & Gartler, 1983), all of which are associated with 
allele or gene silencing. Moreover, treatment of mammalian cells with the 
demethylating agent 5’-aza 2’-deoxycytidine has been shown to re-activate 
silenced genes on the inactive X chromosome (Mohandas et al, 1981).  
However, there is still some debate about whether DNA methylation is the 
cause of repression (De Smet et al, 1999) or is rather a result of repression. For 
example, methylation of the Hrpt gene on the inactive X chromosome occurs 
after chromosome inactivation (Lock et al, 1987), and silencing of the X 
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chromosome is not dependent on DNMTs (Sado et al, 2000; Sado et al, 2004). 
In some circumstances, methylation is thought to stabilise DNA silencing, as 
when X inactivation takes place in extra-embryonic tissue; if there is no DNA 
methylation, the genes on the inactive chromosome slowly become reactivated 
(Samollow et al, 1995). It has also been suggested it may play a role in 
controlling transcription from multiple promoters, for example, despite 
methylation of the CGI promoter for PARP12, expression was still evident from 
an alternative start site, downstream of the CGI (Rauch et al, 2009).  
The function of DNA methylation may be dependent on the genomic region. 
Although methylation within CGIs is associated with gene repression, within 
gene bodies it is linked with gene expression (Lister et al, 2009). Within CpG 
poor regions, the majority of CpGs are methylated, but little is known about the 
significance of this. It has been suggested that methylation in this context 
provides genomic stability, for example in telomeres (Gonzalo et al, 2006), and 
DNMT3B mutation in the severe developmental disorder ICF syndrome, which 
is associated with hypomethylation of the centromeric regions and frequent 
cytogenetic alterations (Okano et al, 1999). 
1.3.3 Techniques for analysis of DNA methylation 
There are several techniques available to analyse DNA methylation, 
summarised in Table 1.4. At present, these are all based on one of three 
methods, namely, paired restriction enzyme isoschizomers, both of which 
recognise the same CpG-containing restriction site but with differing methylation 
sensitivities; antibodies to either 5’-methylcytidine or methyl-binding proteins to 
specifically pull down methylated DNA; or bisulfite conversion, which is 
considered the gold standard as it can be used to measure methylation at 
individual base resolution (Patterson et al, 2011). Bisulfite treatment converts 
unmethylated cytosine to uracil, which is subsequently amplified as thymine, 
whereas 5’ methylcytosine remains unchanged. Hence bisulfite conversion 
creates single nucleotide polymorphisms (SNPs) that reflect the underlying level 
of methylation originally present at each CpG site (Frommer et al, 1992). All 
these methods can be used to analyse specific regions of DNA to produce 
binary, semi-quantitative or fully quantitative results. All three techniques have 
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also been coupled with array platforms to assess CpG methylation on a 
“genome-wide” scale, although at present these technologies are not truly 
genome-wide and at most look at only 1-2% of the CpG sites.  
An example of a restriction digestion enzyme technique combined with an array 
that has been used to analyse AML is HELP, HpaII tiny fragment Enrichment by 
Ligation-mediated PCR. The restriction enzymes HpaII and MspI both recognise 
the restriction site 5’-CCGG-3’. HpaII only cleaves if the internal CpG within the 
restriction site is unmethylated, and MspI will cleave regardless of methylation 
status. Fragments of differing lengths are thus created by the restriction 
enzymes depending on the methylation status of the CpG sites, and this can 
then be analysed on an array (Khulan et al, 2006). One disadvantage of this 
technique is that it is limited to analysing CpG sites that are within the 5’-CCGG-
3’ recognition sequence.  
Antibodies to 5’-methylcytidine or methyl-binding proteins to specifically pull 
down methylated DNA followed by hybridisation with a tiling array have also 
been used, termed MeDIP, ChIP-chip or MBDCap (Cross et al, 1994; Rauch et 
al, 2006; Weber et al, 2005; Yalcin et al, 2013). Both MeDIP and MDBCap are 
subject to bias according to CpG density. MeDIP is based on 
immunoprecipitation of single-stranded DNA fragments, and as CpG-rich 
regions often remain double-stranded this favours the pull down of CpG-poor 
regions. In contrast, MBDCap has increased affinity for CpG-rich regions 
(Robinson et al, 2010). Enrichment-based techniques do not provide 
information at the single CpG level, and require statistical modification to 
account for differing CpG densities in different regions. Furthermore, they can 
be susceptible to measurement errors in cases with copy number variation.  
The Illumina Infinium Human Methylation array uses bisulfite-converted DNA 
that is whole genome amplified and hybridised to an array with 50mer probes 
targetting specific CpGs to quantify the methylation at those sites. The choice of 
CpG sites has been selected by a panel of experts, with most CpGs 
interrogated being in CGIs and shores (Bibikova et al, 2011; Bibikova et al, 
2009; Sandoval et al, 2011). Given that this methodology analyses single CpG 
sites, there is an assumption that differentially-methylated CpGs are   
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Table 1.4 Main methods of analysing DNA methylation 
 Sample treatment 
 Enzyme digestion 
Affinity 
enrichment 
Bisulfite 
conversion 
Regional analysis-
qualitative results 
HpaII-PCR MeDIP-PCR 
COBRA 
MSP 
Regional analysis- 
quantitative 
results 
MSRE-qPCR  
Pyrosequencing 
Sanger 
sequencing 
MALDI-TOF 
Array-based 
analysis 
HELP 
MeDIP 
ChIP-chip 
Illumina Infinium 
NGS-based 
analysis 
HELP-seq MeDIP-seq 
RRBS 
WGBS 
COBRA, combined bisulfite conversion and restriction assay; HELP, HpaII tiny 
fragment enrichment by ligation-mediated PCR; MALDI-TOF, matrix-assisted 
laser deionisation time-of flight analysis mass spectrometry; MeDIP, Methylated 
DNA immunoprecipitation; MSP, methylation specific PCR; MSRE-qPCR, 
methylation sensitive restriction enzyme and quantitative PCR; NGS, next 
generation sequencing; qPCR, quantitative PCR; RRBS, reduced 
representation bisulfite sequencing; seq, sequencing; WGBS, whole genome 
bisulfite sequencing. 
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representative of differentially-methylated regions, which are considered 
biologically the more important (Eckhardt et al, 2006). This technology is reliant 
on efficient bisulfite conversion for accurate quantification, however as a control 
for the conversion it does contain probes that interrogate non-CpG cytosines, 
which would be expected to be fully unmethylated and thus fully converted to 
thymine. Another issue is if the cytosine analysed is also the location of a C/T 
SNP, the array will not be able to differentiate between a T-containing allele and 
an unmethylated cytosine that had been converted to thymine by bisulfite 
conversion. This may be seen in up to 4% of the cytosines analysed (Price et al, 
2013).  
Studies published using these different techniques are difficult to compare 
directly with one another, as they generally analyse different CpG sites or, in the 
case of affinity-based methods, methylation levels in regions rather than single 
CpGs. It should also be noted that none of these approaches can differentiate 
hydroxymethylcytosine from 5-methylcytosine without additional steps being 
included in the protocols (Bhattacharyya et al, 2013), and hydroxymethylation is 
increasingly being recognised as biologically important due to the significant 
levels seen in the bodies of active genes in somatic tissues (Nestor et al, 2012). 
Furthermore, these array-based techniques do not interrogate cytosine 
methylation in a non-CpG context, which is rare in mammalian cells but does 
exist, particularly in embryonic stem cells (Ramsahoye et al, 2000; Ziller et al, 
2011). There are also important statistical considerations when analysing the 
array results from any of the platforms, for example, the methylation scale is 
finite and not normally distributed; and inter-array normalisation, such as that 
used for gene expression arrays, cannot be used as the overall amount of DNA 
methylation is different between samples (Aryee et al, 2011).  
1.3.4 Histone modification 
The DNA of eukaryotic cells is organised into higher order structures that can 
also have an impact on gene expression. Every 147 bases of DNA are wrapped 
around an octamer complex consisting of four different histones, H2A, H2B, H3 
and H4. These repeating units, known as nucleosomes, are attached to one 
another by the continuation of the DNA strands and also by H1 histone linkers. 
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The modification of histones is more complex than DNA, not only can the 
position of modification vary, but also there are a number of modifications that 
can occur, including methylation, acetylation, ubiquitination and 
phosphorylation. All these alterations can lead to changes in chromatin 
structure, and thereby affect gene expression.  
1.3.4.1 Lysine methylation by Polycomb proteins as an example of histone 
modifications 
The Polycomb and trithorax families of proteins were initially discovered in 
Drosophila as, respectively, repressors and activators of Hox genes that encode 
transcription factors specifying cell identity along the anteroposterior axis of 
segmented animals. Subsequently, they were shown to maintain the expression 
state of the Hox genes through modification of histones, not just in Drosophila 
but also in vertebrates (Schuettengruber et al, 2007). Two different complexes 
of Polycomb proteins are seen in humans. Polycomb repressive complex 2 
(PRC2) is comprised of EZH2, SUZ12, EED and RbAp46/48. EZH2 has been 
shown to catalyse the trimethylation of lysine 27 on histone 3 (H3K27me3), and 
deletion of the Drosophila homologue E(z) leads to absence of H3K27me3 (Cao 
et al, 2002). This trimethylation mark is recognised by the polycomb complex 
PRC1, which ubiquitinates histone H2A at lysine 119 (H2AK119ub) and leads to 
transcriptional repression by blocking the action of RNA polymerase (Wang et 
al, 2004). Using murine embryonic stem (ES) cells, Boyer et al (2006) showed 
that PRC1 and PRC2 complexes co-localise to nucleosomes with the 
H3K27me3 marks, and that this was associated with many genes important in 
development. Furthermore, three Polycomb target genes with low transcript 
levels in wild type ES cells had significantly increased transcript levels in ES 
cells deficient for Eed, a component of the PRC2.  
However, this is likely to be an oversimplification of transcriptional control by the 
polycomb proteins. For example, PRC2 and PRC1 do not always co-localise 
(Ku et al, 2008). Moreover, H3K27me3 is not always associated with repressed 
genes, and is sometimes found together with active histone marks such as 
H3K4me3 at so called bivalent domains (Young et al, 2011). 
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1.3.5 Interaction of histone modification and DNA methylation 
There is a tight link between histone regulation and DNA methylation, with one 
being able to impact on the other and vice versa. Confirmation of this 
connection has been seen in studies of how methylation marks are established 
in embryonic development. Recent evidence suggests that it may be histone 
marks that allow CGIs to remain unmethylated during the embryonic stage. In 
the proposed model, RNA polymerase II, which is located at actively transcribed 
regions of DNA, recruits histone methyltransferases, which in turn mediate the 
methylation of lysine 4 on histone 3 (H3K4) at these points (Guenther et al, 
2007). Usually DNMT3L binds to H3 to recruit DNMT3A and DNMT3B to allow 
de novo methylation of the associated DNA, however in regions where there is 
H3K4 methylation, DNMT3L is inhibited from binding and thus the underlying 
DNA remains unmethylated (Ooi et al, 2007). Indeed, it has been shown in 
many tissue types that the presence or absence of H3K4me is associated with 
the absence or presence respectively of DNA methylation (Meissner et al, 
2008). 
As well as histone marks directing the location of DNA methylation, it has been 
suggested that DNA methylation, which is maintained by DNMT1, serves as a 
“memory” for the chromatin structure, allowing it to reform when it has been 
disrupted, for example after cell replication. Chromatin immunoprecipitation 
studies have shown that unmethylated DNA tends to assemble in nucleosomes 
containing acetylated histones, whereas methylated DNA assembles in 
nucleosomes containing non-acetylated H3 and H4 and adopts a more compact 
heterochromatin conformation (Eden et al, 1998; Hashimshony et al, 2003). 
There is also evidence that either DNA methylation itself, or methylcytosine 
binding proteins such as MECP2 or MBD2, may direct or inhibit enzymes 
capable of histone modification. For example, DNA methylation directs H3K9 
methylation, a mark of repressive chromatin, through interaction of G9a and 
DNMT1 (Esteve et al, 2006). 
Further evidence of this link comes from comparison of the genome-wide 
distribution of histone methylation patterns and DNA methylation patterns 
(Meissner et al, 2008). For example, in ES cells regions with the repressive 
H3K27me3 are highly correlated with CGIs that develop DNA methylation as 
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the cells differentiate (Mohn et al, 2008). The relationship between the histone 
methylation mark and subsequent DNA methylation is considered to be through 
interacting enzymes, for example, G9a and EZH2, both of which catalyse 
histone methylation through SET domains, are responsible for recruiting the 
DNMTs from a separate domain. Thus mutations can occur in the SET domain 
of these enzymes that will affect the histone modification but not DNA 
methylation (Dong et al, 2008).  
1.3.6 Epigenetic changes in cancer 
When compared to the normal counterpart tissue, the cancer epigenome shows 
both global changes in chromatin structure and DNA methylation as well as 
local changes in specific regions. For example, the overall 5-methylcytosine 
content decreases in malignancy whereas some CGIs become aberrantly 
hypermethylated (Feinberg & Vogelstein, 1983; Gonzalez-Zulueta et al, 1995; 
Greger et al, 1989; Herman et al, 1994). Similarly, loss of H4 acetylation at 
lysine 16 and trimethylation at lysine 20 are also common hallmarks of 
malignancy (Fraga et al, 2005). Less is known about histone changes in 
malignancy due to the current limitations in analysing these changes on a 
genome-wide scale.  
1.3.6.1 The cancer methylome 
The lower level of DNA methylation seen in malignant cells compared to their 
normal counterpart cell is due to loss of methyl groups in repetitive DNA 
sequences and demethylation of coding regions and introns. In mouse models 
with progressive tumours, as the neoplasm progresses from a benign 
proliferation to an invasive cancer, the degree of hypomethylation increases 
(Fraga et al, 2004). It has been proposed that this generalised hypomethylation 
contributes to tumour development either by increasing chromosomal instability, 
which increases the risk of deletion or translocation of chromosomes (Eden et 
al, 2003), or by reactivation of transposable elements that had been silenced by 
methylation, or through loss of imprinting.  
In contrast, since the initial discovery of hypermethylation of the Rb promoter in 
retinoblastoma (Greger et al, 1989; Sakai et al, 1991), tumour-specific 
hypermethylated CGIs associated with inactive tumour suppressor genes have 
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been identified in several tumour types (Costello et al, 2000). However, when 
the methylome of a colorectal tumour was analysed, the regions showing the 
most differential methylation compared to normal colorectal tissue were located 
in the CpG shores, i.e. overlapping with the tissue-specific differentially 
methylated regions (Irizarry et al, 2009). 
Aberrant CGI hypermethylation in tumours was therefore proposed as an 
alternative to inactivating mutations of tumour suppressor genes. The sites of 
the aberrant hypermethylation often correspond to genes that are known to be 
mutated in that type of tumour. For example, the colorectal carcinoma cell line 
HCT116 has a heterozygous mutation in p16INK4A, the cyclin-dependent kinase 
inhibitor, and hypermethylation of the wild type allele, so that only the mutant 
allele is expressed. Transcription of the wild type allele can be restored by 
treatment with the demethylating agent 5-aza-2'-deoxycytidine (Myohanen et al, 
1998). Similarly, CEBPA, a gene that is commonly mutated in AML, has been 
shown to be hypermethylated in a subset of AML patients, although they had 
wild type CEBPA (Jost et al, 2009).  
However, studies of a prostate cancer cell line, PC3, found that many of the 
aberrantly hypermethylated genes were already silenced in the corresponding 
normal prostate epithelial cells (Gal-Yam et al, 2008). Comparison of gene 
expression and methylation data has now demonstrated this association in 
several other different cancer types, including AML (Sproul et al, 2012). This 
may explain the lack of correlation reported in many studies between gene 
expression and the corresponding methylome (Pike et al, 2008), suggesting that 
rather than aberrant DNA methylation being a result of selection pressure, it 
may be determined by a pre-programmed targeting mechanism. For example, 
some de novo methylated CGIs identified in embryonal carcinoma, embryonal 
stem cells and the colon tumour cell line, Caco-2, correspond to target sites for 
Polycomb protein binding (Ohm et al, 2007; Schlesinger et al, 2007).  
1.3.6.2 Interaction of epigenetic and genetic factors in cancer 
There are marked changes both in the genetic and epigenetic milieu in 
malignancy, but how they interact and influence one another is still being 
elucidated. Methylated cytosines are inherently prone to deamination to become 
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thymine, and this process has also been associated with many recurrent 
mutations seen in cancer, for example p53 mutations (Rideout et al, 1990). 
However, although epigenetic modifiers are enzymes that are either involved in 
creating the epigenetic code, e.g. methyltransferases, or proteins that interpret 
the epigenetic code to affect further change, e.g. methyl binding proteins, and 
are encoded by genes that are recurrently mutated in several malignancies, the 
mutations do not necessarily lead to the expected epigenetic changes. For 
example, mutations in DNMT3A found in AML may be expected to lead to very 
marked changes in the methylation status of malignant cells, but one study 
showed no difference in global methylation levels in AML samples with and 
without DNMT3A mutations, and another only showed a small, albeit significant, 
reduction in methylation in samples with the most common DNMT3A mutation, 
R882 (Ley et al, 2010; Russler-Germain et al, 2014). However, both studies 
demonstrated specific regions with differential methylation between AML 
samples with and without DNMT3A mutations. Hence, inactivating mutations in 
DNMT3A do not disturb the methylome as much as would be expected given its 
role in methylation maintenance.  
Thus, despite malignancies displaying aberrant DNA methylation and histone 
modifications characteristic of the type and subtype of cancer (Costello et al, 
2000; Esteller et al, 2001), the role of these epigenetic changes remains 
unclear. Nevertheless, an improved understanding of these changes is 
important and relevant to clinical practice as their potential reversibility makes 
them an attractive therapeutic target.  
 
1.4 Aims of this thesis 
The preliminary aim of the studies reported in this thesis was to investigate 
whether genome-wide alterations in the epigenetic make-up of patients with 
AML could provide additional information in predicting response to treatment, 
and whether this could be used to refine the current prognostic classification. 
Samples from two highly selected cohorts of patients with chemosensitive and 
chemoresistant disease were first interrogated to assess whether there were 
differences in methylation between the two groups (chapter 3). The results of 
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this array are explored further with particular reference to the underlying CEBPA 
genotype. The different types of CEBPA mutations and their methylation 
patterns are examined in chapter 4, and data is presented looking specifically at 
methylation of the CEBPA promoter region. In addition, patient samples were 
screened for mutations in the epigenetic modifier ASXL1 and the prognostic 
impact determined in cohorts stratified according to age and disease status 
(Chapter 5).  
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CHAPTER 2:MATERIALS AND METHODS 
2.1 Molecular Biology 
2.1.1 Reagents 
Acetonitrile (VWR International Ltd., Lutterworth, UK) 
Agar (Sigma-Aldrich Company Ltd., Poole, UK)  
Agarose (Bioline, London, UK) 
BIOTAQ™ DNA polymerase (Bioline, London, UK) 
BIOTAQ™ DNA polymerase buffer and magnesium chloride (Bioline, 
London, UK) 
Boric acid (VWR International Ltd., Lutterworth, UK) 
Bromophenol blue (Merck, Frankfurt, Germany)  
Carbenicillin (Melford Laboratories Ltd., Ipswich, UK) 
Dimethylformamide (Sigma-Aldrich Company Ltd., Poole, UK) 
Dimethyl sulfoxide (DMSO) (Sigma-Aldrich Company Ltd., Poole, UK) 
dNTPs (Bioline, London, UK) 
Ethylenediamine tetraacetic acid disodium salt (EDTA) (VWR International 
Ltd., Lutterworth, UK) 
Ethidium bromide (Sigma-Aldrich Company Ltd., Poole, UK) 
Glycerol (VWR International Ltd., Lutterworth, UK) 
GoTaq® DNA polymerase (Promega, Madison, USA) 
GoTaq® Colourless Flexi reaction buffer and magnesium chloride 
(Promega, Madison, USA) 
Luria-Bertani (LB) broth capsules (MP Biomedicals, London, UK) 
One Shot® Max Efficiency® DH5α-T1 competent E. coli (Invitrogen Life 
Technologies, Paisley, UK) 
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Optimase® DNA Polymerase (Transgenomic Ltd, Glasgow, UK) 
Optimase® Buffer and Magnesium Chloride (Transgenomic Ltd, Glasgow, 
UK) 
peqGOLD MicroSpin Cycle-Pure PCR Purification Kit (Peqlab, Salisbury, 
UK) 
Phusion® Hot Start High-Fidelity DNA Polymerase (New England Biolabs 
UK Ltd., Hitchin, UK) 
Phusion® HF buffer (New England Biolabs UK Ltd., Hitchin, UK) 
Primers, unlabelled (Integrated DNA Technologies, Leuven, Belgium) 
QIAquick PCR Purification kit (QIAGEN, Crawley, UK) 
Restriction enzymes and buffers (New England Biolabs UK Ltd., Hitchin, 
UK) 
Super optimal broth with catabolite repression (S.O.C.) (Invitrogen Life 
Technologies, Paisley, UK) 
TOPO® cloning kit (Invitrogen Life Technologies, Paisley, UK) 
Tri-ethylene ammonium acetate (TEAA) (Transgenomic Ltd., Glasgow, UK) 
Tris base (Tris(hydroxymethyl)aminomethane) (VWR International Ltd., 
Lutterworth, UK)  
WellRED oligos (Sigma-Aldrich Company Ltd., Poole, UK) 
X-Gal (Invitrogen Life Technologies, Paisley, UK) 
2.1.2 Polymerase Chain Reaction (PCR) 
PCR was used to amplify specific regions of genomic DNA. It required 
addition of short oligonucleotide primers complementary to either end of 
the region of interest, to polymerase enzyme, nucleotides and appropriate 
buffers. A mastermix of this was created and an aliquot added to each 
DNA sample to be analysed. These mixtures were then subjected to 
successive cycles of 3 different temperatures to allow denaturation of the 
template DNA, annealing of the primers, and extension of newly formed 
DNA strands respectively.  A negative control (water added instead of 
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DNA) was included with each PCR, to ensure there was no contamination 
of the master mix. Four different DNA polymerase enzymes were used in 
this work.  
BIOTAQ™ DNA polymerase (Bioline, London, UK) was used when 
experiments did not require a hot start or proof reading polymerase, or if 
the PCR product was to be cloned. A standard master mix comprised 1x 
manufacturer’s buffer, 1.5mM MgCl2, 200µM each dNTP, 0.5 µM each 
primer, and 0.5 units of polymerase, to which 30ng of DNA was added, 
total volume 20µl. The mixture was then subjected to 35 cycles of 
denaturation at 95°C for 30 seconds, an annealing step at a temperature 
appropriate to the primers for 30 seconds, and an extension at 72°C for 
30 seconds, followed by a final extension of 72°C for 5 minutes. 
Conditions for the other three DNA polymerases are given in the 
appropriate sections. GoTaq® Hot Start polymerase (Promega, 
Wisconsin, USA) was used for amplification of bisulfite-converted DNA, as 
it has improved specificity compared to non-hotstart enzymes. Optimase® 
polymerase (Transgenomic Ltd., Glasgow, UK) was used for PCR of 
samples to be analysed on the WAVE platform, as this enzyme has 3’-5’ 
exonuclease proofreading capabilities necessary for high-fidelity 
amplification. If samples were not successfully amplified with BIOTAQ™ or 
Optimase®, then Phusion® Hot Start High Fidelity DNA polymerase (New 
England Biolabs, Hitchin, UK) was used as an alternative.   
2.1.3 Agarose gel electrophoresis 
Buffers 
10x TBE: 108.9g Tris base, 55.7g boric acid and 7.4g EDTA in 1 litre of 
ddH2O 
5x Loading buffer: 30% glycerol and 0.025% bromophenol blue in 1x 
TBE 
Agarose gel electrophoresis was used to detect and assess the quality of 
the PCR products and to ensure the negative control was as expected. It 
was also used to detect fragments of different sizes if a digest had been 
performed. Agarose (1-2g according to the percentage of gel required) 
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was dissolved in 50ml of 1xTBE by heating. Once the solution had cooled 
slightly, 5µl of 1mg/ml ethidium bromide was added and the gel poured 
into the mould, with combs inserted to create wells. Once set, the gel was 
covered in 1xTBE running buffer containing ethidium bromide (0.01µg/ml) 
and the combs removed. An aliquot (5-10µl) of product was mixed with 
loading buffer and pipetted into each well. Samples were electrophoresed 
at a current of approximately 70mA for 5-30 minutes. Fragments were 
detected by UV illumination and recorded in a digital photograph.  
2.1.4 Screening for mutations using dHPLC 
Denaturing high performance liquid chromatography (dHPLC) using the 
WAVE® platform is a fast, sensitive method of screening a large number 
of samples for nucleotide substitutions, insertions or deletions. It requires 
the presence of heteroduplexes and relies on the different chemical and 
physical properties of heteroduplexes and homoduplexes. DNA template 
(30ng) was amplified using Optimase® DNA polymerase in an Optimase® 
master mix containing 1x manufacturer’s buffer, 1.5mM MgSO4, 200µM 
each dNTP, 0.5 µM each oligonucleotide primer, 0.5U of Optimase® 
polymerase and sterile ddH2O to make up to 20µl. The mixture was 
subjected to an initial denaturation step of 95°C for 5 minutes followed by 
35 cycles of denaturation at 95°C for 45 seconds, a 45 second annealing 
step at a temperature that was dependent on the primers and a 45 second 
extension step at 72°C, and then a final extension step of 72°C for 15 
minutes. If no products were produced with Optimase®, a PCR using 
Phusion Hot Start High Fidelity DNA polymerase (0.2U per reaction) was 
performed using a master mix of 1x manufacturer’s HF buffer, 0.2U 
polymerase and the same concentration of primers, dNTPs and 
magnesium as for the Optimase PCR. Cycling conditions in this case were 
an initial denaturation step of 98°C for 2 minutes followed by 35 cycles of 
denaturation at 98°C for 42 seconds, annealing at the appropriate 
temperature for 42 seconds and extension at 72°C for 42 seconds and 
then a final extension step at 72°C for 15 minutes.  
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PCR products to be analysed were mixed with known wild-type PCR 
product in a ratio of approximately 4:1, as estimated visually from the 
agarose gel. The PCR mixes were denatured by incubating at 95°C for 5 
minutes and then slowly cooled using 40 cycles, each of one minute, 
starting at 92°C and gradually decreasing the temperature by 1.5°C for 
each subsequent cycle, to allow random reannealing of PCR strands. 
Thus if a mutation was present, even if it was homozygous, the mix would 
now contain both heteroduplexes and homoduplexes. The samples were 
individually injected through a polystyrene-divinyl benzene copolymer DNA 
separation column located in an oven at the temperature required for 
analysis. This was calculated by the Navigator™ software and was 
dependent on the sequence and length of the PCR product. Temperatures 
were chosen so that the sequence of interest was 50-95% helical. Where 
necessary, the same sample was analysed at two or three different 
temperatures to account for sequence domains of differing helicity across 
the amplicon. TEAA acts as an ion-pairing agent and allowed the PCR 
products to bind to the column. Over the course of a run, the concentration 
of ACN in the buffer flowing through the column was increased and the 
resulting change in pH decreased the effectiveness of the TEAA as an ion-
pairing agent. Heteroduplexes, due to the mismatch in paired DNA 
strands, bound less strongly to the column and thus were eluted from the 
column before homoduplexes. The products released were detected by a 
UV detector measuring the absorbance at 260nm and this was recorded 
by the software in real time by a peak on the chromatogram. For a mixture 
of heteroduplexes and homoduplexes, this would be seen by a minimum 
of two peaks, whereas a wildtype sample would only have a single 
homoduplex peak.   
2.1.5 Restriction Enzyme Digestion 
Digestion of PCR products using restriction enzymes was performed 
according to manufacturer’s instructions. PCR product (4-8µl) was added 
to 1x appropriate buffer, 10U restriction enzyme, 100pg bovine serum 
albumin if required and ddH20 in a total volume of 10µl. This was then 
incubated at 37°C or 60°C for 2-16 hours depending on the enzyme used. 
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The products were either analysed by agarose gel electrophoresis with the 
appropriate DNA ladder (Bioline, London, UK) to estimate fragment size, 
or on the Beckman Coulter CEQ™ 8000 DNA Genetic Analysis System 
(Beckman Coulter UK Ltd., Buckinghamshire, UK) if quantification of the 
fragments was required.  
2.1.6 DNA sequencing 
PCR products were purified using either QIAquick PCR Purification kit 
(QIAGEN, Crawley, UK) or peqGold microspin cycle pure kit (Peqlab, 
Southampton, UK) according to the manufacturer’s instructions and then 
sent to the UCL Cancer Institute Scientific Support Service for direct 
nucleotide sequencing. 
2.1.7 Fragment analysis of PCR and restriction enzyme digestion 
products 
Fragment analysis was used to either detect products of varying lengths 
that were not adequately separated on an agarose gel, or to quantify the 
relative amount of multiple products generated by PCR or following 
restriction enzyme digestion. A BIOTAQ™ PCR was performed using one 
fluorescently labelled primer and one unlabelled primer. Standard PCR 
conditions were used (see section 1.1.2) but with only 5pmols of primers 
and fewer cycles in order to prevent saturation of the fluorescence 
detector and reduce heteroduplex formation. If required, PCR products 
were then subject to restriction enzyme digestion.  
PCR product or digest (2µl) was added to 37.75µl formamide sample 
loading solution and 0.25µl DNA Size Standard 600 (Beckman Coulter, 
High Wycombe, UK) and fragments size-separated by capillary 
electrophoresis on the Beckman Coulter CEQ™ 8000 DNA Genetic 
Analysis System (Beckman Coulter UK Ltd., High Wycombe, UK). 
Fragment size was estimated by the instruments’ software based on 
elution time with reference to the size standards, and the relative amount 
of each product calculated using the area under the peak as a proportion 
of the total area under all peaks. 
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2.1.8 LB Broth and agar plates 
LB broth: 6 LB capsules in 250ml ddH2O 
LB agar plates: 12 LB capsules and 7.5g agar in 500ml ddH2O 
The broth and agar mixtures were autoclaved and allowed to cool to 50°C 
before adding carbenicillin to a final concentration of 100µg/ml. Plates were 
then poured and left to set. Prior to use, plates were spread with 40µl of 
40mg/ml X-gal in dimethylformamide and incubated at 37°C for a minimum 
of 30 minutes.  
2.1.9 TOPO® TA cloning of PCR products 
The TOPO® TA Cloning Kit with One Shot® MAX Efficiency® DH5α-T1R 
E.coli (Invitrogen Life Technologies, Paisley, UK) was used for cloning. 
Fresh PCR products were prepared using the non-proof reading 
polymerase BIOTAQ as this adds a single deoxyadenosine to the 3’ end of 
the PCR product, and 1-2µl incubated at room temperature for 5 minutes 
with 1µl linearised pCR 2.1-TOPO vector and 1µl salt solution in a total 
volume of 6µl. The vector can ligate the PCR product as it has a single 3’ 
thymidine overhang, and has topoisomerase I covalently bound to 
catalyse the reaction. Ligation reaction (1µl) was added to one vial of 
thawed One Shot® Max Efficiency® DH5α- T1E.coli cells and incubated 
on ice for 30 minutes. The cells were then heat-shocked at 42°C for 30 
seconds; 250µl of SOC medium was added and the mix incubated in a 
shaking incubator at 37°C for 1 hour. An aliquot of 80µl of the transformed 
bacteria was mixed with 20µl SOC medium, spread on an LB agar plate 
(see section 2.1.8) and then incubated at 37°C overnight to allow colony 
formation.  
The pCR 2.1-TOPO vector contains a LacZα gene which can hydrolyse X-
gal leading to the formation of blue bacterial colonies. However, if a PCR 
product has been inserted into the vector, this disrupts the gene leading to 
white bacterial colonies. White colonies were therefore plucked, seeded 
into 200µl LB broth containing carbenicillin in a 96 well plate, and 
incubated at 37°C overnight. The individual bacterial cultures were then 
used as template for PCR amplification using standard conditions but with 
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an initial step of 95°C for 2 minutes to lyse the cells and inactivate 
nucleases. 
2.2 Analysis of DNA methylation 
Bisulfite conversion was the chosen method to detect DNA methylation as 
this can be used for quantification at the single CpG level (see chapter 1, 
section 1.3.3). 
2.2.1 Reagents 
EZ DNA Methylation-Gold Kit™ (Zymo Research, California, USA) 
PyroMark Binding Buffer 
PyroMark Wash Buffer 
Pyromark Annealing Buffer 
Sodium Hydroxide Solution 
Ethanol 
Streptavidin Beads 
PyroMark Gold Q96 Reagents 
 
2.2.2 Bisulfite conversion of DNA 
Sodium bisulfite treatment of DNA leads to deamination of non-methylated 
cytosines to form uracil, which is amplified as thymine by downstream 
techniques such as PCR (Frommer et al, 1992; Hayatsu et al, 1970), 
whereas methylated cytosines are “protected” from deamination and thus 
remain as cytosines (Figure 2.1). The proportion of cytosines compared to 
the total number of cytosines and thymines at a particular site can 
therefore provide a surrogate marker for the level of methylation.  
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Figure 2.1 Chemical effect of bisulfite treatment on cytosine and 5’ 
methylcytosine. 
 
Using the EZ DNA methylation-gold kit, 350-500ng DNA in 20µl water was 
added to 130µl CT conversion agent, mixed and incubated at 50°C for 16 
hours, with a denaturation step of 95°C for 30 seconds at the beginning of 
every hour. The periodic cycling has been suggested as an alternative 
incubation to the manufacturer’s recommendations as it improves 
conversion efficiency (Thirlwell et al, 2010). After conversion, the samples 
were purified according to manufacturer’s instructions using the buffers 
and Zymo-Spin™ IC columns provided in the kit. The bisulfite-converted 
DNA was eluted into 10-20µl elution buffer depending on the type of 
downstream analysis planned. 
2.2.3 Methylation-Specific PCR to check conversion efficiency 
To check for efficiency of conversion, several samples were randomly 
selected from each converted batch and subjected to methylation-specific 
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PCR by performing two PCRs of the HLA-B gene for each sample, one 
using primers that would only amplify bisulfite-converted DNA and the 
other using primers that would only amplify unconverted DNA (Appendix 
1). For each PCR, 1µl converted DNA was added to 1x manufacturer’s 
buffer, 25pmols each primer, 200µM dNTPs, 1U GoTaq DNA polymerase 
(Promega, USA) and 3mM MgCl2 in 25µl total volume. An initial 
denaturation step of 95°C for 6 minutes was followed by 36 cycles of PCR, 
each of 94°C for 30 seconds, annealing temperature for 30 seconds and 
72°C for 90 seconds, with 2 cycles at annealing temperatures of 60oC, 
59oC and 58oC, then 30 cycles at 57°C, followed by a final extension step 
of 72°C for 15 minutes. PCR products were then run on a 2% agarose gel. 
Samples were considered to be successfully bisulfite-converted if they had 
a PCR product with the primers for bisulfite-converted DNA but no product 
with the primers for unconverted DNA. 
2.2.4 Pyrosequencing 
Pyrosequencing is a method of sequencing short regions of DNA. Single-
stranded PCR product acts as a template to which nucleic acids are added 
sequentially in a pre-defined order to create a complementary DNA strand. 
If the nucleotide added is incorporated into the newly forming DNA strand, 
it releases pyrophosphate, which sets off a cascade of enzymatic 
reactions culminating in the release of light proportional to the number of 
nucleotides added.  
Pyrosequencing assays to interrogate specific CpG sites were designed 
using the PyroMark Assay Design Software 2.0 (Qiagen, Germany). PCRs 
were performed using a master mix of 1.25U GoTaq DNA polymerase, 
one biotin-labelled and one unlabelled primer each at 0.2 µM, 1x 
manufacturer’s buffer, 3.5mM MgCl2 and 200µM of each dNTP, to which 
25ng DNA was added and the final volume made to 20µl by the addition of 
ddH2O. The mixtures were denatured at 95°C for 5 minutes then subjected 
to 50 cycles of denaturation at 95°C for 30 seconds, annealing at the 
appropriate temperature for 30 seconds and an extension step of 72°C for 
45 seconds, then a final extension step at 72°C for 15 minutes. Fifty cycles 
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of amplification were necessary to ensure that all biotinylated primers were 
incorporated into PCR products. The presence of PCR products and 
absence of primer bands was checked by agarose gel electrophoresis, 
then 5-15µl aliquots were mixed with streptavidin beads to bind the biotin-
labelled products. Using the PyroMark Q96 Vacuum Prep Tool, the beads 
were captured and treated with ethanol, then sodium hydroxide to 
denature the DNA and leave only the bound single-stranded biotin-labelled 
PCR product, and finally washed. The beads were dispensed into a 
pyrosequencing plate containing the appropriate sequencing primer, 
heated to 85°C, cooled to allow binding of the primer to the template and 
analysed on the PyroMark Q96 MD Pyrosequencer (Qiagen, Germany) 
using the Pyromark Gold Q96 enzyme, substrate mixes and nucleotides. 
Results of the analysis were displayed as a pyrogram, which shows the 
order in which the nucleotides were added into the mixture and the 
amount of light released for each nucleotide added, with the peak height 
for each nucleotide thus proportional to the number of nucleotides 
incorporated.  
Each pyrogram was assessed by the software for three parameters. At 
least five non-CpG nucleotides were quantified to ensure that the peak 
heights were as expected for the number of nucleotides incorporated; a 
background (negative) control was checked for the absence of nucleotide 
incorporation; and quantification of a non-CpG C (or G if the 
complementary strand was being analysed) was checked for complete 
conversion to T (or A). If these parameters were satisfactory, the 
proportion of methylated alleles at the CpG site of interest was calculated. 
The C and T (or G and A) peak heights at the specified CpG site were 
summed to ensure that they were equivalent to the expected number of 
nucleotides incorporated, and the proportion of methylated alleles was 
calculated by the Pyro-Q-CpG software based on the relative peak heights 
of the pyrogram for the C and T (or G and A) nucleotides at that site.  
For each assay, four negative controls were analysed to ensure that the 
template or primers did not give any background signal. These were 
respectively adding (i) sequencing primer alone without PCR product, (ii) 
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biotin-labelled primer alone, (iii) sequencing and biotin-labelled primers, 
and (iv) PCR product alone. In addition, for each PCR run, the negative 
water control from the PCR was included to ensure there was no 
contamination. All samples were analysed in duplicate using fresh PCRs 
and run on separate occasions. The mean methylation level was 
calculated and expressed as a percentage of total alleles.  
Prior to assessing patient samples, the accuracy, precision and sensitivity 
of the methylation quantification for each assay was analysed using DNA 
mixtures with varying proportions of fully unmethylated and fully 
methylated DNA. These mixes were then bisulfite-converted and assayed. 
Initially, whole genome amplified DNA was used as the fully unmethylated 
control (provided by Dr Andy Feber, UCL Cancer Institute, UK), and DNA 
treated with the methyltransferase enzyme SssI (New England Biolabs, 
USA) as the fully methylated control DNA. However this did not always 
provide accurate mixes for the regions of interest, and therefore the 
Epitect Control DNA set (Qiagen, Crawley, UK) containing bisulfite-
converted fully methylated and unmethylated DNA was used to test some 
assays.  
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CHAPTER 3:ASSOCIATION OF CEBPA GENOTYPE 
WITH METHYLATION PATTERNS IN AML 
3.1 Introduction 
There has been an increasing number of recurrent mutations identified in AML, 
some of which have been shown to have prognostic impact (as discussed in 
Chapter 1). A two-hit model proposed by Kelly and Gilliland (2002) suggested 
that for AML to occur, two genetic hits were required, one that led to 
uncontrolled proliferation and the other a block in differentiation. One of the first 
genes identified to lead to a block in differentiation when mutated was CEBPA. 
3.1.1 CEBPA structure and function 
CCAAT/enhancer-binding protein alpha, C/EBPα, is coded for by the intronless 
CEBPA gene located on chromosome 19q. It is a member of the C/EBP family 
of basic leucine zipper transcription factors. The full length 42kDa protein has 
358 amino acids with several functional regions including two transactivation 
domains, a DNA binding domain (DBD) and leucine zipper domain (LZD) 
(Figure 3.1). C/EBPα dimerises with either another C/EBPα molecule or a 
different member of the C/EBP family, mediated through an α-helix within the 
LZD, to form a coiled-coil structure which is necessary for its function. The DBD 
recognises CCAAT motifs in the promoters of downstream target genes. An 
internal ATG start site exists in the CEBPA mRNA and translation from this 
leads to a truncated p30 isoform that lacks the initial transactivation domain. It 
has been shown that the p30 protein has reduced transactivation potential when 
compared to the p42 protein (Pabst et al, 2001b). C/EBPα is widely expressed 
in normal tissue, and at high levels in terminally differentiated liver and adipose 
cells. Within myeloid cells, the expression of C/EBPα is relatively high in early 
myeloid progenitors and decreases during granulocytic differentiation (Scott et 
al, 1992). The p30 protein is also expressed in liver and adipose cells and the 
ratio of p42 to p30 isoform expression is tightly regulated by upstream signalling 
pathways (Calkhoven et al, 2000). 
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Figure 3.1 Structure and functional domains of C/EBPα There are two transactivation domains (TAD1 and TAD2), a DNA 
binding domain (DBD) and a leucine zipper domain (LZD). The translational start sites for the p42 and p30 proteins are shown. 
Amino acid (aa) and nucleotide (nt) numbering are indicated above and below the diagram. Adapted from Mueller and Pabst 
(2006). 
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C/EBPα plays an important role in both hepatocyte and adipocyte development 
(Ramji & Foka, 2002). Mice that are homozygous for deletion of the entire 
C/ebpα-coding sequence die in the immediate post-natal period due to severe 
hypoglycaemia, caused by an inability of the mice to store glycogen in the liver 
(Wang et al, 1995). C/ebpα-null mice also lack white adipose tissue. Within the 
myeloid lineage, absence of mature neutrophils and eosinophils has been 
observed in null mice, with a corresponding increase in myeloid blasts (Zhang 
et al, 1997). Further work using conditional knock-out mice demonstrated that 
disruption of C/ebpα blocks the transition of common myeloid progenitors to 
granulocyte/ monocyte progenitors, but not further differentiation (Zhang et al, 
2004).  
As a transcription factor, C/EBPα binds to DNA at the CCAAT sequence found 
in the promoters of several genes including those encoding growth factor 
receptors, for example, the receptor for granulocyte colony-stimulating factor, 
and secondary granule proteins such as lactoferrin (Koschmieder et al, 2009). 
However, C/EBPα has also been shown to have inhibitory functions which 
prevent cell proliferation, for example, by binding directly to other proteins such 
as the cdk2 and cdk4 enzymes, which are cyclin-dependent kinases important 
in cell cycle regulation (Wang et al, 2001), or by blocking the action of the E2F 
complex and thereby inhibiting cell cycling (Porse et al, 2001; Slomiany et al, 
2000). C/EBPα can also negatively regulate c-Myc through this mechanism, 
allowing early myeloid precursors to enter the differentiation pathway (Johansen 
et al, 2001). 
3.1.2 CEBPA mutations in AML 
Due to the importance of C/EBPα in granulocyte development and the absence 
of mature granulocytes in Cebpa-null mice, Pabst et al (2001b) screened the 
CEBPA gene in samples from 137 patients with AML and found that it was 
mutated in 7% of cases. Since this initial study, several groups have also shown 
that CEBPA is recurrently mutated in AML, with an overall mutation rate of 10% 
(Table 3.1). The location and type of mutations are non-random, with the 
majority of mutations falling into one of two categories. Most of the mutations at  
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Table 3.1 Published studies investigating incidence and impact of CEBPA mutations in patients with AML. 
Reference 
Total 
no. of 
patients 
CEBPA
MUT
 
(%) 
CEBPA
SM 
(% of 
CEBPA
MUT
) 
CEBPA
DM
  
(% of 
CEBPA
MUT
) 
Prognostic impact of mutant 
compared to wild-type CEBPA 
Notes 
Pabst et al (2001b) 137 9 (7) 8 (89) 1 (10) n/a  
Gombart et al (2002) 78 6 (8) 5 (83) 1 (17) n/a  
Preudhomme et al (2002)* 135 15 (11) 7 (47) 8 (53) 
OS improved in univariate and 
multivariate analysis 
 
Barjesteh van Waalwijk van 
Doorn-Khosrovani et al 
(2003) 
277 12 (4) 0 (0) 12 (100) 
OS improved in univariate and 
multivariate analysis 
N terminus only examined if 
C terminus had mutation 
present 
Snaddon et al (2003) 99 8 (8) 6 (75) 2 (25) No difference  
Frohling et al (2004)* 236 33 (14) 18 (55) 15 (45) 
OS increased in univariate and 
multivariate analysis 
 
Bienz et al (2005)* 67 12 (18) 5 (42) 7 (58) 
OS increased in univariate and 
multivariate analysis 
50% of CEBPA
MUT
 had 
aberrant CD7 expression 
Lin et al (2005) 104 16 (15) 2 (12) 14 (88) 
Trend for longer CR (19 months vs 
9 P=0.2) 
Higher levels of CD7, 
CD15, CD34, and HLA-DR 
expression in CEBPA
MUT 
Frohling et al (2005)* 166 17 (10) 2 (12) 15 (88)  
Included 41 del(9q) AML 
samples
 
Shih et al (2006) 149 22 (15) 2 (9) 20 (91)   
Fuchs et al (2008) 152 14 (9) 11 (79) 3 (21)   
Juhl-Christensen et al (2008) 485 20 (4) 15 (75) 5 (25)   
Benthaus et al (2008) 469 38 (8) 18 (47) 20 (53)  CN-AML 
Marcucci et al (2008) 175 32 (18) 18 (56) 14 (44) 
OS increased in univariate and 
multivariate analysis 
CN-AML 
Wouters et al (2009)* 598 41 (7) 13 (32) 28 (68) 
OS increased in univariate and 
multivariate analysis for CEBPA
DM 
only 
CEBPA
DM
 had distinct gene 
expression profile 
Renneville et al (2009) 638 53 (8) 29 (55) 24 (45) 
CEBPA
DM
 had trend towards better 
survival over CEBPA
SM
. CEBPA
MUT
 
better OS if FLT3-ITD neg 
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Table 3.1 Continued 
Reference 
Total 
no. of 
patients 
CEBPA
MUT
 
(%) 
CEBPA
SM 
(% of 
CEBPA
MUT
) 
CEBPA
DM
  
(% of 
CEBPA
MUT
) 
Prognostic impact of mutant 
compared to wild-type CEBPA 
Notes 
Pabst et al (2009) 224 19 (8) 7 (37) 12 (63) 
OS increased in univariate and 
multivariate analysis for CEBPA
DM 
only 
 
Hou et al (2009) 543 71 (13) 24 (34) 47 (66) 
OS increased in univariate and 
multivariate analysis for CEBPA
DM 
only 
 
Dufour et al (2010)* 467 38 (8) 18 (47) 20 (53) 
OS increased in univariate and 
multivariate analysis for CEBPA
DM 
only 
CN-AML 
 
Green et al (2010b) 1427 107 (7) 48 (45) 59 (55) 
OS increased in univariate and 
multivariate analysis for CEBPA
DM 
only 
 
Taskesen et al (2011) 1182 151 (13) 60 (40) 91 (60) 
OS increased in univariate analysis 
for CEBPA
MUT
 and multivariate 
analysis for CEBPA
DM 
only 
CN-AML 
 
Dufour et al (2012) 663 59 (9) 28 (47) 31 (53) 
CEBPA
SM
 associated with a good 
prognosis in NPM1
MUT
 subgroup 
 
Fasan et al (2014) 2296 244 (11) 140 (57) 104 (43) 
CEBPA
DM 
associated with good 
prognosis in univariate and 
multivariate analysis 
 
TOTAL 9098 881 (10) 420 (48) 461 (52)   
*These studies are excluded from total numbers as subsequent studies included the same patients 
Abbreviations, CN-AML, Cytogenetically normal AML; CR, complete remission; OS overall survival.
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the N terminus are nonsense or frameshift mutations, hereafter called “classic N 
mutations”, and are predicted to lead to absence of the full-length p42 C/EBPα 
protein but, as they occur upstream of the internal start site, retain p30 isoform 
expression. At the C terminus, in-frame insertions or deletions in the DBD or 
LZD predominate, which are presumed to disrupt DNA binding or C/EBPα 
dimerisation, hereafter termed “classic C mutations”. Approximately 50% of the 
patients with CEBPA mutations have two mutations, CEBPA double mutant 
(CEBPADM) (Green et al, 2010b). In most cases this consists of a classic N 
mutation on one allele and a classic C mutation on the other allele, i.e. biallelic, 
hereafter named a classic double mutation, which does not produce any fully 
functional C/EBP but retains p30 expression. 
When considering the impact of CEBPA status on outcome, initially all mutated 
CEBPA (CEBPAMUT) cases were considered together, and they were shown to 
have a more favourable outcome than CEBPAWT cases (Table 3.1). However, 
more recent studies have indicated that the favourable outcome is restricted to 
CEBPADM and in most studies the outcome for patients with a single CEBPA 
mutation, CEBPASM, is more similar to patients who are CEBPAWT (Dufour et al, 
2010; Green et al, 2010b; Hou et al, 2009; Wouters et al, 2009). These findings 
have led to suggestions that patients with AML who have CEBPADM at 
diagnosis should be considered in the favourable prognostic category, and 
therefore should not be recommended for a stem cell transplant in first 
remission as the risks would outweigh the benefits (Cornelissen et al, 2012). 
Furthermore, studies which have analysed CEBPADM separately from CEBPASM 
have confirmed that CEBPADM have other characteristics that are distinct from 
both CEBPAWT and CEBPASM. For example, the rate of co-incidence of other 
mutations differs as both NPM1 and FLT3/ITD mutations are inversely 
correlated with CEBPADM but not CEBPASM (Green et al, 2010b), and CEBPADM 
samples have a distinct gene expression profile (Dufour et al, 2010; van Vliet et 
al, 2013; Wouters et al, 2009) and DNA methylation profile (Figueroa et al, 
2010b). 
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3.1.3 Types of CEBPA mutations 
Although the majority of CEBPADM have a frameshift mutation in the N terminus 
of one allele and an in-frame insertion or deletion in the C terminus of the other 
allele, approximately one quarter of patients with CEBPADM have either non-
classical mutations or a non-classical combination of mutations (Table 3.2). All 
CEBPADM are included in published studies that look at outcome and thus are 
considered as favourable prognostic alterations, however there is no definitive 
evidence that this is the case for non-classical CEBPADM. The non-classical 
mutations are too few in number and also too varied to truly assess their impact 
on outcome compared to other AML samples.  
In vitro functional studies of CEBPA mutations have included transactivation 
(TA) assays, which assess the ability of C/EBP to bind and activate target 
promoters by coupling the promoters to luciferase assays. Insertion of a single 
classic N or classic C mutant CEBPA construct led to a reduction in TA activity 
compared to wild-type (Gombart et al, 2002; Kato et al, 2011; Pabst et al, 
2001b). Furthermore, when both a classic N and classic C construct were 
transfected simultaneously, to mimic a classic double mutant case, this led to a 
marked reduction of TA activity to the equivalent of vector alone (Pabst et al, 
2009). However, only one of these studies investigated three non-classical 
mutations. Pabst et al (2001b) showed that a missense mutation in the N 
terminus led to the same TA activity as the wild-type construct, a frameshift in 
the C terminus (V351fs) caused a decrease in TA activity, whereas a frameshift 
in the middle of the gene (R165fs) resulted in an increase in TA activity when 
compared to wild-type.  
Several groups have explored the effects of classical CEBPA mutations in 
mouse models. Bereshchenko et al (2009) competitively transplanted fetal liver 
cells from knock-in mice with wild-type, homozygous classic N, homozygous 
classic C or  classic double compound heterozygous mutations into sublethally 
irradiated mice together with wild-type competitor bone marrow cells. All mice 
that were transplanted with mutant cebpa developed leukaemia. Kato et al 
(2011) transduced murine bone marrow mononuclear cells with retroviral 
constructs expressing either a classic N mutation, a classic C mutation or both, 
then transplanted the cells into irradiated syngeneic mice. In this model, all mice 
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Table 3.2 Published studies that list type of CEBPADM mutations in AML 
Reference Total no. of patients 
No. of 
CEBPA
DM 
(%) 
No. of classic CEBPA
DM
 
(% of all CEBPA
DM
)
 
No. of homozygous 
classic CEBPA
DM
 
(% of all CEBPA
DM
) 
No. of other 
atypical CEBPA
DM
 
(% of all 
CEBPA
DM
) 
Pabst et al (2001b) 137 1 (1) 1 (100) 0 (0) 0 (0) 
Gombart et al (2002) 78 1 (1) 1 (100) 0 (0) 0 (0) 
Preudhomme et al (2002) 135 8 (6) 5 (62) 1 (13) 2 (25) 
Barjesteh van Waalwijk van 
Doorn-Khosrovani et al (2003) 
277 12 (4) 11 (92) 1 (8) 0 (0) 
Snaddon et al (2003) 99 2 (2) 2 (100) 0 (0) 0 (0) 
Frohling et al (2004) 236 17 (7) 15 (88) 0 (0) 2 (12) 
Bienz et al (2005) 67 7 (10) 4 (57) 0 (0) 3 (43) 
(Lin et al, 2005) 104 14 (13) 11 (79) 1 (7) 2 (14) 
Frohling et al (2005) 166 15 (9) 13 (87) 0 (0) 2 (13) 
Shih et al (2006) 149 20 (13) 18 (90) 1 (5) 1 (5) 
Fuchs et al (2008) 152 4 (3) 2 (50) 0 (0) 2 (50) 
Juhl-Christensen et al (2008) 485 5 (1) 4 (80) 0 (0) 1 (20) 
Benthaus et al (2008) 469 20 (4) 14 (70) 0 (0) 6 (30) 
Wouters et al (2009) 598 28 (5) 18 (64) 4 (14) 6 (22) 
Pabst et al (2009) 224 12 (5) 11 (92) 0 (0) 1 (8) 
Dufour et al (2010) 467 20 (4) 19 (95) 0 (0) 1 (5) 
Green et al (2010b) 1427 59 (4) 46 (78) 1 (2) 12 (20) 
Wen et al (2014) 233 11 (5) 6 (55) 1 (9) 4 (36) 
Fasan et al (2014) 2296 104 (5) 60 (58)  0 (0) 44 (42) 
Behdad et al (2015) 2393 74 (3) 43 (58) 11 (15) 20 (27) 
TOTAL 10192 434 (4) 304 (70) 21 (5) 65 (25) 
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that were transplanted with a classic C mutant or both N and C mutants 
developed leukaemia. The latter studies were subsequently extended to look at 
the effect of different C mutants (Togami et al, 2015). They showed that two 
different classic C mutants (S299_K304dup and K313dup) and also a C 
terminal missense mutant (N321D) all induced AML in the mice. However, 
disease latency with the N321D mutation was much shorter than with the 
classical mutations at 107 days compared to 151 or 298 days, perhaps 
indicating that the pathogenesis differs between the different types of mutations.  
CEBPADM samples have a distinct gene expression profile compared to 
CEBPASM or CEBPAWT (Wouters et al, 2009). In this study, unsupervised 
principal component analysis of only CEBPAMUT samples revealed a separation 
of CEBPASM from CEBPADM (Figure 3.2). The first principal component 
separated the three homozygous C CEBPADM samples from the classic 
CEBPADM. Four further CEBPADM samples were not located within the 
remaining cluster of 19 samples by both prinicipal components one and two. All 
these samples were non-classic CEBPADM, two had a classic N mutation with a 
missense mutation in the C terminus, and the other two had a classic N 
mutation coupled with a frameshift mutation in the middle of the gene. Thus 
there is a suggestion that not all non-classical CEBPADM form part of the 
distinctive CEBPADM group and this may have implications when grouping 
patients into prognostic categories.  
3.1.4 DNA methylation in AML 
Whole genome sequencing of numerous AML samples has revealed 
surprisingly few recurrent mutations compared to other malignancies (2013; Ley 
et al, 2008; Stratton, 2011; Welch et al, 2012). Furthermore, many of the 
mutations recently identified do not fit into one of the proposed classes of 
genetic mutations affecting proliferation or differentiation, which has led to 
questioning of the original model. Several of the mutated genes are known to 
have epigenetic functions, e.g. DNMT3A, TET2, IDH1, IDH2, WT1 and ASXL1 
(Table 1.3). An aberrant epigenetic state has thus been postulated to play a role 
in the pathogenesis of AML. The most studied epigenetic alteration is DNA 
methylation. This is due not only to the stability of the additional methyl group
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(COPYRIGHT PROTECTED IMAGE REMOVED)  
 
Figure 3.2 Unsupervised components analysis of gene expression data 
from 38 CEBPAMUT samples.  
Figure adapted from Wouters et al (2009). CEBPADM samples are represented 
by red boxes and CEBPASM by blue boxes. Non-classical CEBPADM samples 
have been circled. Homozygous C mutant samples are circled in green, 
samples with a classic N mutation and missense mutation in the C terminus are 
in yellow, and those with a classic N mutation and frameshift in the middle or C 
terminus of the gene are in purple.
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 on nucleotide bases, but also because of the relative ease with which this can 
be investigated in primary DNA samples compared to histone modifications.  
Initially the DNA methylation analysis was at the single gene level, for example 
methylation of the estrogen receptor was found in a subset of patients using 
methylation-sensitive restriction enzyme digestion followed by PCR (Li et al, 
1999). In this study, 261 samples were analysed, of which 61% had a 
methylated CGI within the promoter of the estrogen receptor (defined as >15% 
methylation as quantified by Southern blot). As the number of genes shown to 
be aberrantly methylated in AML increased, many studies investigated the 
methylation status of several genes to see whether there was a specific 
“methylation phenotype” in a subset of samples. For example, the methylation 
of CGIs associated with eight genes previously shown to be methylated in 
leukaemia (including calcitonin, E-cadherin, p15, p16, Retinoblastoma) was 
analysed using bisulfite genomic sequencing in 20 AML and nine normal bone 
marrow samples (Melki et al, 1999). Apart from one normal bone marrow that 
had methylated calcitonin, all the other normal samples were completely 
unmethylated at all eight CGIs. Conversely, the AML samples all had at least 
one methylated CGI, and 75% of them had at least two methylated CGIs. The 
authors concluded that the aberrant methylation was therefore suggestive of 
general dysregulation of methylation mechanisms rather than targeted to 
specific genes.  
With advances in the technology, more regions were simultaneously analysed 
in each sample. For example, Bullinger et al (2010) used bisulfite-converted 
DNA and mass spectrometry, MALDI-TOF, to quantify methylation at 
approximately 2000 CpG sites in 92 genomic regions in 256 samples. They 
found that the majority of CpG sites analysed showed very little variability in 
methylation levels across all samples. Most CpG sites were hypomethylated 
(median methylation level 10%) and a second smaller group of CpGs were 
predominantly hypermethylated (median level 70%). Unsupervised cluster 
analysis of the methylation profiles segregated the samples into several 
clusters, some of which correlated with underlying cytogenetic abnormalities, for 
example, most inv(16) samples clustered together, similarly t(15;17) and t(8;21) 
samples mainly clustered within individual groups. 
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This link between genetic abnormalities seen in AML and the DNA methylation 
profile has been corroborated in three studies that have investigated the 
“methylome” of AML in large numbers of unselected patients. Figueroa et al 
(2010b) used the HELP assay to interrogate over 50,000 CpG sites contained 
within approximately 14,000 genes in 344 patients. Deneberg et al (2011) used 
the Illumina Infinium Methylation 27K array in samples from 118 cytogenetically 
normal AML patients. Most recently, the Cancer Genome Atlas Research 
Network (2013) published a comprehensive genetic and DNA methylation 
analysis of 190 patients that were analysed using the Illumina Infinium 
Methylation 450K array. All three papers identified clusters of samples with 
unique methylation profiles. In the two largest studies which both looked at 
unselected patients, the DNA methylation profile could distinguish samples with 
inv(16), t(8;21) or t(15;17) from those without these aberrations with a high 
degree of accuracy, both in terms of sensitivity and specificity. Furthermore, all 
three studies highlighted that unsupervised cluster analysis led to several 
clusters with different methylation patterns, and when these were correlated 
with the molecular status of the samples, some clusters were enriched for 
certain mutations. For example, samples with NPM1 mutations were enriched in 
particular clusters in all three studies. However, the findings between these 
studies were not all consistent, for example, CEBPA mutations were identified 
predominantly in just 2 of 16 clusters by Figueroa et al (2010b), but Deneberg et 
al (2011) did not find that they were enriched in any particular cluster.  
3.1.5 Significance of aberrant DNA methylation in AML  
Given that analysis of DNA methylation profiles has repeatedly been shown to 
differentiate AML from normal bone marrow (Figueroa et al, 2010b) and other 
malignancies (Hansen et al, 2011), and also differentiates some cytogenetic 
and molecular subcategories of AML (2013; Figueroa et al, 2010b), it is unlikely 
that aberrant methylation in AML is simply a random feature of general 
epigenetic dysregulation. DNA methylation of CGIs associated with tumour 
suppressor genes has been considered to be an alternative to loss-of-function 
mutations as a silencing mechanism that would lead to the same phenotype, 
which would be consistent with the fact that aberrant hypermethylation has 
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often been seen in promoters of genes known to be recurrently mutated in AML, 
e.g. CEBPA and DNMT3A (Hackanson et al, 2008; Jost et al, 2014). There is, 
however, evidence that aberrant methylation of CGIs occurs in genes which are 
already silenced in the cell of origin. By analysing the methylation of gene 
promoters in 19 breast cancer cell lines and comparing the results with 
previously published transcriptome data, Sproul et al (2011) demonstrated that 
genes methylated in the cancer cell lines were not expressed in the normal 
tissue of origin. Furthermore, demethylation of these cell lines using 5 aza 
cytidine led to derepression and expression of only 10% of the genes shown to 
be methylated. They subsequently extended this study to examine published 
methylation array and RNA-sequencing data in over 1000 malignancies in 
seven different tissue types, including AML, and found that genes that were 
prone to hypermethylation were not constitutively expressed (Sproul et al, 
2012). This suggests that aberrant DNA may be a passenger event rather than 
driving the disease.  
There are several reasons why it is important to ascertain whether DNA 
methylation is pathogenic or not. Firstly, targeting DNA methylation as part of 
the treatment for AML is an attractive option as methylation is considered to be 
“reversible” (Kelly et al, 2010). Indeed, there has been some success in 
treatment of MDS and AML with DNMT inhibitors, but it is unclear if the activity 
of these drugs is due to their demethylating ability (Silverman et al, 2006). 
Secondly, knowledge of the functional role of specific DNA methylation patterns 
might aid in categorising patients who lack a mutation in a particular gene but 
have a methylation profile similar to those patients who do have the mutation. 
For example, Figueroa et al (2010b) found that in one cluster of 31 patients, 22 
had t(8;21), which is associated with a favourable prognosis, and the remaining 
nine patients had neither the translocation nor a cryptic AML1-ETO fusion gene, 
but their survival curve was indistinguishable from the 22 t(8;21) patients. 
Thirdly, given that clustering of patients based on their methylation profile can 
be associated with specific cytogenetic and molecular abnormalities, some of 
which have prognostic impact, the methylation profiles themselves could 
potentially aid in prognostic stratification. This would be especially useful in AML 
as many patients fall into the heterogeneous intermediate risk prognostic 
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category, of which approximately 20% have no known mutations with prognostic 
value. Two studies that looked at the “methylome” in 118 cytogenetically normal 
and 344 unselected patients used supervised principal components analysis to 
create methylation profiles that would predict for prognosis (Deneberg et al, 
2011; Figueroa et al, 2010b). Both groups created methylation predictor 
signatures consisting of approximately 300 CpG sites and 18 HpaII fragments 
respectively to classify patients as good or poor outcome. They validated the 
predictors in an independent set of patients. Both studies showed that the 
methylation profile retained its prognostic significance in multivariate analysis 
when age, white cell count, NPM1 and FLT3/ITD status (Deneberg et al, 2011) 
or age, cytogenetic risk, NPM1, CEBPA and FLT3/ITD status (Figueroa et al, 
2010b) were taken into account. Of note, both the methods used to quantify the 
methylation and the CpG sites analysed differed between these groups and the 
corollary was that the two signatures were completely different from one 
another, with no overlapping regions. 
The preliminary aim of the studies presented in this chapter was to ascertain 
whether prognosis could be associated with the methylation pattern of samples 
taken at diagnosis. Therefore, rather than screening a large number of 
unselected patients, as in previously published studies, samples were used 
from two highly selected cohorts with known outcome, each of 21 patients, that 
were at either extreme of clinical response, either chemosensitive or 
chemoresistant. Using the information available at the time of the 
commencement of the studies, common cytogenetic alterations and mutations 
known to correlate with outcome were excluded so that all samples analysed 
were from patients with a normal karyotype (NK) and WT for NPM1, FLT3/ITD 
and FLT3/TKD. Initial analyses identified a specific methylation profile that, with 
the availability of additional molecular characterisation, was found to be 
associated with CEBPA mutations. This then became the focus of further 
investigations.  
3.2 Patients, Materials and Methods 
Preliminary data was available from the methylation analysis of a cohort of 42 
samples that formed the starting point of the studies presented here. Our initial 
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collaborators, Dr Andy Feber and Dr Andrew Teschendorff, UCL Cancer 
Institute, UK, prepared the samples for the arrays and performed preliminary 
cluster analysis respectively. All subsequent cluster analysis was performed by 
Dr Duncan Sproul, Institute of Genetics and Molecular Medicine, University of 
Edinburgh, UK.  
3.2.1 Sample selection 
The initial cohort of 42 DNA samples were selected from AML patients entered 
onto the UK MRC AML10 and AML12 trials and analysed using the Illumina 
Infinium 27K HumanMethylation array. Samples were available from a DNA 
Biobank held in the Department of Haematology, UCL Cancer Institute. Ethical 
approval for the use of the samples was obtained from the Multi-Centre 
Research Committee of Wales. Informed consent was obtained in accordance 
with the Declaration of Helsinki. The samples were from patients known to have 
an NK, and to be WT for three common mutations, NPM1, FLT3/ITD and 
FLT3/TKD (Gale et al, 2008; Mead et al, 2007). To ascertain whether clinical 
outcome was associated with a particular methylation profile, patients were 
selected to be at either extreme of clinical response. Half of the patients chosen 
were chemosensitive, defined as in continuous complete remission for at least 3 
years, and the other half were chemoresistant, defined as either failure or slow 
to respond to chemotherapy or early relapse within 4 months of completing 
chemotherapy. Two follow-up cohorts of 48 samples each were also selected 
for analysis from the UK MRC AML trials’ DNA bank. Further details of these 
patients are provided in the results section.  
During the course of the project, mutation status for the CEBPA, GATA2, IDH1, 
IDH2, DNMT3A, TET2 and WT1 genes was determined (Gale et al, 2015; 
Green et al, 2010a; Green et al, 2011; Green et al, 2010b; Green et al, 2013; 
Virappane et al, 2008). 
3.2.2 Sample analysis on the Illumina Infinium Methylation Arrays 
For samples to be analysed on the Illumina Infinium Methylation array (Illumina 
inc, California, USA), 500ng DNA was bisulfite-converted, as described in 
section 2.2.2. To assess the quality of the conversion, random samples from 
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each converted batch were subjected to methylation-specific PCR. Two PCRs 
of the HLA-B gene were performed per sample assessed, one that would only 
amplify bisulfite-converted DNA, and the other that would only amplify 
unconverted DNA. Samples were considered to be successfully bisulfite-
converted if they had a PCR product with the primers for the bisulfite-converted 
DNA but no product with the primers for the unconverted DNA. Details of the 
conditions for the PCRs are given in section 2.2.3.  
Bisulfite-converted samples were sent to UCL Genomics for analysis on the 
Infinium Methylation array according to the manufacturer’s protocol. Briefly, 
each bisulfite-converted DNA sample was whole genome amplified, 
enzymatically fragmented and precipitated, then hybridised to the BeadChip. 
Two different arrays were used during the course of this project. The first cohort 
was analysed with the HumanMethylation 27K BeadChip, which examines over 
27,000 CpG sites predominantly located in CpG islands. Each CpG locus 
analysed is represented by two bead types, one corresponding to the 
methylated allele and the other to the non-methylated allele. Both bead types 
have 50mer probes attached that differ only in their last base which 
corresponds to the cytosine under investigation, i.e. one bead has a guanine as 
the last base to bind to methylated cytosines, the other has adenine to bind to 
thymine for non-methylated cytosines, or C and A respectively if the 
complementary allele is being interrogated. Labelled nucleotides are then 
added for single base extension of the correctly hybridised oligonucleotides 
(Figure 3.3). The proportion of the labelled nucleotides is measured indirectly by 
multi-layer immunohistochemical staining and laser excitation and the level of 
light emitted recorded.  
The HumanMethylation 450K BeadChip, which was used to examine cohorts 2 
and 3, analyses over 450,000 CpG sites. It covers 94% of the CpGs analysed 
on the 27K BeadChip, 99% of the RefSeq genes, as well as intergenic regions. 
Not only is there greater coverage of the genome but also more CpGs are 
analysed per gene, on average 17 probes compared with two for the 27K 
BeadChip. The limiting factor for the number of CpGs that can be assessed with 
the array is the number of beads that can be assembled on each BeadChip. To 
accommodate the extra beads required to analyse over 485,000 CpG sites, the
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Figure 3.3 Illumina Infinium I assay.  The assay uses an unmethylated (U) and 
methylated (M) bead type for each CpG analysed. In the top panel, the CpG site 
being analysed is methylated and thus binds to the methylated bead type enabling 
single base extension and detection, however this will not bind with the unmethylated 
bead type due to the sequence mismatch. The reverse situation is shown in the 
bottom panel. (Figure taken from http://www.illumina.com/technology/beadarray-
technology/infinium-methylation-assay.ilmn.) 
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450K BeadChip uses two different assays. Approximately 28% of the CpG sites 
are analysed by the Infinium I assay, which is the technology employed with the 
27K BeadChip. The remaining 72% of CpG sites are analysed by the Infinium II 
assay that has a single bead type per CpG locus that allows the complementary 
DNA fragment to hybridise, regardless of the methylation status of the CpG 
under investigation, rather than an unmethylated and methylated bead type. 
Methylated and non-methylated alleles are differentiated from one another by 
generating green and red coloured signals respectively and thus can be 
quantified separately.  
For each CpG site interrogated, the fluorescence intensities measured for the 
methylated and unmethylated probes were converted to a raw β value 
corresponding to the methylated signal over the total (methylated plus 
unmethylated) signal for that CpG site. Hence, the β value was between 0 and 
1, with 0 being fully unmethylated and 1 fully methylated. CpG sites analysed 
using the Infinium II assay were normalised to account for the slight bias in β 
values produced by this assay from the differently coloured signals 
(Dedeurwaerder et al, 2011). All CpG sites analysed were subjected to filtering 
to exclude those with a low signal-to-background ratio, based on the detection 
p-value >0.01. Probes interrogating CpG sites on the X and Y chromosome 
were excluded from the cluster analyses, as were any other probes displaying 
gender-specific biases, defined as those with Wilcoxon test p-values <0.05 
between genders. For display in figures, β values were converted to estimated 
percentage methylation levels by multiplying them by 100.  
3.2.3 Methylation quantification using pyrosequencing 
Pyrosequencing was performed as outlined in section 2.2.4. The primers for 
each assay were designed using the PyroMark Assay Design Software 2.0 
(Qiagen, Germany), and initially tested using titration standards. Titration 
standards containing 0%, 10%, 25%, 50%, 75%, 90% and 100% methylated 
DNA were prepared by two methods. One method used in-house mixes of fully 
unmethylated DNA, created by whole genome amplification of normal genomic 
DNA, and fully methylated DNA, created by using the enzyme SssI (New 
England Biolabs, USA) to methylate DNA, followed by bisulfite conversion of the 
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individual mixes. The other method mixed purchased bisulfite-converted fully 
unmethylated and fully methylated Epitect DNA standards (Qiagen, Crawley, 
UK). If the mixes showed methylation bias with the known standards, new 
primers were designed to improve the accuracy of the analysis. Once the 
assays produced by the titration curves were considered to be sufficiently 
accurate, aliquots of patient samples were bisulfite-converted and analysed in 
duplicate.  
Pyrosequencing assays were created for four CpG sites to validate the results 
from the methylation array. The mean of the duplicate values for each sample 
were compared to the corresponding β value. Analysis of correlation data was 
performed using GraphPad Prism (Version 6.01 for windows, GraphPad, USA). 
Three further pyrosequencing assays were created to analyse the methylation 
levels of CpG sites in AML samples with favourable prognostic cytogenetic or 
molecular changes. 
3.3 Results 
At the commencement of these studies, preliminary data was available from the 
initial cohort of 42 patients (21 chemosensitive and 21 chemoresistant) that had 
been processed by Dr Andy Feber and analysed by Dr Andrew Teschendorff. β 
values for each CpG site for all patients was provided, as well as the top 100 
CpG sites that showed the largest difference between the chemosensitive 
patients and the chemoresistant patients. Four of these CpG sites were chosen 
to verify the results of the methylation array using pyrosequencing.  
3.3.1 Validation of array results using pyrosequencing 
Pyrosequencing assays were designed and titration curves created for four 
CpG sites associated with the SOCS2, WNT1 and PRF1 genes, as detailed in 
the Materials and Methods. Fresh patient samples were bisulfite-converted and 
tested in duplicate. 
Suppressor of cytokine signalling 2, SOCS2, is a negative regulator of the JAK-
STAT pathway (Krebs & Hilton, 2001), and has been identified as being 
upregulated in murine leukaemia stem cells transfected with a FLT3/ ITD 
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(Mizuki et al, 2003). The SOCS2 CpG site evaluated, CG04797323, is located 
in the intron between exons 2 and 3. The coding sequence for this gene begins 
in exon 2. Representative examples of the pyrograms obtained with this assay 
are shown in Figure 3.4. The titration curve obtained using the DNA mixes 
showed a good correlation between the expected and observed levels of 
methylated alleles, r2= 0.99 (p<0.0001) (Figure 3.5A). In the patient samples, 
the range of methylation values was 3%-89%, mean 33% and median 25% 
(Figure 3.6A). There was a highly significant correlation between the 
methylation levels predicted by pyrosequencing and those predicted by the 
Illumina methylation array, r2 =0.93 (p<0.0001) (Figure 3.7A). Comparing the 
pyrosequencing results of the chemosensitive and chemoresistant patients, 
there was a significant difference in median levels of methylation between the 
two groups, 40% and 9% respectively (p=0.02). 
Wingless type 2, WNT2, is a protein implicated in the WNT- β catenin signalling 
pathway that is required for self-renewal of leukaemic stem cells (Wang et al, 
2010).  The CpG site evaluated, CG018302894, is located 149 bases upstream 
of the transcription start site (TSS) for WNT2. The titration curve showed a good 
correlation between observed and expected values, r2 =0.98 (p<0.0001) (Figure 
3.5B). The patient samples had methylation values ranging from 8%-91%, with 
mean 43% and median 46% (Figure 3.6B). Comparing the pyrosequencing 
results with the β values from the methylation array, a highly significant 
correlation was seen, r2= 0.93 (p<0.0001) (Figure 3.7B). The chemosensitive 
and chemoresistant cohorts had significantly different median levels of 
methylation, 49% versus 29% respectively (p=0.01). 
Perforin 1, PRF1, is a major component of cytolytic vesicles and a key effector 
of natural-killer cell-mediated cytolysis (Yanai et al, 2003). The gene has been 
reported to be significantly differentially methylated in DNA samples from 
patients with de novo and secondary AML (Figueroa et al, 2009a). Two CpG 
sites were investigated for this gene, CG02374486 (PRF1A), 222 bases 
upstream, and CG09914304 (PRF1B), 298 bases downstream of the TSS. 
Although both had titration curves with significant correlation co-efficients, r2 
=0.79 (p<0.0001) and r2 =0.81 (p<0.0001) respectively (Figure 3.5C and D), 
there was evidence of preferential amplification of the methylated alleles at both
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Figure 3.4 Pyrosequencing assay design and representative pyrograms for the SOCS2 probe. (A) Sequence with the individual 
bars showing the expected relative peaks for each nucleotide. Negative controls are included in the design, as well as controls to ensure that 
complete bisulfite conversion has occurred, i.e. non-CpG Cs (or Gs if the complementary strand is being examined) that should be completely 
converted to T (or A). The shaded areas represent the CpG sites analysed in the assay, the one corresponding to the CpG site analysed in the 
Illumina methylation array is boxed. (B) and (C) are examples of pyrograms produced with this assay. The percentage methylation is given for 
each CpG site analysed. E and S represent addition of enzyme and substrate mix respectively.
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Figure 3.5 Titration curves for the percentage methylation obtained using standards in the pyrosequencing assays.  For (A) 
– (D), mixes for titration standards were made pre-bisulfite conversion (BC). For (E) – (F), fully methylated and fully unmethylated 
DNA were bisulfite-converted and then mixed to create standards.
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Figure 3.6 Pyrosequencing results for the patient samples as analysed at the selected CpG sites. 
 (A) SOCS2, (B) WNT2, (C) PRF1A, (D) PRF1B. Each column represents a patient sample, blue columns represent samples from patients with 
chemosensitive disease and red columns those with chemoresistant disease.
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Figure 3.7 Comparison of the methylation values obtained by pyrosequencing with beta values from the methylation array. 
SOCS2
0 20 40 60 80 100
0
20
40
60
80
100
r2=0.93, p<0.0001
(A)
% methylation (  value from array)
%
 m
et
h
yl
at
io
n
(p
yr
o
se
q
u
en
ci
n
g
)
WNT2
0 20 40 60 80 100
0
20
40
60
80
100
r2=0.93, p<0.0001
(B)
% methylation (  value from array)
%
 m
et
h
yl
at
io
n
(p
yr
o
se
q
u
en
ci
n
g
)
PRF1B
0 20 40 60 80 100
0
20
40
60
80
100
r2=0.76, p<0.0001
(D)
% methylation (  value from array)
%
 m
et
h
yl
at
io
n
(p
yr
o
se
q
u
en
ci
n
g
)
PRF1A
0 20 40 60 80 100
0
20
40
60
80
100
r2=0.84, p<0.0001
(C)
% methylation (  value from array)
%
 m
et
h
yl
at
io
n
(p
yr
o
s
eq
u
en
ci
n
g
)
 82 
 
sites, as the data points would best fit a second order curve rather than a line. 
This is a recognised complication of PCR of bisulfite-converted DNA, 
particularly in CpG islands where the final GC content will vary greatly in 
methylated versus unmethylated DNA strands (Warnecke et al, 1997). 
However, an alternative explanation was that the DNA mixes created were not 
accurate for this particular chromosomal region, or that the bisulfite conversion 
itself was the source of bias. By mixing purchased bisulfite-converted fully 
methylated and unmethylated DNA, an improvement in the correlation between 
observed and expected was seen (Figure 3.5E and F). In patient samples, the 
range of methylation values was 23%-95% and 12%-91% for the two sites 
respectively, means 65% and 58%, and medians 68% and 63% (Figure 3.6C 
and D). Despite the preferential amplification of methylated alleles, both CpG 
sites had a significant correlation between the methylation levels predicted by 
pyrosequencing and those predicted by the methylation array, r2= 0.84 
(p<0.0001) and 0.76 (p<0.0001) respectively (Figure 3.7C and D). Comparing 
the chemosensitive to the chemoresistant cohort, there was a significant 
difference in median levels of methylation between the two groups, 49% versus 
83% (p=0.0004) and 45% versus 74% (p=0.0003) respectively. 
Bland-Altman plots showing the difference between the quantification by 
pyrosequencing and array for each sample compared to the mean result from 
both methods were produced for each probe (Figure 3.8). A negative point 
indicated that the pyrosequencing level was lower than that measured by the 
array. Overall, there was a good correlation between methylation levels 
measured by the two methods. In three of the four probes, there was a 
consistent bias in that pyrosequencing quantified the level to be approximately 
10% less than the array (consistent with the titration curves). In PRF1A there 
was a proportional bias, with pyrosequencing giving lower methylation levels in 
largely unmethylated samples, but higher levels than the array in more 
methylated samples. However, the standard deviation of the difference between 
the two methods was low for all four probes (range 7-11%). Furthermore, 
biologically a difference of 10% methylation is not thought to be significant. 
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Figure 3.8 Bland-Altman plots to compare the pyrosequencing and methylation array quantification results. The mean 
result for each sample as calculated by each method is plotted against the difference in values (pyrosequencing result minus the 
array result). A result below zero on the x axis signifies that the array estimates the methylation level to be higher than the level 
measured by pyrosequencing. The dotted lines represent the 95% confidence intervals.
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3.3.2 Cluster analysis of samples based on methylation array results 
The data from the methylation array was analysed further by Dr Duncan Sproul, 
using both unsupervised and supervised cluster analysis of CpGs located within 
CGIs. Two samples were excluded from the analysis as they failed quality 
control measures, leaving 20 patients in each cohort. The majority of CpG sites 
analysed showed little variation in methylation levels across the whole cohort, 
however a proportion of the CpG sites had a wide range of methylation values. 
Samples were therefore grouped according to the methylation levels of the most 
differential probes using unsupervised cluster analysis, and methylation levels 
of CGIs (as defined in (Illingworth et al, 2010) were derived by calculating the 
mean β value of probes at these locations (Figure 3.9). Two main groups were 
found showing either a predominantly hypermethylated (n=16) or 
hypomethylated (n=24) profile. These clusters did not correlate with outcome, 
six of the patients in the hypermethylated group were chemoresistant and ten 
were chemosensitive, whereas in the hypomethylated group 14 were 
chemoresistant compared to 10 chemosensitive (p=0.20).  
Although not known at the commencement of the study, by the time analysis of 
the methylation array was performed, the mutation status for the IDH1, IDH2, 
CEBPA, WT1, TET2 and DNMT3A genes had been determined for all samples. 
All samples from CEBPAMUT patients (n=10) had a “hypermethylated 
phenotype”. Further investigation showed that all these CEBPAMUT samples 
were CEBPADM; eight of them (80%) were classic DM, one had a homozygous 
missense mutation in the C terminus and the other was predicted to produce 
p30 only as it had a classic N mutation with a second frameshift mutation after 
the second ATG site (Table 3.3 and Appendix Table 2). The mean CpG island 
methylation level for the classic CEBPADM samples was significantly higher than 
that of the CEBPAWT samples (Figure 3.10). Conversely, all patients with a 
DNMT3A (n=7), IDH2 (n=6) and IDH1 (n=5) mutation were in the 
hypomethylated group, apart from one patient who had both IDH1 and CEBPA 
mutations. One patient with a WT1 mutation and one of two with a TET2 
mutation were in the hypermethylated group, however these patients also had a 
CEBPA mutation.
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Legend
Prognosis: Chemoresistant Chemosensitive
Gender: Female Male
Mutations: Mutant WT Not done
CEBPA: Classic DM Non-classic DM WT
 
Figure 3.9 Unsupervised cluster analysis based on the most differentially 
methylated CpG sites. CpG sites on the X chromosome were excluded from 
the analysis. The median CpG β value for each sample is shown in the bottom 
panel and the clustering in the top panel. The red and blue columns indicate 
samples with a predominantly hypermethylated or hypomethylated profile 
respectively. Patient characteristics and genotype are given in the top panel. 
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Table 3.3 CEBPA genotype of samples investigated using methylation 
arrays 
 
Cohort 
(n) 
CEBPA 
genotype* 
Mutation type n Predicted functional 
consequence 
1 
(40) 
DM 
 
 
 
WT 
Classic N + C 
Classic C + C-frameshift 
Homozygous C-missense 
 
 
 
8 
1 
1 
 
30 
p30 + C-LOF 
C-LOF 
C-LOF 
 
WT 
2 
(48) 
DM 
 
 
 
SM 
 
 
 
 
WT 
Classic N + C 
Classic N + mid-frameshift 
Homozygous C-missense 
 
Classic N 
Classic C 
Mid-frameshift 
C-missense 
13 
2 
1 
 
2 
3 
2 
1 
 
24 
p30 + C-LOF 
p30 
C-LOF 
 
p30 + WT 
C-LOF + WT 
Null + WT 
C-LOF + WT 
 
WT 
3 
(47) 
DM 
 
 
 
 
 
 
 
SM 
 
 
 
 
 
 
 
WT 
Classic N + C 
Classic N + C-missense 
Homozygous classic C 
Homozygous C-missense 
Classic C + C-missense 
Classic N + mid-frameshift 
Classic N + C-frameshift 
 
 Classic N 
 Classic C 
 Mid-indel      
 Mid-frameshift 
 Mid-missense 
 C-frameshift 
 C-missense 
 
 
4 
3 
2 
1 
1 
3 
1 
 
7 
2 
3 
7 
5 
2 
4 
 
2 
p30 + C-LOF 
p30 + C-LOF 
C-LOF 
C-LOF 
C-LOF 
p30 
p30 
 
p30 + WT 
C-LOF + WT 
UNK + WT 
Null + WT 
UNK + WT 
Null + WT 
C-LOF + WT 
 
WT 
 
*Details of the specific mutations are given in Appendix 2. 
Abbreviations: C, C-terminal mutation; C-LOF, C-terminal loss-of-function; indel, 
in-frame insertion and/or deletion; N, N-terminal mutation; n, number of patients; 
UNK, unknown; WT, wild-type 
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Figure 3.10 Boxplot showing the mean CpG Island methylation level in 
classic CEBPADM.and CEBPAWT samples.  β values were derived from the 
Illumina Infinium Methylation 27K array analysis of the 40 samples in cohort 1, 
median methylation levels for each CGI were determined and a mean overall 
level for all probes was then calculated. 
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3.3.3 Creation of CEBPA methylation signatures 
Given the strong segregation of CEBPAMUT from CEBPAWT in the cluster 
analysis, Dr Sproul used a supervised approach to create a classic CEBPADM 
and a CEBPAWT methylation signature, the two non-classic CEBPADM were not 
considered in this analysis. In a given sample, probes were defined as 
methylated if their beta value was >0.3 and unmethylated if beta was ≤0.3. CpG 
probes were considered differentially methylated if there was at least one 
unmethylated and one methylated sample. The signature comprised the top 25 
most differentially methylated CpG sites (Table 3.4). The function of the 20 
genes associated with these 25 sites varies and none of them are known to be 
C/EBP targets. Six of these genes have been reported to have infrequent 
mutations in AML samples (TMEM125, LTBP3, AHNAK, GRHL3, NDFIP1 and 
LAMA4) (Table 3.5). Furthermore, five of the genes (RAB34, KHNYN, LTBP3, 
NDFIP1 and ARPP21) were differentially expressed in CEBPADM AML samples 
compared to other AML samples, including three which were included as gene 
expression predictors to identify CEBPADM samples (Hollink et al, 2011; 
Taskesen et al, 2011; Wouters et al, 2009). Promoter methylation in AML 
samples has been reported in three of the genes (GNMT, TMEM125 and 
ARPP21). Two genes encode T cell proteins, CD52 and LY9, and aberrant 
expression of T cell markers has been reported in some AML samples (Lewis et 
al, 2007; Wouters et al, 2007).  
Comparison of the derived signatures with published methylation data of 
different blood cell types (Calvanese et al, 2012) showed that the methylation 
profile of both normal CD34+ cells and neutrophils were more similar to the 
CEBPAWT signature than the classic CEBPADM signature, suggesting that the 
changes seen in mutated samples were not simply due to a change in the 
predominant cell type within each sample (Figure 3.11). 
The patient samples were then ordered according to their similarity to the 
classic CEBPADM signature, and two distance scores were calculated for each 
sample based on the Euclidian distance between their methylation levels at 
these signature probes and the median profile of classic CEBPADM and 
CEBPAWT samples (Figure 3.12). By comparing the two scores for each sample 
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Table 3.4 List of the genes or regions associated with the 25 differentially methylated CpG sites in the CEBPA methylation 
signature. 
Table 3.4 continued 
 
Genomic Location 
    
Signature Details 
 
Probe ID Chr Position 
Dist 
to 
TSS ENSEMBL Gene ID Symbol Description 
In 
CpG 
Island 
WT 
Median 
Beta 
Classic 
DM 
Median 
Beta 
Median 
Δ 
cg21237418 17 24069170 -157 ENSG00000109113 RAB34 RAB34, member RAS oncogene family FALSE 0.153 0.928 0.775 
cg14338887 6 43036478 0 ENSG00000124713 GNMT Glycine N-methyltransferase TRUE 0.170 0.918 0.748 
cg17186163 10 44794323 7 ENSG00000165507 C10orf10 Chromosome 10 open reading frame 10 FALSE 0.155 0.907 0.752 
cg24101359 6 43036473 5 ENSG00000124713 GNMT Glycine N-methyltransferase TRUE 0.199 0.904 0.705 
cg13105904 14 23969884 -903 ENSG00000100441 KHNYN KH and NYN domain containing TRUE 0.306 0.889 0.583 
cg01274660 7 100303561 -675 ENSG00000087077 TRIP6 Thyroid hormone receptor interactor 6 FALSE 0.317 0.888 0.572 
cg04355435 1 43508877 117 ENSG00000179178 TMEM125 Transmembrane protein 125 FALSE 0.349 0.879 0.531 
cg10056627 6 43036751 -273 ENSG00000124713 GNMT Glycine N-methyltransferase TRUE 0.249 0.877 0.629 
cg27588902 6 43036129 349 ENSG00000124713 GNMT Glycine N-methyltransferase TRUE 0.265 0.854 0.589 
cg25651505 2 85665534 -492 ENSG00000168899 VAMP5 Vesicle associated membrane protein 5 TRUE 0.347 0.837 0.489 
cg23696834 6 43036323 155 ENSG00000124713 GNMT Glycine N-methyltransferase TRUE 0.102 0.822 0.720 
cg24081819 8 27404857 -295 ENSG00000120915 EPHX2 Epoxide hydrolase 2, cytoplasmic TRUE 0.243 0.817 0.574 
cg08965235 11 65081734 541 ENSG00000168056 LTBP3 Latent TGF beta binding protein 3 TRUE 0.266 0.804 0.538 
cg16068833 1 26517102 -104 ENSG00000169442 CD52 CD52 molecule FALSE 0.227 0.763 0.536 
cg19764555 11 62071695 -787 ENSG00000124942 AHNAK AHNAK nucleoprotein TRUE 0.272 0.763 0.491 
cg00350296 11 65841417 -343 ENSG00000174807 CD248 CD248 molecule, endosialin FALSE 0.253 0.738 0.485 
cg10798171 7 8268826 -59 ENSG00000003147 ICA1 Islet cell autoantigen 1 TRUE 0.249 0.715 0.466 
cg15032239 15 20443395 709 ENSG00000068793 CYFIP1 Cytoplasmic FMR1 interacting protein 1 TRUE 0.195 0.708 0.513 
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Table 3.4 continued 
 
Genomic Location 
    
Signature Details 
 
Probe ID Chr Position 
Dist 
to 
TSS ENSEMBL Gene ID Symbol Description 
In 
CpG 
Island 
WT 
Median 
Beta 
Classic 
DM 
Median 
Beta 
Median 
Δ 
cg16155382 1 24518778 -135 ENSG00000158055 GRHL3 Grainyhead-like transcription factor 3 FALSE 0.101 0.678 0.577 
cg13490971 5 141468305 203 ENSG00000131507 NDFIP1 Nedd4 family interacting protein 1 TRUE 0.203 0.653 0.450 
cg21697134 17 78287128 -331 ENSG00000167363 FN3K Fructosamine 3 kinase FALSE 0.090 0.614 0.524 
cg08897388 6 112682398 44 ENSG00000112769 LAMA4 Laminin subunit alpha 4 TRUE 0.135 0.575 0.440 
cg12417466 3 35658823 30 ENSG00000172995 ARPP21 CAMP regulated phosphoprotein 21kDa FALSE 0.720 0.179 -0.541 
cg05615150 3 35658819 34 ENSG00000172995 ARPP21 CAMP regulated phosphoprotein 21kDa FALSE 0.668 0.113 -0.555 
cg18920397 1 159032429 123 ENSG00000122224 LY9 Lymphocyte antigen 9 FALSE 0.625 0.071 -0.554 
 
1CpG ID as numbered by Illumina Methylation BeadChip. 
Abbreviations: Chr, chromosome; Dist, distance; DM, double mutant; TSS, transcription start site; WT, wild-type
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Table 3.5 Published associations between genes in the CEBPA signature and leukaemia. 
Table 3.5 continued 
Gene
1 
Mutations 
seen in 
AML
2 
Changes in expression in AML Evidence of methylation in AML References 
RAB34  
Top 50 most significantly differentially expressed genes 
comparing the CEBPA cluster (↓) vs other AML samples 
 Hollink et al (2011) 
RAB34  
Top 25 differentially expressed genes comparing CEBPA
DM
 
(↓) vs other AML samples  
 Taskesen et al 
(2011) 
Wouters et al (2009) 
GNMT  
 Promoter methylation seen in AML 
Associated with improved survival 
in univariate analysis 
Wilop et al (2011) 
KHNYN  Downregulated expression in CEBPA
MUT 
 Marcucci et al (2008) 
TMEM125  
 Hypermethylated in transformed 
PV/ MPN compared to non-
transformed. 
Perez et al (2013) 
TMEM125 
1 in germline 
CBL
MUT 
  Becker et al (2014) 
EPHX2  
Differential expression associated with promoter methylation 
seen in childhood T-ALL 
 Borssen et al (2013) 
LTBP3 1/193 
  COSMIC COSU377 
Cancer.sanger.ac.uk 
Forbes et al (2015) 
LTBP3  
Increased expression in R172 IDH2 mutant AML samples 
compared to IDH1/2 WT 
 Marcucci et al (2010) 
CD52  
Lymphocyte differentiation Ag expressed in approx. 36% 
AML samples, associated with high EVI1 expression.  
 Saito et al (2011) 
CD52  
Decreased expression in CEBPA
DM 
compared to other AML 
samples 
 Dufour et al (2010) 
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Table 3.5 continued 
Gene
1 
Mutations 
seen in 
AML
2 
Changes in expression in AML Evidence of methylation in AML References 
AHNAK 2/182 
  COSMIC COSU544 
Cancer.sanger.ac.uk 
Forbes et al (2015) 
GRHL3 1/182 
  COSMIC COSU544 
Cancer.sanger.ac.uk 
Forbes et al (2015) 
NDFIP1 1/182 
  COSMIC COSU544 
Cancer.sanger.ac.uk 
Forbes et al (2015) 
NDFIP1  
Differential expression in CEBPA
DM 
(↓) compared to other 
AML samples 
 Dufour et al (2010) 
NDFIP1  
Part of 25 probe set differentiating CEBPA
DM 
(↓ expression) 
from other AML samples 
 Taskesen et al 
(2011) 
Wouters et al (2009) 
LAMA4 2/182 
  COSMIC COSU544 
Cancer.sanger.ac.uk 
Forbes et al (2015) 
ARPP21  
Top 50 most significantly differentially expressed genes 
comparing the CEBPA cluster (↑) vs other AML samples 
 Hollink et al (2011) 
ARPP21 
 Used as part of a gene expression predictor to identify 
silenced CEBPA samples (↑ in methylated CEBPA) 
 Wouters et al (2007) 
1
All CpG sites in the signature associated with the genes listed in the table are hypermethylated in the classic CEBPA
DM 
apart from ARPP21 which is 
hypomethylated.  
2
number of samples with mutations detected/ number of samples analysed 
↑= Increased expression;  ↓= decreased expression
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Figure 3.11 Comparison of the classic CEBPADM and CEBPAWT 
methylation signatures to the methylation levels at these 25 CpG sites in 
normal bone marrow and blood cells.  β values were derived from published 
methylation levels (Calvanese et al, 2012). Cell subtypes had been purified 
using magnetic bead separation and FACS sorting. Blood1 and blood2 are 
peripheral blood samples, i.e interrogating all peripheral mononuclear blood 
cells; NK, natural killer cells; CD34_HSC, CD34 selected haematopoietic stem 
cells; CD34_DIFF, CD34 cells differentiated in vitro.
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Figure 3.12 Heatmap showing methylation values for each sample at the 
25 CpG sites in the CEBPA methylation signature.  Each column represents 
a different patient. Patient characteristics and genotype are given at the top of 
the diagram (key as in Figure 3.9). Methylation levels are as in Figure 3.11. The 
classic CEBPADM signature is shown to the left of the heatmap, and the 
CEBPAWT signature to the right. Samples are ordered according to which 
signature they are most alike. The bottom panel shows how alike each patient 
sample is to the two signatures. The green circles represent the similarity of the 
methylation levels of the sample to the CEBPADM signature, and the white 
circles to the CEBPAWT signature. The lower the y axis position of the circle, the 
more closely the patient sample matches that particular signature.
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and also the difference between the two scores, a cluster of 10 samples was 
identified that consisted of all 10 CEBPADM samples and no CEBPAWT samples 
(Figure 3.13). This clustering did not correlate with prognosis as three out of the 
ten samples were chemoresistant. 
3.3.4 Validation of results in two further cohorts of samples 
A further two cohorts of samples from a total of 96 patients were selected and 
analysed as previously except using the Illumina Infinium Methylation 450K 
BeadChip array. For cohort 2, 48 samples were chosen with the same criteria 
as the first cohort, namely NK, WT for NPM1, FLT3/ITD and FLT3/TKD. 
However, following on from the results of the first cohort, samples with known 
CEBPAMUT genotype were targeted, and 16 were CEBPADM, 8 CEBPASM and 
24 CEBPAWT (Table 3.3 and Appendix Table 2). Overall, 20 were known to be 
chemosensitive and 18 chemoresistant. Outcome was not available in 10 cases 
(3 CEBPADM, 7 CEBPASM). Cohort 3 consisted of samples from 48 patients that 
were specifically selected to analyse the profiles of different types of CEBPA 
mutations, in particular non-classic mutations. One sample was subsequently 
excluded from analysis due to low signal to noise ratios for all CpG sites. Of the 
remaining 47 samples, 15 were CEBPADM, of which 11 were non-classic DM; 
30 were CEBPASM, of which 21 were non-classic, seven were classic N and two 
were classic C mutations; and two were CEBPAWT (Table 3.3 and Appendix 
Table 2). It was not possible to select samples in the latter cohort that were all 
NK and WT for NPM1 and FLT3 and only eight patients fulfilled all these 
criteria. Of the other 39 patients, 14 were NK, nine had an abnormal karyotype 
of intermediate prognostic significance, five had an adverse karyotype, and 
karyotype was unknown in 11; 16 patients were WT for all three mutations, 14 
had an NPM1 mutation, nine a FLT3/ITD and seven a FLT3/TKD. Overall 
therefore in these two cohorts, 31 samples (33%) were CEBPADM, 17 (18%) 
with classic mutations and 14 (15%) with non-classic mutations, 38 (40%) were 
CEBPASM and 26 (27%) CEBPAWT. 
In view of the increased depth of coverage for each gene analysed in cohorts 2 
and 3 using the 450K HumanMethylation BeadChip, all CpG sites relating to 
four of the 20 genes in the CEBPA methylation signature were examined to 
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Figure 3.13 Distance from the classic CEBPADM and CEBPAWT signatures for the cohort 1 samples.  (A) Comparison of the 
distance from each of the two signatures. (B) Distance from the classic CEBPADM signature compared to the difference between the 
distance from each signature.
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check that differential methylation was maintained at the specific CpGs used in 
the signature, and to assess whether neighbouring sites also showed the same 
variation. The sites selected, GNMT, KHNYN, VAMP5 and LY9, all showed a 
marked difference in β values between CEBPADM and CEBPAWT samples in 
cohorts 2 and 3, which was consistent with the results from cohort 1. Three 
were more hypermethylated (GNMT, KHNYN and VAMP5) and LY9 was more 
hypomethylated in the CEBPADM samples (Figure 3.14). They were associated 
with 36, 17, 11 and 21 CpG sites respectively on the 450K array.  
A heatmap was created to show the methylation levels of the validation cohorts 
at all CpG sites associated with the four genes (Figure 3.15). Of the 36 CpG 
sites associated with GNMT, 27 were differentially methylated (as defined in 
Section 3.3.3). Of these, 25 showed a difference in median β value of >0.2 
between classic CEBPADM and CEBPAWT samples, and 12 were >0.5. Similarly, 
nine of the 17 CpG sites related to KHNYN were variably methylated, but only 
one site which was included in the signature showed a difference in median β 
value between classic CEBPADM and CEBPAWT samples of 0.4. The LY9 gene 
had five differentially methylated CpG sites, two of which showed a difference in 
mean β value between classic CEBPADM and CEBPAWT. VAMP5 had ten 
variably methylated CpG sites, of which four showed a difference in mean β 
value of >0.2. Thus the variability in methylation seen between CEBPADM and 
CEBPAWT samples was restricted to small regions associated with particular 
genes rather than the whole gene, in three of the four cases this was within or 
on the edge of a CGI, for LY9, where the closest CGI is approximately 5000 
bases downstream of the TSS, the differentially methylated CpGs were close to 
the TSS. 
Unsupervised cluster analysis was performed on the two follow-up cohorts 
using the same method as for cohort 1. The majority of samples in cohort 2 had 
been selected based on their outcome. When assessing whether unsupervised 
cluster analysis of this cohort separated samples based on prognosis, for the 38 
samples with known outcome, 12 of the 20 chemosensitive samples clustered 
together in the high methylation cluster and none of the 18 chemoresistant 
samples were seen in this cluster. However, this was linked to CEBPA 
genotype as all 12 samples were CEBPADM. Of the remaining eight 
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Figure 3.14 β values from patients studied in cohorts 2 and 3 with the 450K array at four of the sites in the CEBPA 
methylation signature.  Results have been grouped according to CEBPA genotype. Samples highlighted in red are non-classic 
CEBPADM. Medians for each cohort are given and significance compared to CEBPADM, *P<0.05; **P<0.01; ***P<0.001. (A) LY9, (B) 
VAMP5, (C) KHNYN, (D) GNMT.
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Figure 3.15 Methylation levels at all the CpG sites investigated on the 450K arrays that relate to 4 specific genes in the methylation 
signature.  (A) LY9 (21 CpG sites), (B) VAMP5 (11 CpG sites), (C) KHNYN (17 CpG sites) and (D) GNMT (36 CpG sites). Each row represents 
a different CpG site and they have been arranged in sequential order. The arrows to the right of the diagram indicate the location of the CpG 
islands. The arrows on the left indicate the CpGs assayed on the 27K array that were included in the methylation signature. Patient samples 
(columns) are arranged in the same order as Figure 3.12 with CEBPA status indicated at the top, classic DM, ■; non-classic DM, ■; SM, ■ and 
WT, □.
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(C) 
(D) 
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chemosensitive samples, seven were CEBPAWT. Further analyses therefore 
focussed on the CEBPA genotype, regardless of outcome. Overall, in both 
follow-up cohorts, 25 of the 31 CEBPADM samples analysed (81%) clustered 
together and, as before, they had a relatively hypermethylated profile compared 
to the other samples (Figure 3.16). Of the six CEBPADM samples that did not fall 
in this cluster, five were non-classic DM samples. The majority of the CEBPASM 
samples (31 of 38, 82%) clustered with the CEBPAWT samples.  
Given the confirmation from these follow-up cohorts that CEBPADM samples 
have a methylation profile that is distinct from non-DM samples, the 25 CpG site 
CEBPA methylation signature created from cohort 1 was assessed in these 
samples. As before, samples were ordered according to how close to the 
classic CEBPADM signature they were (Figure 3.17). Seventeen of these cases 
were classic DM. When the score for the distance to the mutant signature was 
plotted against the difference between the scores for the mutant and wild-type 
signatures, all classic CEBPADM except one formed a cluster equivalent to that 
observed in cohort 1 (Figure 3.18A). The remaining non-classic CEBPADM and 
CEBPASM cases will be considered further in chapter 4.  
3.3.5 Definition of criteria for a classic CEBPADM methylation profile 
In total, 25 cases in the three cohorts were classic CEBPADM and 56 were 
CEBPAWT. From the cluster analysis (Figure 3.18A), one CEBPADM case in 
cohort 2 was clearly an outlier. Possible reasons for this are presented in 
chapter 4, and it was excluded from further analyses. Data from the remaining 
24 classic CEBPADM cases were then combined and used to define criteria for a 
classic CEBPADM methylation profile. The mean score ± 2SD for the distance to 
the CEBPADM signature was 0.65 ± 0.44, and the mean difference between the 
distance to the classic CEBPADM and the CEBPAWT signatures was -2.14 ±0.90. 
Together the upper limits of these scores were used as cut-offs to define a 
classic CEBPADM quadrant (Figure 3.18B). All classic CEBPADM cases fell in 
this quadrant, although one was borderline for the difference between the two 
distance scores. No CEBPAWT samples were located within the CEBPADM 
quadrant. These criteria were then used to examine the non-classic CEBPADM 
samples and this data is presented in the next chapter.
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Figure 3.16 Unsupervised cluster analysis of cohorts 2 and 3.  The top panel shows the clustering. The middle panel shows the 
karyotype and molecular status for the specified genes. The bottom panel displays the mean methylation level for all CpG sites 
assayed on the arrays and located within CpG islands for each patient. 
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Figure 3.17 Heatmap showing methylation values for the CEBPA signature loci in the 95 patients analysed in the follow-up 
cohorts.  The ordering of the samples and the distance to the signatures for each sample is plotted as given for Figure 3.12.. 
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Figure 3.18 Comparison of the distance from the CEBPAMUT signature with the difference in the distance from each of the 
signatures in classic CEBPADM cases.  (A) Classic CEBPADM cases in the follow-up cohorts. (B) The 24 classic CEBPADM cases 
used to define a classic CEBPADM quadrant.
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3.3.6 Correlation of methylation array results with other mutations 
Although the majority of the samples in cohort 2 and all samples in cohort 3 
were selected based on their CEBPA genotype, clustering associated with other 
mutations was also examined. There was a suggestion that IDH1/2-mutated 
samples clustered together. Within cohorts 2 and 3, eight of the 18 IDHMUT 
samples were located in one cluster within the hypermethylated group, of which 
four were non-classic CEBPADM and four were CEBPASM (Figure 3.16). Five of 
the 10 IDHMUT samples that were within the hypomethylated group were 
CEBPAWT and the other five were CEBPASM. Cohort 1 contained 11 IDHMUT 
samples. One also had a CEBPADM and was in the hypermethylated group; the 
other 10 samples were all located within the hypomethylated group, and five of 
these clustered together (Figure 3.9). In cohorts 2 and 3, four of the 17 TET2MUT 
samples were in the hypermethylated group, three associated with CEBPADM 
and one with CEBPASM. A TET2 sub-group could be seen within the 
hypomethylated cluster which consisted of nine samples including six TET2MUT 
and one IDH2MUT sample.  The remaining 11 TET2MUT samples did not cluster 
based on their methylation profile. Similarly, the six WT1MUT samples in cohorts 
2 and 3 did not cluster.  
Overall, there were 22 samples with DNMT3A mutations, 21 of which were 
within the hypomethylated cluster. In cohort 1, four of the seven DNMT3AMUT 
were tightly clustered together although these samples also all had IDHMUT. In 
the follow-up cohorts one subgroup of seven samples had five with 
DNMT3AMUT. Overall, 14 samples with NPM1 mutations were studied all of 
which also were CEBPASM; six clustered together within the hypomethylated 
group on unsupervised analysis. 
3.3.7 Assessment of other samples within the good-risk prognostic 
category 
To assess whether the methylation signature created was specific to CEBPADM 
or whether other mutations and cytogenetic alterations that correlate with good-
risk prognosis also had a similar profile, the methylation level at three 
differentially methylated CpG sites was quantified in samples that had either 
inv(16) (n=21) or t(8;21) (n=19), or were NPM1MUTFLT3WT (n=42). 
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Pyrosequencing assays were created and titration curves prepared as 
described in section 1.2.3. Good correlations between the observed and 
expected results were obtained for all three sites (r2≥0.96) (Figure 3.19). PCRs 
were also performed on seven patient samples that had been investigated using 
the Illumina methylation arrays, to confirm the accuracy of the assays. These 
samples were selected as they were known to have a range of methylation 
values. The results of the pyrosequencing and arrays were highly comparable in 
all three assays (r2≥0.98) (Figure 3.20). The test samples were then bisulfite 
converted and analysed in duplicate using all three assays, and the mean of the 
replicates for each sample compared to the beta values multiplied by 100 for 
the 24 classic CEBPADM and 56 CEBPAWT samples.  
Samples from patients with core-binding factor leukaemias had similar results to 
the CEBPADM samples for LY9 but were significantly different for VAMP5 and 
KHNYN (Figure 3.21). The NPM1MUTFLT3WT samples were significantly 
different from the CEBPADM samples for KHNYN and LY9. These results 
indicate that the methylation levels observed in the CEBPADM samples were not 
due to a “good prognostic signature”. They also did not simply reflect reduced 
C/EBP activity, which is a recognised feature of core-binding factor 
leukaemias (Helbling et al, 2005; Pabst et al, 2001a). The Euclidian distance 
between these methylation scores and the median for CEBPADM was calculated 
for each sample. All three subgroups were significantly different from CEBPADM 
(Figure 3.22).
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Figure 3.19 Titration curves for the percentage methylation obtained using standards in the pyrosequencing assays.  
Results shown are the mean of duplicates. (A) LY9, (B) VAMP5, (C) KHNYN.
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Figure 3.20 Comparison of the pyrosequencing results and array beta values for patient samples.  The expected line for 
100% concordance is indicated. (A) LY9, (B) VAMP5, (C) KHNYN.
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Figure 3.21 Pyrosequencing results of samples from good-risk prognostic patients at three of the 25 CpG sites in the 
CEBPAMUT signature.  Mean of duplicate results from 21 inv(16), 19 t(8;21) and 42 NPM1MUTFLT3WT patients. The results of the 56 
CEBPAWT and 24 classic CEBPADM samples are the beta values x100 from the methylation arrays. Medians for each cohort are 
given and significance compared to CEBPADM, *P<0.05; **P<0.01; ***P<0.001.
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Figure 3.22 Euclidian distance of samples from patients in the good risk prognostic groups from the median profile of 
CEBPADM. The distances have been calculated from the results shown in Figure 3.21. The mean and 95% confidence interval for 
each group is shown and significance is compared to CEBPADM. 
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3.4 Discussion 
Specific cytogenetic abnormalities and mutations in AML patients correlate with 
particular prognostic groups that have marked differences in predicted 5-year 
survival rate ranging from approximately 5% to 60% (Grimwade et al, 2010). 
This has led to changes in management of these patients based on their 
prognostic category. However, approximately 50% of newly diagnosed patients 
fall into the intermediate prognostic category, thus there is a need to find new 
features at diagnosis that will aid in stratifying this cohort further. Previously 
published studies have assessed the methylome in large numbers of 
unselected patients and have found that those samples with the same 
karyotype or certain mutations in genes such as CEBPA and NPM1 have 
similar methylation patterns. Only two groups have created signatures 
predicting prognosis based on methylation status of defined CpG sites 
(Deneberg et al, 2010; Figueroa et al, 2010b). However, there was no overlap in 
the CpG sites analysed in the predictors developed by these groups, which 
probably reflects the different methodologies used as well as the different 
cohorts assessed. In the studies presented here, the approach used was to 
assess whether prognosis was associated with the methylation patterns of 40 
highly selected AML patients that were at the extremes of clinical outcome, 
either chemosensitive or chemoresistant, and lacked common cytogenetic or 
molecular abnormalities that were associated with prognosis, i.e. they all had an 
NK and were WT for NPM1, FLT3/ITD and FLT3/TKD. This approach was only 
possible due to the availability of over 1000 well-characterised samples in the 
departmental AML DNA Biobank, as only a small proportion of these patients 
fulfilled all the clinical and molecular criteria. 
Pyrosequencing was used to verify the β values of four of the CpG sites that 
showed the greatest variability in methylation between the chemosensitive and 
chemoresistant patients on the array. There was a highly significant correlation 
between the methylation level as quantified by the Illumina methylation array 
and pyrosequencing at all four CpG sites, with correlation coefficients ranging 
between 0.76 and 0.93 (p<0.0001 for all sites). Thus the percentage of 
methylated alleles at a particular site, as measured by the Illumina methylation 
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array, was reproducible using another method of analysis. However, both 
techniques used bisulfite conversion, and so would not pick up any biases in the 
conversion process. Furthermore, neither would be able to differentiate between 
an unmethylated C that had been converted to a T during bisulfite conversion 
and C/T SNPs, which theoretically could be an issue as 5-methylcytosine 
conversion to thymine is the most common evolutionary mutation seen on a 
genome-wide level (Bird, 1980). It has been reported that this may affect up to 
8% of CpG sites analysed (Morris & Lowe, 2012).  
By unsupervised cluster analysis of methylation levels of CpGs within CGIs, the 
40 samples included in the initial cohort could be divided into two groups, one 
with a hypermethylated phenotype and the other a hypomethylated phenotype. 
There was no evidence that these cohorts correlated with prognosis, as 38% of 
the hypermethylated group and 58% of the hypomethylated group were 
chemoresistant. However, when the cluster analysis was correlated with the 
mutant status of other recurrently mutated genes that had been investigated 
since the project started, there was a striking association between CEBPAMUT 
and the hypermethylated group. All ten CEBPAMUT samples in cohort 1 were in 
this group, and all these samples had double rather than single mutations. The 
incidence of CEBPAMUT in this cohort (25%) was higher than the incidence seen 
in published studies (9%), but this was due to the selection criteria used given 
that an NK, WT NPM1 and FLT3, and a favourable outcome are all known to be 
associated with CEBPADM (Green et al, 2010b). Of note however, three of the 
10 CEBPADM samples (30%) were from patients in the chemoresistant group, 
hence the methylation profile did not correlate with outcome despite the known 
association between CEBPADM and prognosis.  
A second cohort of samples was chosen to validate these results suggesting 
that prognosis per se did not correlate with methylation profile but CEBPAMUT 
status did, and to further assess whether the difference was restricted to 
CEBPADM or related to all CEBPAMUT. A third cohort was subsequently chosen 
based on the various types of CEBPA mutations to assess whether CEBPADM 
with classic and non-classic mutations had different methylation profiles. Both of 
these cohorts were analysed using the 450K BeadChip array as this had 
superseded the 27K BeadChip array. As the Infinium II assay used for the 450K 
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BeadChip has been shown to lead to some bias and to be less sensitive to 
either extreme of methylation (Dedeurwaerder et al, 2011), a statistical 
normalisation was performed by Dr Sproul to account for this within-batch 
variation for cohorts 2 and 3.  
Unsupervised cluster analysis of cohort 2 confirmed that there was no 
association between overall prognosis and methylation profile. Only 12 of the 20 
chemosensitive samples (60%) clustered together and all of them were 
CEBPADM. Further analysis therefore focussed on CEBPA genotype. Analysis 
of cohorts 2 and 3 confirmed that CEBPADM had a distinctive methylation 
profile, with 81% of the CEBPADM samples in the hypermethylated cluster. Only 
seven of the 38 CEBPASM (18%) and none of the 26 CEBPAWT samples were in 
the hypermethylated group. These results are similar to those in the study 
published by Figueroa et al (2010b) where 14 of the 24 patients with CEBPADM 
(58%) were in a unique cluster with a hypermethylated profile. They also found 
a second cluster of nine patients, five CEBPADM, two CEBPASM and two 
CEBPAWT, which had a predominantly hypomethylated phenotype. Conversely, 
using the same Illumina methylation array as the one used in the studies 
presented here, Deneberg et al (2011) did not find an association between 
CEBPAMUT and methylation profile, but only six of the 118 patients they 
analysed had CEBPAMUT, and they did not state whether they were single or 
double mutations. This clustering is supported by data from published gene 
expression arrays, which also show that CEBPADM samples form unique 
clusters (Grossmann et al, 2013; Taskesen et al, 2011; Valk et al, 2004; van 
Vliet et al, 2013; Wouters et al, 2009). Together with other factors, including for 
example the inverse correlation with NPM1 mutations and the improved overall 
survival seen in patients with CEBPADM compared to CEBPAWT or CEBPASM 
(Dufour et al, 2010; Green et al, 2010b; Pabst et al, 2009; Wouters et al, 2009), 
this data provides further evidence that CEBPADM is a distinct biological entity. 
Only limited conclusions can be drawn about the correlation of methylation 
profiles with other mutant genes as the selection of a high proportion of 
CEBPAMUT samples would have influenced the cluster analysis. However, there 
was a suggestion that IDH1/2-mutated samples clustered together based on 
their methylation profile. Samples with IDHMUT have been reported to have a 
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hypermethylated profile (Deneberg et al, 2010; Figueroa et al, 2010a), although 
in the analysis presented here, only ten of the 30 IDHMUT clustered in the 
hypermethylated group. A hypomethylated cluster of nine samples included one 
IDH2MUT and six TET2MUT samples, suggesting that these mutations, which are 
known to be mutually exclusive, can be associated with similar methylation 
profiles. Mutations in DNMT3A are known to be inversely correlated with 
CEBPADM, and in these cohorts only three of the 22 DNMT3AMUT samples also 
had CEBPADM (Gale et al, 2015). All bar one of the samples with DNMT3AMUT 
clustered within the hypomethylated group. DNMT3AMUT have been associated 
with hypomethylation in other studies, which is consistent with the mutations 
being loss-of-function and dominant-negative, thus affecting the protein’s ability 
to catalyse de novo methylation of CpG sites (2013; Hajkova et al, 2012; Qu et 
al, 2014; Russler-Germain et al, 2014). Overall, 14 samples with NPM1 
mutations were studied; six clustered together on unsupervised analysis, which 
has also been seen in other studies (2013; Figueroa et al, 2010b). Of note, all 
14 also had a CEBPASM, which may have influenced the analysis. Together 
these studies suggest that the clustering of samples by their methylation profiles 
can be linked with the underlying molecular status of the samples, but there is 
still variability in these profiles, even in samples with the same mutations, which 
may partly be explained by co-incident mutations.   
A CEBPA methylation signature was created based on the 25 most differentially 
methylated CpG sites between classic CEBPADM and CEBPAWT samples 
investigated in the first cohort. None of the genes connected to these CpG sites 
were known to be associated with CEBPA, and none of them were included in 
the published methylation signatures that were related to prognosis (Bullinger et 
al, 2010; Figueroa et al, 2010b). The distance to the mutant signature and the 
difference between the distance to the wild type and the mutant signature for 
each sample was plotted. All ten CEBPADM and no CEBPAWT samples were 
located within this cluster. The CEBPA methylation signature was then validated 
using 17 additional classic CEBPADM and 26 CEBPAWT cases. Sixteen of the 17 
classic CEBPADM had a methylation profile closest to the CEBPAMUT signature, 
and conversely all 26 CEBPAWT samples had a signature closest to the 
CEBPAWT signature. Criteria to define a classic CEBPADM quadrant were then 
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derived from the distance scores for the 24 classic CEBPADM samples, 
excluding the outlier in the follow-up cohort.   
Pyrosequencing assays of a subset of differentially methylated CpG sites were 
used to assess the methylation levels of samples from patients with other 
categories of good-risk AML. The results showed that samples from patients 
with core binding factor leukaemia had very similar methylation levels at two of 
the three CpG sites analysed, and from patients with NPM1MUT/ FLT3WT at one 
of the sites. However, the levels were significantly different between CEBPADM 
and the core-binding factor leukaemias at two of the three probes, and at two of 
the three probes when compared to NPM1MUT/ FLT3WT samples. This suggests 
that the methylation profile produced is not due to reduced C/EBPα activity 
alone or good-risk prognostic AML, but is specific to CEBPADM samples. This is 
in agreement with published data that shows that these subtypes of AML cluster 
separately based on their methylation profiles (Figueroa et al, 2010b).  
In the next chapter, the methylation signature created that is associated with 
classic CEBPADM samples is explored further to examine whether non-classic 
CEBPADM and CEBPASM also have a similar methylation profile.
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CHAPTER 4:INVESTIGATION OF NON-CLASSIC 
CEBPA
DM
 AND CEBPA
SM
 SAMPLES AND 
METHYLATION OF THE CEBPA PROMOTER 
4.1 Introduction 
As discussed in the previous chapter, approximately 75% of patients with a 
CEBPADM have a frameshift or nonsense mutation in the N terminus coupled 
with an in-frame insertion and/or deletion in the C terminus on the other allele. 
The N-terminal mutation occurs between amino acids 1-119, leading to 
increased translation from an internal ATG start site at amino acid 120 and 
production of a truncated p30 protein lacking the first transactivation domain 
(TAD) (Figure 3.1). The C-terminal mutations, occurring between amino acids 
278-358 that encode the bZIP DNA binding domain and leucine zipper domain, 
are predicted to lead to a non-functional protein with impaired ability to bind 
DNA or dimerise, C-loss of function protein (C-LOF) (Figure 3.1). However, the 
remaining 25% non-classic CEBPADM are varied, with differing predicted 
consequences of the mutations. Approximately 5% of patients with CEBPADM 
have either a homozygous classic N mutation, predicted to lead to p30 protein 
only, or a homozygous classic C mutation, predicted to lead to C-LOF protein 
only (Table 3.2). Many non-classic mutations have also been reported, including 
missense mutations in the C terminus predicted to also give rise to C-LOF 
protein, and frameshift or nonsense mutations located after the first TAD that 
would lead to a truncated protein and are likely to be associated with nonsense-
mediated decay and haploinsufficiency (Frischmeyer & Dietz, 1999). As 
discussed in section 3.1.3, functional work with non-classic mutations is limited, 
however there is a suggestion that they do not behave as classical mutations 
from gene expression studies and mouse models (Togami et al, 2015; Wouters 
et al, 2009). 
The methylation array data presented in the previous chapter and published by 
other groups highlight that AML samples with particular mutations, e.g. 
CEBPADM or DNMT3AMUT, often have similar DNA methylation profiles. This 
chapter explores whether the methylation profiles of non-classic CEBPADM and 
CEBPASM samples are similar to that of classic CEBPADM; why some CEBPADM 
  
116 
    
might have a methylation profile more like wild-type; and finally whether 
methylation of the CEBPA promoter could provide an explanation for some 
CEBPASM samples having a methylation profile like classic CEBPADM.  Given 
that patients with CEBPADM lacking a FLT3/ITD are classified as good-risk and 
are therefore not usually considered for a stem cell transplant in first remission 
(Cornelissen et al, 2012), the methylation profile of non-classic CEBPADM 
samples may improve our understanding of the prognostic significance of these 
mutations and whether they should also be considered good-risk. 
4.1.1 Allelic status of CEBPADM and CEBPA mutant level 
The two mutations in CEBPADM samples are presumed to be biallelic by most 
groups, leading to a complete lack of WT allele. This is supported by 
competitive transplantation models of cebpa mutations in mice, as only mice 
receiving cells with two mutant alleles subsequently developed leukaemia 
(Bereshchenko et al, 2009). Only a few groups have investigated patient 
samples by cloning the entire CEBPA coding sequence and sequencing the 
clones to determine whether these mutations are indeed biallelic or if they are 
both located on the same allele. The distinction is an important one to make as, 
if the mutations are monoallelic, the impact would be predicted to be more akin 
to a CEBPASM than a CEBPADM genotype and this would have prognostic 
implications. Overall, seven studies have reported data from 87 CEBPADM 
patients that showed only three CEBPADM cases (3%) were likely to be 
monoallelic (Barjesteh van Waalwijk van Doorn-Khosrovani et al, 2003; Dufour 
et al, 2010; Frohling et al, 2004; Green et al, 2010b; Lin et al, 2005; 
Preudhomme et al, 2002; Shih et al, 2006).  
Knowledge that the two mutations found in CEBPADM samples are located on 
different alleles does not, however, prove that both mutations are located within 
the same cell. In theory, they could represent two separate AML subclones 
containing different CEBPA mutations, which would require single cell analysis 
for confirmation. Quantifying the level of the mutants may, however, provide 
some indication as to whether the mutations are likely to be within the same cell 
as the level of the two mutations would be expected to be equivalent. Mutant 
level has also been associated with prognosis, for example, in the case of 
FLT3/ITD, a higher mutant level is associated with a worse overall prognosis 
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(Gale et al, 2008). Lastly, assuming that the mutation is in the dominant 
leukaemic clone, mutant levels may provide an estimate of the presence of non-
leukaemic cells in a sample, which would be relevant to other analyses 
including the methylation profile. Only one paper provided details of mutant 
level of CEBPA in AML patients (Green et al, 2010b). The median level for 102 
mutations was 44% (range 9-97%), and the level was at least 35% in 87% of 
the samples, suggesting that the mutation is likely to be acquired early in the 
disease pathogenesis. Furthermore, the mutant level of paired mutations in 26 
CEBPADM cases was highly correlated, suggesting that they were likely to be 
found within the same cell.  
4.1.2 Promoter hypermethylation in AML 
When aberrant methylation was detected in CGIs of cancer cells, initially it was 
thought that this could be an alternative mechanism for silencing genes and 
was coined an “epimutation” (Esteller, 2002; Herman & Baylin, 2003). Indeed, 
many of the genes that are recurrently mutated in AML are also found to have 
promoter hypermethylation in a subset of samples, e.g. DNMT3A and CEBPA 
(Fasan et al, 2013a; Jost et al, 2014). Furthermore, those samples with 
mutations and those with epimutations seem to be mutually exclusive (Shen & 
Laird, 2013). However, contrary to the hypothesis that methylation is causing 
the genes to be silenced, many of these genes, although unmethylated, are not 
expressed in the normal cell of origin (Sproul et al, 2012). This has led to the 
proposal that DNA methylation stabilises long-term repression rather than 
initiates it (Feldman et al, 2006), or that DNA methylation in promoter regions is 
a consequence of lack of transcription factor binding to the gene promoter 
rather than the cause of repression (Gebhard et al, 2010).  
4.1.3 Promoter hypermethylation of CEBPA 
Given the role that C/EBPα plays in myeloid differentiation, and the fact that its 
expression is reduced in certain sub-types of AML, Chim et al (2002) 
investigated whether this was due to aberrant hypermethylation of the CEBPA 
promoter. Analysing bisulfite-converted DNA from 70 AML samples using 
methylation-specific PCR, they found that two of the samples showed promoter 
methylation (2.8%). The primers used covered regions around the transcription 
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start site (TSS), the so-called “core promoter region”. Following this, it was 
noted that methylation of the CEBPA promoter also occurred in other 
malignancies such as head and neck, and lung cancer (Bennett et al, 2007; 
Tada et al, 2006). However, in these cases, the methylation was seen 
approximately 800-1000 bases upstream from the TSS, “the proximal and distal 
regions”. This prompted several groups to examine methylation of the CEBPA 
promoter in these regions in AML, as well as the core region (Table 4.1). In 
these studies, the frequency of methylation in the core region in AML ranged 
from 1-16% and in the distal region from 13-51%. The variable frequencies 
seen by the different groups may partly reflect the different methods used to 
assess methylation levels, and also how methylation or hypermethylation has 
been defined, as there is no set standard.  
The published data on whether methylation of the CEBPA promoter is 
associated with CEBPA silencing in AML varies. Although APML is associated 
with lower levels of CEBPA expression, Santana-Lemos et al (2011) found no 
direct correlation between gene expression and aberrant methylation of the core 
or distal promoter in these samples. Hackanson et al (2008) also found no 
association between CEBPA gene expression and distal region methylation in 
unselected AML samples. However, some studies have reported a link between 
mRNA expression and core promoter methylation (Hollink et al, 2011; Szankasi 
et al, 2011), and others a link with distal methylation (Fasan et al, 2013a; Lin et 
al, 2011; Musialik et al, 2014).  
When the gene expression profile of 285 unselected AML samples was 
analysed using an unsupervised cluster approach, two distinct clusters were 
identified that were comprised primarily of CEBPAMUT cases but in one of these 
clusters, six of the 15 samples did not have mutations in CEBPA (Wouters et al, 
2007). Further analysis of the data revealed that they did, however, have 
minimal or absent CEBPA expression. Bisulfite sequencing showed that of 
these six samples, four had methylation in the core region of the CEBPA 
promoter and the authors suggested that methylation may indeed have a similar 
impact on gene expression profile of AML samples as mutations in the gene. 
This group of CEBPA-silenced samples also had abnormal expression of T cell 
markers and were associated with activating mutations in NOTCH, a gene that 
encodes a transmembrane receptor. 
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Table 4.1 Frequency of CEBPA promoter methylation reported in diagnostic AML samples 
Table 4.1 continued 
Reference 
Total 
no. of 
patients 
No. with CEBPA 
methylation
1
 (%) 
Method of 
analysis 
Region of 
analysis
2 
Prognostic impact of 
CEBPA methylation 
Association of CEBPA 
methylation with other 
molecular markers 
Chim et al (2002) 70 2 (3) MSP Core Not assessed  
Agrawal et al (2007) 81 9 (11) MALDI TOF 
Proximal and 
core 
Not assessed   
Wouters et al (2007) 285 4 (1) 
Bisulfite 
sequencing 
Proximal Not assessed  
Hackanson et al 
(2008) 
39 20 (51) 
COBRA/ 
bisulfite 
sequencing 
Distal, proximal 
and core 
Not assessed 
More frequent in inv(16) and 
t(15;17) cytogenetic 
subgroups 
Jost et al (2009) 80 10 (13) 
MSP/ bisulfite 
sequencing 
Core Not assessed  
Griffiths et al (2010) 169 27 (16) MSP Core Not assessed 
No association with 
cytogenetic risk group or 
FLT3 or NPM1 status 
Lu et al (2010) 53 7 (13) MSP Core Not assessed 
Inverse association with 
FLT3/ITD and NPM1
MUT 
CEBPA
METH
 and CEBPA
MUT
 
mutually exclusive 
Szankasi et al (2011) 102 5 (5) Pyrosequencing Core Not assessed 
CEBPA
METH
 and CEBPA
MUT
 
mutually exclusive 
All 5 samples had CD7 
expression 
Hollink et al (2011) 237
2 
3 (1) MSP Core Not assessed  
Lin et al (2011) 193 28 (15) MALDI TOF 
Distal, proximal 
and core 
Higher methylation 
associated with better 
OS 
Mutual exclusion with 
NPM1
MUT 
Santana-Lemos et al 
(2011)  
39
3 
17 (13) 
MSP/ bisulfite 
sequencing 
Distal and core Not assessed  
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Table 4.1 continued 
Reference 
Total 
no. of 
patients 
No. with CEBPA 
methylation
1
 (%) 
Method of 
analysis 
Region of 
analysis
2 
Prognostic impact of 
CEBPA methylation 
Association of CEBPA 
methylation with other 
molecular markers 
Fasan et al (2013a) 623 238 (38) 
MSP/ bisulfite 
sequencing 
Distal, proximal 
and core 
No association between 
methylation and 
prognosis 
Inverse association with 
NPM1
MUT 
CEBPA
METH
 and CEBPA
MUT
 
mutually exclusive 
Musialik et al (2014) 76 28 (37) qMSP 
Distal, proximal 
and core 
Not assessed 
Associated with good 
cytogenetic risk group 
 
1
The definition of CEBPA methylation varied between papers. 
2
Paediatric AML samples analysed only. 
3
Acute promyelocytic leukaemia samples analysed 
only. 
COBRA, combined bisulfite restriction analysis; MALDI TOF, matrix-assisted laser desorption/ ionisation- time of flight; METH, methylated promoter as defined 
by authors; MSP, Methylation-specific PCR; MUT, mutant gene; OS, overall survival; qMSP, quantitative methylation-specific PCR 
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Comparing the methylome of the CEBPA-silenced cases with that of CEBPAMUT 
showed that the two groups were epigenetically distinct, with the silenced cases 
showing marked hypermethylation at over 90% of the variable sites compared 
to the mutant cases (Figueroa et al, 2009b). Furthermore, there were biological 
differences between the two groups, with the CEBPA-silenced patients 
exhibiting significantly worse survival.   
The aims of this chapter were to further characterise the CEBPADM samples, 
including assessing the allelic status and the level of the mutations, and then to 
use the CEBPA methylation signature to examine the non-classic CEBPADM 
and CEBPASM samples. Finally, methylation of the CEBPA promoter itself was 
analysed. 
 
4.2 Materials and Methods 
4.2.1 Allelic status of CEBPADM samples 
To assess the allelic status of CEBPADM samples, PCR products spanning the 
entire coding region were prepared, cloned, and the clones then analysed to 
determine whether they contained one, both or neither of the mutations. 
Amplicons were prepared using primers CEBPA 1F and 3R (Appendix Table 1) 
with standard BIOTAQ polymerase mix plus 5% DMSO (Chapter 2, section 
2.1.2). The time for each denaturation, annealing and extension step was 
extended to 60, 60 and 90 seconds respectively, and the final extension step 
was 10 minutes. Once the presence of products had been confirmed on an 
agarose gel, aliquots of each product were cloned as described in Chapter 2 
(section 2.1.9). At least 20 colonies per sample were picked, seeded into 96 
well plates and incubated overnight at 37°C.  
Each clone was assessed with the two relevant PCRs to examine whether they 
had one, both or neither of the known mutations for each sample. The method 
of mutation detection varied depending on the type of mutation being analysed 
(Table 4.2). If the mutation resulted in a size change of ≤2 nucleotides, a 
restriction digest was performed to differentiate mutant from WT clones. 
Standard BIOTAQ PCRs with 5% DMSO were performed with 1µl of bacterial 
culture. An initial hotstart at 95°C for 5 minutes preceded all reactions to ensure 
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Table 4.2 Methods used to differentiate between WT and mutant alleles in CEBPA mutation quantification and clone 
characterisation 
Patient No. Mutation 
Forward 
Primer1 
Reverse 
Primer1 
Method used 
post PCR 
Expected size of WT 
fragment(s) 
Expected size of 
mutant fragment(s) 
27 
334_335insGC 1F* 1R3 RED AscI 219+329* 550* 
912_913InsTTG 3F* 3R CEQ 424* 427* 
53 
113 delG 1F* 1R3 RED Eco109I 37+54+141+142*+174 37+54+141+315* 
938_939insTA 3F* 3R CEQ 424* 426* 
63 
198_201dup 1F* 1R3 CEQ 548* 552* 
890G>C 3F* 3R RED FspI 84+142*+198 198+226* 
76 232delC 1F* 1R3 RED BstNI 103+183+262* 103+444* 
899G>C 3F* 3R RED BanII 126+298* 126+147+151* 
1Primers as detailed in Appendix 1. *Fluorescently labelled primers and fragments 
PCR, polymerase chain reaction; RED, restriction enzyme digest.  
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lysis of the bacteria. The presence of products was confirmed by agarose gel 
and then 6µl of each product was digested with the appropriate enzyme. 
Presence or absence of a mutation in a particular colony was assessed by 
running the digested products on an agarose gel with a DNA ladder to assess 
the length of the digested fragments. If the mutation resulted in a size change of 
≥3 nucleotides, or there was no restriction enzyme digest readily available for 
mutations with a size change of 1-2 bases, then clones were amplified with 
BIOTAQ PCRs using a fluorescently labelled primer and the products were 
analysed by size separation on the CEQ (section 2.1.7). To ensure accurate 
fragment sizing, each product was run twice, once unmixed and once mixed 
with known WT amplicons. Thus if two peaks were seen in the mixed run, and 
the size difference was as expected, then the clone carried the mutation under 
investigation. 
4.2.2 Quantification of CEBPA mutant level 
PCRs covering the mutations were performed using a fluorescently labelled 
primer. They were analysed by size separation on the CEQ as detailed in 
chapter 2 (section 2.1.7) and above for allelic status determination, with 
restriction enzyme digestion where required, but without mixing with WT 
amplicons. The area under the wild-type and mutant peaks was assessed by 
the instrument software and used to calculate the relative level of mutant alleles 
as a percentage of total alleles.  
4.2.3 Analysis of CEBPA promoter methylation 
Methylation levels in the CEBPA promoter region were initially analysed using 
data from the 27K and 450K arrays. To examine a greater number of CpG sites 
in this region, three PCRs were designed for bisulfite sequencing. The regions 
chosen were based on previously published data, namely, the core and distal 
regions (Lin et al, 2011). Primers were designed using the PyroMark Assay 
Design Software 2.0 (Qiagen, Germany) (Appendix Table 1). Amplicons were 
prepared using GoTaq DNA polymerase with a standard reaction mix (section 
2.2.4). Products were purified and sent for DNA sequencing. Methylation levels 
were estimated by comparing the peak height of the “C” nucleotide in a CpG 
site over the total peak heights of the “C” and “T” nucleotides.  
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Fresh aliquots of bisulfite-converted DNA were prepared for all 135 samples 
analysed on the arrays. Samples from each batch were checked for conversion 
efficiency as detailed in Chapter 2 (section 2.2.3). Each bisulfite-converted 
sample was then subjected to three PCRs to examine the core region, and the 
distal region in both the forward and reverse direction. Products were sent for 
DNA sequencing and the methylation levels estimated as outlined above.  
 
4.3 Results 
4.3.1 Further investigation of the CEBPADM samples  
In total, 31 CEBPADM cases were investigated in the two validation cohorts. 
When these cases were evaluated using the parameters for the classic 
CEBPADM quadrant, as defined in the previous chapter, 12 (39%) did not satisfy 
the criteria and one case was borderline (Figure 4.1). Only one of the latter 
cases was a classic CEBPADM. 
4.3.1.1 Allelic status of the CEBPADM samples 
Six of the samples investigated (all classic CEBPADM) that were within the 
classic CEBPADM quadrant had previously been shown to be biallelic (Green et 
al, 2010b). As it is known that a small proportion of CEBPADM samples may be 
monoallelic, and thus may behave more like CEBPASM, the distribution of the 
two mutations in some of the 12 CEBPADM that were not located in the classic 
CEBPADM quadrant was investigated. Two were homozygous C-terminal 
mutations and thus had to be biallelic. Full-length amplicons were cloned from 
one classic CEBPADM and five non-classic cases. No full-length PCR product 
could be obtained for one of these samples. At least 19 full-length CEBPA 
clones were analysed for the remaining five samples (range, 19-37). In three 
samples all clones had just one of the mutations, and in two samples, just one 
clone of the 24 and 19 clones contained both mutations, indicating that all five 
samples were biallelic, including the classic CEBPADM case that did not fall in 
the classic CEBPADM quadrant (Table 4.3).
  
 
    
1
2
5
 
 
 
 
Figure 4.1 Distance scores for all CEBPADM and CEBPAWT samples in the validation cohorts.  
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Table 4.3 Mutation screening of full length clones from CEBPADM samples 
Patient No. 
No. of clones 
analysed 
No. of clones 
with 1 
mutation 
No. of clones 
with both 
mutations 
No. of WT 
clones 
12 19 15 1 3 
27 37 36 0 7 
49 27 27 0 0 
53 24 18 1 5 
76 21 16 0 5 
 
4.3.1.2 Mutant level in CEBPADM samples 
The relative mutant level of both mutants in 37 of the 41 CEBPADM cases in the 
three cohorts was already known (Green et al, 2010b) or had been quantified by 
other members of the department. This included 12 cases (16% of all 
mutations) that were estimated using peak heights in the sequence 
chromatogram, with the mean of at least five peaks, because the mutations did 
not lead to size changes and there were no restriction enzymes available to 
differentiate between the mutant and wild-type alleles. Mutant levels were 
measured in the remaining four cases (Table 4.4). Overall therefore, 77 
mutations were quantified from the 41 CEBPADM samples analysed on the 
array. Assuming that the mutant allele level was half of the total mutant level for 
the five homozygous mutant samples, the mean mutant level was 44% (range, 
24%-57%). Of note, the one classic CEBPADM case that did not fall within the 
classic quadrant had mutant levels of 24% and 31%, consistent with only half 
the cells in the sample carrying the mutations. Thus the methylation profile in 
this case could have been affected by the presence of a significant proportion of 
non-leukaemic cells. The remaining 24 classic CEBPADM cases had a mean 
mutant level of 44%, range 28%- 57%. The mean mutant level for the five non-
classic cases that fell within the classic quadrant was 45% (range, 40%-50%), 
and it was 45% (range, 26%-54%) for the eleven cases that were outside the 
classic quadrant. One of the non-classic CEBPADM cases that did not fall into 
the classic quadrant group, patient number 69 had low mutant levels of 26% 
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and 38%. Apart from the two patient samples discussed, mutant level did not 
differ between samples within the classic quadrant from those outside of the 
quadrant. 
Table 4.4 Mutant levels of compound heterozygous CEBPADM samples 
Patient no. Mutation 1 Level (%) Mutation 2 Level (%) 
27 334_335insGC 24 K304_Q305insL 31 
53 113delG 46 938_939insTA 48 
63 198_201dup 38 890G>C 54 
76 232delC 36 899G>C 41 
 
4.3.2 Methylation profile of non-classic CEBPADM cases 
The initial cohort included two non-classic CEBPADM samples, both of which 
clustered with the classic CEBPADM samples on unsupervised cluster analysis 
(Figure 3.9). The follow-up cohorts contained 14 such cases, with a variety of 
different mutations, five of which fell in the relatively hypomethylated cluster 
(Figure 3.18). All these non-classic CEBPADM cases were therefore considered 
according to the predicted functional consequence of their mutations in order to 
assess their methylation profile. 
Six cases were predicted to produce just p30 protein due to a classic N 
mutation on one allele and a frameshift mutation after the 2nd ATG site on the 
second allele (Figure 4.2A). Only one of these fulfilled the classic CEBPADM 
criteria, the remaining five were all more distant from the mutant signature. 
Three samples were predicted to produce only C-LOF protein; two had 
homozygous classic C mutations and the other one a classic C mutation 
coupled with a frameshift mutation after the 2nd ATG site. Two of the three 
cases fulfilled the classic CEBPADM criteria (Figure 4.2B). The remaining seven 
cases all had at least one missense mutation in the C terminus of unknown 
functional consequence (Figure 4.2C). Three of these samples had a classic N 
mutation with a missense mutation in the C terminus (p.A295P, p.R297P and 
p.R300P), thus if the missense mutation led to a C-LOF protein then these 
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Figure 4.2 Distance scores for the non-classic CEBPADM and the CEBPASM cases. CEBPADM cases predicted to produce (A) p30 only, 
(B) C-LOF only, (C) with missense mutations. (D) CEBPA
SM 
cases. Null indicates a frameshift or nonsense mutation after the second ATG site. 
Abbreviations: C-LOF, C-terminal loss of function mutation; MID-missense, missense mutation in the middle of the gene; MUT, mutation; p30, classic N 
mutation; WT, wild-type. 
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cases would be predicted to be equivalent to a classic CEBPADM case with p30 
plus a C-LOF protein. All three samples were located outside the classic 
CEBPADM quadrant (Figure 4.2C). Three samples had homozygous missense 
mutations in the C terminus; one of these cases with a p.V314G mutation was 
in the first cohort. One further case had a classic C terminus mutation with a 
missense mutation. Assuming that all these mutations led to a C-LOF protein, 
these four cases would be predicted to produce just C-LOF protein without p30. 
Two of these samples satisfied the classic CEBPADM criteria (homozygous 
p.V314G and p.N321S/p.R306_V314dup) and two did not (homozygous 
p.N321S and homozygous p.L317Q). 
4.3.3 Analysis of CEBPASM samples in the validation cohort 
The follow-up cohorts included 38 CEBPASM cases, nine were classic N 
mutations and five classic C mutations, and the others were a range of non-
classic mutations. On unsupervised analysis, seven (18%) clustered with the 
CEBPADM samples (Figure 3.16). By assessing the methylation levels using the 
CEBPA signature, only one satisfied the criteria for classic CEBPADM and was 
located within that quadrant and another was borderline; both of these samples 
had a classic C mutation (Figure 4.2D). One possible explanation is that the 
wild-type allele in these two cases was silenced leading to functional 
hemizygosity. Unfortunately, RNA was not available in these cases to examine 
relative expression of the mutant and WT alleles.  
4.3.4 Methylation of the CEBPA promoter 
4.3.4.1 Data from the arrays 
It has been reported that the promoter region of the CEBPA gene can be 
methylated in AML and that this leads to a similar gene expression profile to 
CEBPADM (Wouters et al, 2007). To determine whether methylation of the 
CEBPA promoter, CEBPAMETH, could be influencing the methylation signatures 
of the samples investigated in these studies, the CpGs associated with the 
CEBPA gene that were analysed on the Illumina Methylation Arrays were 
assessed. The 27K HumanMethylation BeadChip analysed 2 CpG sites which 
were 516 bases upstream and 790 bases downstream from the TSS (Figure 
4.3, probes 7 and 14). 
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Figure 4.3 Location of probes on the Illumina methylation arrays that are associated with the CEBPA gene.  
The black line represents the DNA, with the numbering depicting the distance from the transcription start site of CEBPA. The 
transcribed region is shown by the upper box, with the translated region shaded in black. The location of the CGI and shores is 
shown in the lower box. The unshaded triangles represent the location of the 2 CpG sites analysed on the 27K Illumina Methylation 
array. All 17 triangles represent the locations of the CpG sites examined by the 450K Illumina Methylation array. The three arrows 
indicate the distal (D), proximal (P) and core (C) regions of the CEBPA promoter as defined by Lin et al (2011). 
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The 450K HumanMethylation BeadChip analysed 17 CpG sites between the 
shelves from 4618 bases upstream to 4960 bases downstream of the TSS, 
including the two sites analysed on the 27K array.  
The heatmap from the 450K array data of the samples from cohorts 2 and 3 is 
shown in Figure 4.4. Most CpG sites showed little variance in the methylation 
level across the whole cohort; all samples were unmethylated (β value <0.10) 
within the CGI (probes numbered 6-14 on Figure 4.4) and hypermethylated (β 
value >0.45) outside the shores (probes 1 and 17). The differential methylation 
within the cohort occurred at the outer boundaries of the CGI (probes 3-5 and 
15) and shores (probes 2 and 16). For example probe 2 (cg21715751 on the 
BeadChip), 1919 bases upstream of the TSS was generally hypomethylated in 
all the CEBPADM samples, median β value 0.07 (range, 0.03-0.35) (Figure 4.5). 
Conversely, it was predominantly hypermethylated in the CEBPASM and 
CEBPAWT samples, medians 0.6 (range, 0.04-0.92) and 0.79 (range, 0.08-0.92) 
respectively. The difference across all three groups was statistically significant 
(P<0.0001). Neither of the two CEBPADM samples that were outliers with β 
values >0.2 fulfilled the classic CEBPADM criteria based on the methylation 
signature. One of these was the classic CEBPADM sample that had low mutant 
levels and was thus thought to have a high proportion of non-leukaemic cells, 
the other had a homozygous missense mutation in the C terminus (p.N321S). 
Otherwise, no difference in methylation levels was observed in classic versus 
non-classic CEBPADM at this probe site. Although the median β value for all 
CEBPASM samples was significantly different from the median for CEBPADM 
samples, the standard deviation was also greater, 0.3 and 0.07 respectively. 
Seven of the 38 CEBPASM samples had methylation levels <0.2 at this probe, 
however this did not correlate with the CEBPA methylation signature. Only one 
of the two CEBPASM samples that was located in or at the border of the classic 
CEBPADM quadrant had a methylation level <0.2 (β values 0.38 and 0.1 
respectively).  
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Figure 4.4 Heatmap showing the methylation values for probes closest to the CEBPA gene in the 95 patients in the 
follow-up cohorts, as analysed on the 450K Illumina Methylation Array.  Each row represents a CpG probe, numbered as 
in Figure 4.3. Probes 3 and 4 fall within the distal region and probe 5 in the proximal promoter region as defined by Lin et al 
(2011). Each column represents a sample, ordered as in Figure 3.17, with the CEBPA genotype indicated above the heatmap, 
■= classic CEBPADM, ■= non-classic CEBPADM, ■= CEBPASM, and □=CEBPAWT.  
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Figure 4.5 β values at probe 2, CG21715751 for the 95 samples in the 
follow-up cohorts, arranged according to CEBPA genotype.  
The median β value is given. The samples highlighted in red in the CEBPADM 
column are those that did not fall within the classic CEBPADM quadrant. The 
sample highlighted in green in the CEBPASM column was located within the 
classic CEBPADM quadrant.   
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The CpG site cg02493939, probe 3, 1275 bases upstream of the TSS, located 
in the distal promoter region as defined by Lin et al (2011) and Fasan et al 
(2013a), was predominantly hypomethylated in all samples. In all CEBPADM 
samples, the maximum β value was 0.15. Of the 28 CEBPASM samples, two had 
a β value >0.4, one of which was located in the classic CEBPADM quadrant. Of 
the 26 CEBPAWT samples, 17 (65%) had a β value >0.15, but only four (15%) 
were >0.5.   
4.3.4.2 Analysis of the CEBPA promoter by bisulfite sequencing 
Only two CEBPA-associated CpG sites interrogated as part of the Illumina 
Infinium Methylation 450K array were located in the distal region of the 
promoter (Probes 3 and 4, 1275 and 1219 bases respectively from the TSS) 
and one in the proximal region (Probe 5, 1085 bases from the TSS) as defined 
by Lin et al (2011). No probes were located in the core region. Thus three PCRs 
were designed to assess the methylation levels in the distal and core regions in 
more detail (Figure 4.6). Just one of 843 AML samples in published studies 
showed evidence of methylation in the proximal region, and thus this region was 
not examined (Fasan et al, 2013a; Lin et al, 2011; Musialik et al, 2014). 
Although bisulfite sequencing is not a truly quantitative method of analysing 
methylation levels in samples, an estimate of the methylation level was sought 
at each CpG site by measuring the height of the cytosine peak over the 
summed height of the cytosine and thymine peaks at that particular site (Jiang 
et al, 2009). To assess the accuracy of this approach, control samples with 
known levels of methylation were prepared by mixing bisulfite-converted fully 
methylated and unmethylated Epitect standards at defined ratios and then 
sequenced.  
One PCR was created to examine the “core promoter region” defined as -11 
bases upstream to +157 bases downstream of the TSS; in total 19 CpG sites 
were analysed between +15 and +98 (Figure 4.6). The PCR was assessed 
using standards of 0%, 50% and 100% methylation. The fully unmethylated 
standard showed 0% methylation at 17 of the 19 CpG sites, the remaining two 
sites had 30% and 11% methylation respectively. The fully methylated standard 
showed 100% methylation at all sites. The control sample that was 50% 
methylated had estimated levels of between 61-84% methylation across the 
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Figure 4.6 Location of the three PCRs designed to investigate methylation in the CEBPA promoter.  The line in the centre 
represents the DNA, numbered according to distance from the transcription start site. The box denotes the CEBPA gene, the 
shaded part is the translated region. The expanded regions indicate all CpG sites in the core and distal regions of the promoter 
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sites. In spite of this marked bias in percentage methylation, all 135 samples 
analysed had 0% methylation at all 19 sites, indicating that there was no 
evidence of methylation at the core promoter region, irrespective of CEBPA 
genotype. 
As most differential methylation occurred in the distal part of the distal region at 
approximately 1400 bases upstream of the TSS in the 238 cases examined by 
Fasan et al (2013a), and this area was not covered by the probes on the array, 
two PCRs were designed specifically for this part of the distal promoter. One 
analysed the forward strand from 1559 to 1245 bases upstream of the TSS 
covering 23 CpG sites, and the other the reverse strand from 1500 to 1238 
bases upstream of the TSS covering 21 CpG sites (Figure 4.6). Although the 
two strands overlapped with 21 CpG sites in common, both were analysed in 
order to investigate possible strand-specific methylation, to validate the level of 
methylation at each CpG, and also to avoid miscalling C/T SNPs as 
unmethylated CpG sites. The forward strand was sequenced from the forward 
primer and thus the first two CpG sites were not seen as they were located 
within the first 30 bases of the amplicon. Similarly, the reverse strand was 
sequenced from the reverse primer, and five CpG sites were close to this primer 
and thus not assessed. Hence, 21 CpG sites were analysed in the forward 
direction (between -1474 and -1277), and 16 of these were also analysed in the 
reverse direction (between -1474 and -1311).  
Three control samples with expected methylation levels of 10%, 50% and 90% 
were first analysed (Figure 4.7). Given that this region has been shown to have 
varying levels of methylation, the controls were selected to confirm that 
preferential amplification of either unmethylated strands or methylated strands 
did not occur, which could bias the results. Apart from one outlier result (CpG 
12 in the forward direction), the estimated methylation of all CpG sites for the 
10% methylation standard was within 13% of the expected level in both 
directions, and for the 90% methylation standard it was within 10% (Figure 4.8). 
There was more variability between the strands for the 50% methylation 
standard. The forward strand overestimated the level by 9-35% and the reverse 
strand underestimated the level by 2-27% at individual CpG sites. The general 
trend was an increase in estimated methylation level in the direction of 
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Figure 4.7 Bisulfite sequence of part of the CEBPA distal promoter region in control samples with known methylation 
levels. 
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Figure 4.8 Estimated methylation levels at individual CpG sites examined 
by bisulfite sequencing of control samples.  (A) 10%, (B) 50%, (C) 90% 
methylation. The 21 sites are those that were measured by the forward (CpG 
sites 1 to 21) and reverse PCRs (CpG sites 16 to 6). CpG sites 1 to 9 in the 
forward direction and 16 to 6 in the reverse direction were used for further 
analysis in patient samples based on peak height on the chromatogram.  
■= Forward PCR; ■= Reverse PCR. 
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sequencing, which reflected the progressive reduction of the overall peak height 
of the T nucleotide along the sequence. This probably resulted from reagent 
depletion due to the repetitive regions and long T homopolymer runs after 
bisulfite conversion. Therefore, to maintain accuracy of methylation estimation, 
analysis of patient samples was restricted to CpG sites 1 to 9 in the forward 
direction and sites 16 to 6 in the reverse direction. The cut-offs were taken from 
the point in the sequences of the standards where the peak height of T 
nucleotides was less than 50% of the height of the T nucleotides at the 
beginning of the sequence.  
 Although one of the CpG sites included in the 450K array (Probe 3, 1275 bases 
upstream of the TSS) was within the forward PCR of the distal region, this CpG 
was not analysed as it was at the end of the sequencing and thus the peaks 
were too small to reliably interpret the methylation levels. Therefore, as the level 
of methylation tends to be similar in nearby CpG sites (Eckhardt et al, 2006), 
the probe 3 β values for the patient samples were compared with the estimated 
levels at CpG site 16 from the reverse PCR, which was 34 bases upstream of 
the probe 3 CpG and the closest of all CpG sites assessed. There was a 
significant degree of correlation between the two methods of quantification (r2= 
0.69, P<0.0001) (Figure 4.9). Of note, although levels at this CpG site were 
underestimated with the 50% standard, there was no evidence of such bias 
when comparing the results to the methylation array. The greatest variability in 
results was at the lower levels of methylation, where small changes in absolute 
nucleotide peak heights would have had a big effect on methylation estimation.    
In order to determine whether there was any evidence for strand-specific 
methylation in the patient samples, the results for both strands at the four 
common CpG sites assessed were compared (CpG sites 6-9 in Figure 4.3). The 
median methylation level for the four sites for all samples analysed was 
calculated for each PCR and the two results compared. The correlation 
between the two estimations was highly significant (r2= 0.56, P<0.0001), again 
with most variability occurring at the lower levels of methylation (Figure 4.10). 
Although the forward PCR consistently estimated a higher methylation value 
than the reverse PCR in the standards, there was no consistent bias in the 
patient samples. Of the 135 samples analysed, 11 (8%) showed a difference of 
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Figure 4.9 Comparison of methylation levels from the 450K array beta 
values with estimated levels from bisulfite sequencing in the distal 
CEBPA promoter region.  
The array results are from probe 3, 1275 bases upstream from the transcription 
start site. The bisulfite sequencing results are the methylation level at a single 
CpG site 34 bases upstream from the array CpG, as estimated from the distal 
reverse PCR.  
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Figure 4.10 Comparison of the median methylation level in the forward 
and reverse strands at four CpG sites in the CEBPA distal promoter 
region  as estimated by bisulfite sequencing in all 135 samples.  
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>20% in methylation level between the forward and reverse strands, 5 were 
more methylated in the forward direction and 6 in the reverse direction. This did 
not correlate with CEBPA genotype as five were CEBPADM, four CEBPASM, and 
three CEBPAWT. One of the CEBPASM samples showed a difference of 76% 
between the two strands; despite repeating the PCRs this discrepancy 
remained.   
Analysing the median methylation levels obtained according to the CEBPA 
genotype revealed that the majority of samples with CEBPADM did not show any 
evidence of methylation in the CEBPA distal promoter region, and those that did 
only showed low levels of methylation, median level 0% in both the 9 sites 
analysed in the forward PCR and the 11 sites in the reverse PCR (range, 0-46% 
and 0-32% respectively) (Figure 4.11).  
The majority of the 38 CEBPASM samples also showed little methylation in this 
region, medians 0% (range, 0-45%) and 0% (range, 0-94%) in the forward and 
reverse directions (Figure 4.11). When individual CpG sites were examined, five 
CEBPASM samples had >25% methylation at at least one CpG site (Figure 
4.12A and B). To assess whether methylation of the CEBPA promoter could 
lead to silencing of the wild-type allele and thus cause some CEBPASM to 
behave like CEBPADM samples, CEBPASM samples were split into CEBPAMETH 
(n=5) and CEBPAHYPOMETH (n=33), with CEBPAMETH defined as >25% median 
methylation in at least one of the two distal PCRs. This level was chosen as it 
would be consistent with one allele being silenced in at least half of the cells, 
although not necessarily the wild-type allele. The methylation profile of the 
samples that were considered CEBPAMETH was then examined. Four of these 
samples did not have methylation signatures similar to CEBPADM (Figure 
4.13A). The remaining sample was one of the two CEBPASM samples that 
satisfied the classic CEBPADM criteria. It had the highest methylation level in the 
CEBPA promoter region, with a marked strand-specific variation in methylation 
level, median 100% in the reverse direction and 0% in the forward direction. 
Furthermore, this sample was the only one of the five CEBPAMETH to have a 
classic C-LOF mutation, the other samples had a classic N mutation, a 
frameshift in the middle of the gene, a missense mutation in the C terminus and 
a missense mutation in the middle of the gene. Thus methylation of the distal 
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Figure 4.11 Median methylation levels in the distal CEBPA promoter region for AML samples according to their CEBPA 
genotype.  
Results from (A) the forward and (B) the reverse PCR products.  
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Figure 4.12 Number of samples with evidence of methylation at individual CpG sites in the CEBPA distal promoter region. 
CEBPASM samples (A) and (B), and CEBPAWT samples (C) and (D) in forward and reverse PCRs respectively. 
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Figure 4.13 Distance scores for cases with hypermethylation in the distal CEBPA promoter region.  
(A) CEBPASM, (B) CEBPAWT cases. Hypermethylation is defined as >25% median methylation in at least one of the two PCRs for 
CEBPASM and >75% median methylation for CEBPAWT cases.
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CEBPA promoter was seen in one CEBPASM sample and if the wild-type allele 
was silenced this might explain why it fell in the CEBPADM quadrant. However, 
no RNA sample was available to confirm this.  
The median results for the 56 CEBPAWT samples ranged from 0-90% in the 
forward direction and 0-88% in the reverse direction (Figure 4.11). The majority 
of samples showed no evidence of methylation at any of the CpG sites in this 
region (Figure 4.12). As before, CEBPAWT samples were split into CEBPAMETH 
(n=4) and CEBPAHYPOMETH (n=52), but here CEBPAMETH was defined as >75% 
median methylation in at least one of the two distal PCRs. This level of 
methylation was chosen as Wouters et al (2007) had previously shown that four 
of their six CEBPA-silenced (CEBPAWT) cases with gene expression profiles 
similar to CEBPADM had >75% methylation in the distal region. Four CEBPAWT 
samples fulfilled this criterion, but as none of them were located within the 
CEBPADM quadrant, there was no evidence that methylation in this region was 
associated with a methylation profile similar to CEBPADM (Figure 4.13B).   
4.4 Discussion 
AML samples with classic CEBPADM have a distinct methylation signature, as 
has been shown in the previous chapter and published literature (Figueroa et al, 
2010b). However, approximately 25% of patients with CEBPADM have a non-
classic combination of mutations. The functional impact of these mutations and 
the prognostic consequences are unknown. As these mutations are very varied, 
it is difficult to assess their impact on prognosis. The aim of the studies 
presented in this chapter was to assess the methylation signature of the non-
classic CEBPADM and CEBPASM samples to explore whether this could serve as 
a surrogate for providing information on the more broad-spectrum functional 
significance of different mutations.   
The first part of this chapter explored some of the potential reasons why certain 
CEBPADM did not satisfy the classic CEBPADM criteria and were located outside 
this quadrant. Cloning of full-length CEBPA amplicons was performed for five 
CEBPADM samples and this showed that they were all biallelic. This is not 
surprising, as most studies have confirmed that the vast majority of mutations in 
CEBPADM are biallelic (Barjesteh van Waalwijk van Doorn-Khosrovani et al, 
  
147 
 
2003; Dufour et al, 2010; Frohling et al, 2004; Green et al, 2010b; Lin et al, 
2005; Preudhomme et al, 2002). There is a suggestion in the data presented 
here that the mutant level of samples may have an impact on the methylation 
signature as the one classic DM sample that was not located within the classic 
CEBPADM quadrant had a lower level of both mutations than all other samples. 
If methylation signatures are to be used to investigate the functional impact of 
different mutations, further work must be done to explore the impact of mutant 
levels on the methylation levels in samples.  
The type of CEBPA mutation also had an impact on the methylation signature of 
the CEBPADM samples. The mutations identified in CEBPA are diverse and are 
predicted to have different functional consequences. The p30 isoform that 
results from classic N-terminal mutations lacks TAD1, which is important for 
transcriptional activation and regulation of cell cycle progression, whereas 
classic C mutants have been shown to disrupt either DNA binding or 
dimerisation of C/EBPα (Friedman, 2015; Ohlsson et al, 2016). However, the 
impact of most of the non-classic mutations has not been investigated 
previously and thus the functional impact of these mutations is still unclear. Five 
of the six samples with mutations that would lead to functional p30 only (classic 
N mutation and frameshift after the second ATG start site) were not located in 
the classic CEBPADM quadrant. Two of the three samples with predicted C loss 
of function satisfied the classic CEBPADM criteria. Thus it seems a key feature 
of the CEBPADM signature is that no wild-type p42 is present, and that a C-LOF 
mutation may be necessary. In their mouse models Kato et al (2011) 
demonstrated that mice transplanted with transduced cells containing a C-
terminal mutation alone developed AML, however if they were transduced with 
an N-terminal mutation alone this did not occur. The seven other non-classic 
CEBPADM samples all had at least one missense mutation, of these two were 
located in the classic CEBPADM quadrant. This demonstrates that missense 
mutations are quite varied and it is difficult to predict their impact on function. Of 
the 38 CEBPASM, only one was located within the CEBPADM quadrant, and one 
was borderline. This is consistent with published data on gene expression 
profiles and the prognostic impact of CEBPASM showing that they are more 
similar to CEBPAWT than CEBPADM.  
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 The CEBPA promoter was analysed to assess whether methylation of the 
promoter was associated with a methylation signature similar to classic 
CEBPADM as previous studies had shown that samples with silenced CEBPA 
secondary to methylation had similar gene expression profiles to CEBPADM 
(Wouters et al, 2007). The core and distal regions of the promoter were 
selected as these regions had been previously been shown to be methylated in 
some AML samples. The degree of methylation of the CEBPA promoter 
observed in the current data set was generally consistent with published data. 
No CEBPAMUT sample had evidence of methylation in the core region. The 
median methylation level in the distal region for CEBPADM and CEBPASM 
samples was 0%; however 12 of the 79 samples (15%) did have methylation 
levels above 20%, so CEBPAMUT and CEBPAMETH were not mutually exclusive, 
as had been reported by other groups (Fasan et al, 2013a; Lu et al, 2010). No 
CEBPAWT samples had evidence of methylation in the core promoter region, in 
keeping with published studies where the rate of methylation for CEBPAWT 
samples in this region is low at approximately 4% (Chim et al, 2002; Fasan et 
al, 2013a; Hackanson et al, 2008; Jost et al, 2009; Lin et al, 2011; Lu et al, 
2010; Musialik et al, 2014; Szankasi et al, 2011). In contrast, the rate of 
methylation in the distal promoter in CEBPAWT samples was 16%, which is 
again consistent with the average rate of 34% reported by others, although 
individual studies have marked differences with a range of 15-51%. This 
variation is likely to reflect the different methods used to detect methylation and 
how it is defined (Fasan et al, 2013a; Hackanson et al, 2008; Lin et al, 2011; 
Musialik et al, 2014).     
The data from the 450K array showed that CpG sites of all samples, regardless 
of underlying CEBPA genotype, were methylated at 4618 bases upstream from 
the TSS for CEBPA (probe 1) and unmethylated from 720 bases upstream to 
1323 bases downstream of the TSS (probes 6-15). Thus somewhere in the 
boundary between the shore and the CGI the CpG sites go from being 
methylated to unmethylated. Of note, one site at 1919 bases upstream of the 
TSS (probe 2), which is further upstream than the defined distal promoter 
region, was significantly differentially methylated between CEBPADM samples 
(median 7% methylated) compared to both CEBPASM and CEBPAWT (medians 
61% and 79% methylated respectively. More extensive analysis of this region 
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would therefore be of interest to explore this finding. All published studies of the 
distal region of the CEBPA promoter have examined the methylation levels at 
CpG sites in a relatively short stretch of DNA, and have classified a sample as 
either “methylated” or “unmethylated”. However, perhaps a more robust way of 
discriminating samples would be to analyse the distance from the TSS at which 
CpG sites change from being methylated to unmethylated. For example, Fasan 
et al (2013a) observed that many of the 238 samples that had >15% 
methylation in the distal region at approximately -1400 bases upstream of the 
TSS gradually became unmethylated closer to the TSS, with half of them 
unmethylated at about -1300 bases and only 8% methylated at -1100 bases. 
Although the data presented here also shows variability in the position that CpG 
sites go from being methylated to unmethylated, the functional significance of 
this is currently unknown. Some studies have shown an association between 
methylation of the distal promoter and decreased CEBPA expression (Fasan et 
al, 2013a; Lin et al, 2011; Musialik et al, 2014), but this association was not 
seen in other studies (Hackanson et al, 2008).  
Of note, a novel long noncoding RNA arising from 800 bases upstream of the 
TSS for CEBPA was recently identified, coined extra coding CEBPA, ecCEBPA, 
which inhibits DNA methylation of the CEBPA promoter in cell lines and leads to 
a concomitant increase in gene expression (Di Ruscio et al, 2013). The TSS 
was predicted to be 800 bases upstream of the canonical CEBPA TSS, 
however ChIP analysis led to enrichment of RNA polymerases from 1800 bases 
upstream. Hence the differential methylation in this distal region at 1919 bases 
upstream seen in this study may be linked to ecCEBPA. Expression of 
ecCEBPA was shown to be concordant with CEBPA expression in normal 
human tissue such as liver and lung, primary haematopoietic samples were not 
examined. CEBPA mutated samples have been shown to have a distinctive 
long noncoding RNA signature, when compared to CEBPAWT samples, but this 
signature did not include ecCEBPA (Garzon et al, 2014). 
Although studies have shown that CEBPAWT samples with methylation of the 
CEBPA promoter have similar gene expression to samples with CEBPADM 
(Figueroa et al, 2009b; Taskesen et al, 2011; van Vliet et al, 2013), there was 
no evidence from the data presented here that the methylome for these two 
groups was similar. All four CEBPAWT samples and four of the five CEBPASM 
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samples exhibiting hypermethylation of the CEBPA promoter did not have 
methylation profiles that were located within the classic CEBPADM quadrant. 
Examining different areas of the CEBPA promoter may lead to different results, 
but the areas interrogated were very similar to those published.  
There were too few cases to determine whether outcome differed for double-
mutated cases with non-classic mutations that had methylation profiles that 
either did (n=5) or did not fall (n=11) in the classic CEBPADM quadrant. Given 
that all CEBPADM patients lacking a FLT3/ITD are classified as good-risk and 
are therefore not usually considered for allogeneic transplantation in first 
remission (Cornelissen et al, 2012), these studies suggest that further work is 
required to determine which non-classic CEBPADM are equivalent to the classic 
CEBPADM, and thus caution should be employed about considering them as 
part of the favourable prognostic group.  
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CHAPTER 5:DETECTION OF ASXL1 MUTATIONS IN 
AML AND THEIR PROGNOSTIC IMPACT 
5.1 Introduction 
In addition to DNA methylation, the structure of chromatin has been implicated 
in the regulation of gene expression. Two families of proteins encoded for by 
evolutionarily conserved genes play a role in post translational modification of 
histones. The Polycomb and trithorax groups lead to repressive and active 
conformations of chromatin respectively. Mutations in these genes were first 
discovered in Drosophila and led to abnormalities in embryonic segmental 
development (Jurgens, 1985; Lewis, 1978). Mutations in Polycomb genes 
resulted in transformation of anterior segments of the Drosophila to posterior 
segments through derepression of homeotic genes, whilst mutations in the 
trithorax group proteins led to silencing of the homeotic genes and the opposite 
phenotype, with features of the anterior segments on the posterior of the fly.  
One of the implicated genes is the Asx (additional sex combs) gene, which was 
first found in Drosophila in 1984 by screening hundreds of embryos with lethal 
mutations and examining their morphology. Mutations in this gene led to partial 
transformation of the head and thorax to additional abdomen and sex combs 
(short bristles found on the males’ front legs that help with mating) (Nüsslein-
Volhard et al, 1984). It was initially classified as a Polycomb gene, as its 
mutation gave rise to ectopic posterior segments (Breen & Duncan, 1986; 
Jurgens, 1985). However, certain mutations in Asx were later noted to also 
cause anterior transformations typical of the trithorax group proteins (Milne et al, 
1999). Given this dual function, Asx was reclassified in a new group, the 
enhancers of trithorax and Polycomb genes (Gildea et al, 2000). 
There are three human homologues of Asx, ASXL1 (Additional sex combs like 
1), ASXL2, and ASXL3. The ASXL1 gene was discovered by searching for 
human sequence similarity to the Drosophila Asx gene and mapped to 
chromosome 20q11, a region that is frequently amplified or deleted in various 
tumours including leukaemias (Fisher et al, 2003).  
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5.1.1 Structure and function of ASXL1 
The ASXL1 gene consists of 12 or 13 exons, depending on whether a 3 base 
pair region is considered as a separate exon, 3 of 13, as originally proposed by 
Fisher et al (2003) or the 5’ end of the following exon. The dominant transcript is 
7031 base pairs and is expressed in most adult tissues at low to moderate 
levels, apart from liver and kidneys where it is not expressed (Fisher et al, 
2003). The ASXL1 protein consists of 1541 amino acids with conserved 
sequence within the ASXH (Asx homology) region, which consists of ASXN 
(Asx N terminus) and ASXM (Asx Middle) regions (Figure 5.1). Within these 
regions there are at least 3 nuclear receptor boxes, two within the ASXM region 
and one further downstream. There is also a conserved plant homeo domain 
(PHD) located in the C terminus. The PHD zinc finger binds specific residues on 
histones and is found in many proteins that modify chromatin structure 
(Sanchez & Zhou, 2011).  
In vitro studies of ASXL1 structure have shown that it interacts with several 
proteins, some of which seem to have opposing effects. For example, in non-
haematopoietic cells, it has been shown that ASXL1 binds HP1a and LSD1, a 
histone demethylase, to repress retinoic acid-receptor activity (Lee et al, 2010). 
Conversely, ASXL1 can interact with SRC-1 to activate retinoic acid receptors 
(Cho et al, 2006). Similarly, transcriptional silencing is initiated or maintained by 
the recruitment of the PRC2 complex by ASXL1 to specific loci, allowing EZH2 
to catalyse the di and tri-methylation of K27 in histone H3. The PRC1 complex 
then recognises the H3K27me3 marks and mediates ubiquitination of Lysine 
119 of histone H2A. Both these histone marks are thought to silence 
transcription through several mechanisms including recruitment of DNA 
methyltransferases, prevention of RNA pol II activity and compaction of the 
chromatin (Abdel-Wahab et al, 2012) (Figure 5.2). On the other hand, in 
Drosophila, ASX has also been shown to interact with the polycomb-repressive 
deubiquitinase, PR-DUB, which removes monoubiquitin from histone H2A, 
causing activation of the homeotic genes (Scheuermann et al, 2010), although 
the PR-DUB complex has not been confirmed in vivo in mammals. 
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Figure 5.1 Representation of ASXL1 locus and PCR fragments used for detection of ASXL1 mutations by WAVE® analysis.  
(A) Chromosome 20 with site of ASXL1. (B) ASXL1 gene with location of PCR fragments and length of each amplicon (base pairs). 
(C) ASXL1 protein with proposed domains. ASXN, conserved domain in the N terminus; ASXM conserved domain in the middle; NR 
box (nuclear receptor) box; PHD, plant homeodomain. Adapted from 
http://atlasgeneticsoncology.org/Genes/ASXL1ID44553ch20q11.html (Huret et al, 2013) 
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(COPYRIGHT PROTECTED IMAGE REMOVED)  
 
 
Figure 5.2 Proposed function of ASXL1 and the polycomb complexes.  Transcriptional silencing is initiated or maintained by 
the recruitment of the PRC2 complex by ASXL1 to specific loci, this allows EZH2 to catalyse the di and tri-methylation of K27 in 
histone 3. The PRC1 complex recognises the H3K27me3 and mediates ubiquitination of Lysine 119 of histone H2A. Removal of 
H2AK119Ub has been shown to occur by the PR-DUB complex (containing BAP1 and ASX) in Drosophila and mammalian cells in 
vitro. Adapted from Shih et al (2012)
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5.1.2 Mutations in the ASXL1 gene 
ASXL1 mutations were first discovered by array comparative genomic 
hybridisation of 40 samples from patients with myelodysplasia (MDS) and 
secondary AML (Gelsi-Boyer et al, 2009). A small deletion in the 20q region that 
included ASXL1 was identified in one of the samples, and therefore the gene 
was sequenced in 35 MDS and 39 chronic myelomonocytic leukaemia (CMML) 
samples and found to be mutated in 5 (11%) and 17 (43%) cases respectively. 
All mutations were localised to exon 12. Since this initial report, several groups 
have published their findings of recurrent ASXL1 mutations in the spectrum of 
myeloid malignancies (Table 5.1). Of the studies that have examined the whole 
gene, only 8 nonsense or frameshift mutations outside exon 12 have been 
identified in 836 samples (1%). Given that this gene is 7031 base pairs and 
initial reports confirmed the majority of mutations were restricted to exon 12, 
which is itself 2907 bases, many studies have limited analysis to this exon only. 
Considering all reported studies of mutations in ASXL1 in myeloid malignancies, 
they are most commonly seen in CMML, with an overall incidence of 40%. They 
are found in MDS and myeloproliferative neoplasms (MPN) at similar rates of 
20% and 23% respectively. Within the MPNs, they are most common in primary 
myelofibrosis (26%). The incidence in AML has varied in studies from 5%-25%, 
however overall it is 11% (Table 5.1). Mutations have also been seen 
infrequently in chronic lymphocytic leukaemia, and non-haematological tumours 
such as prostate and breast cancer (Katoh, 2013). Constitutional mutations in 
this gene have been discovered in the rare Bohring-Opitz syndrome (Hoischen 
et al, 2011; Magini et al, 2012), which is not associated with haematological 
abnormalities, although most patients die in early childhood.  
The mutations are predominantly nonsense or frameshift mutations that would 
lead to premature truncation of the protein and absence of the conserved Plant 
Homeo Domain finger that is necessary for histone binding. The most 
commonly found mutation, c.1934dupG (p.G646WfsX12), is a duplication of a 
guanine within an 8-base guanine homopolymer run. It constitutes 43% of all 
ASXL1 mutations detected in myeloid diseases. One group has suggested that 
this mutation could be a PCR artefact (Abdel-Wahab et al, 2010a), as they 
noted that this alteration was present in paired normal DNA from patients with 
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Table 5.1 Mutation rate of ASXL1 in myeloid malignancies 
Table 5.1 continued 
Reference 
Method of 
analysis 
Exons 
analysed 
Number 
of 
samples 
analysed 
Incidence of ASXL1 mutation (%) 
De novo AML 
Secondary 
AML 
MDS CMML MPN CML JMML 
Gelsi-Boyer et al (2009) Sequencing All 74   4/35 (11) 17/39 (44)    
Carbuccia et al (2009) Sequencing All 64     5/64 (8)   
Carbuccia et al (2010) Sequencing All 63 3/46 (7) 9/17 (53)      
Abdel-Wahab et al (2010b) Sequencing All 63  12/63 (19)      
Boultwood et al (2010a) Sequencing 12 300 8/27 (30) 9/40 (23) 28/182 (15) 17/51 (33)    
Szpurka et al (2010) Sequencing All 23   2/23
1 
(10)
 
    
Sugimoto et al (2010) Sequencing 12 49       2/49 (4) 
Boultwood et al (2010b) Sequencing 12 41      6/41 (15)  
Rocquain et al (2010) Sequencing 12 129 11/64 (17)  12/65 (19)     
Chou et al (2010b) Sequencing 12 501 54/501 (11)       
Gelsi-Boyer et al (2010) Sequencing 12 53    25/53 (47)    
Perez et al (2010) Sequencing 12 68       3/68 (4) 
Makishima et al (2011) Sequencing 12 54      2/54 (4)  
Abdel-Wahab et al (2011) Sequencing All 110    16/39 (41) 9/71
2
 (12)   
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Table 5.1 continued 
Reference 
Method of 
analysis 
Exons 
analysed 
Number 
of 
samples 
analysed 
Incidence of ASXL1 mutation (%) 
De novo AML 
Secondary 
AML 
MDS CMML MPN CML JMML 
Thol et al (2011b) Sequencing 12 193   40/193 (21)     
Roche-Lestienne et al (2011) Sequencing 12 91      8/91 (9)  
Stein et al (2011) Sequencing 12 166     31/166 (19)   
Bejar et al (2011) 
NGS and 
mass 
spectrometry 
All 439   63/439 (14)     
Grossman et al (2011a) Sequencing 12 39      12/39
3 
(31)  
Jankowska et al (2011) Sequencing 12 72  7/20
4
 (35)  24/52 (46)    
Metzeler et al (2011a) Sequencing 12 423 44/423 (10)       
Paschka et al (2011) Sequencing 12 1429 90/1429
5
 (6)      
Martinez-Aviles et al (2012) Sequencing 12 62     3/62 (5)   
Ricci et al (2012) Sequencing 12 65     28/65
2
 (43)   
Pratcorona et al (2012) 
WAVE on 
cDNA 
12
6 
836 35/775 (5) 7/61 (12)      
Brecqueville et al (2012) Sequencing 12 149     17/149 (11)   
Devillier et al (2012) Sequencing 12 48  17/48
7
 (35)      
Traina et al (2012) Sequencing 12 26     5/26
8 
(19)   
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Table 5.1 continued 
Reference 
Method of 
analysis 
Exons 
analysed 
Number 
of 
samples 
analysed 
Incidence of ASXL1 mutation (%) 
De novo AML 
Secondary 
AML 
MDS CMML MPN CML JMML 
Fernandez-Mercado et al 
(2012) 
Sequencing 12 84 2/51 (4) 16/33 (48)      
Ibanez et al (2012) HRM analysis 12 175 16/175 (6)       
Schnittger et al (2013) Sequencing 12 740 127/740
5
 (17)      
Wang et al (2013a) Sequencing 12 153   33/153 (22)     
Itzykson et al (2013) Sequencing 12 314    125/314 (40)    
Schwaab et al (2013) Sequencing 12 39     8/39
8 
(21)   
Hou et al (2014) Sequencing 12 444 49/444 (11)       
Haferlach et al (2014) Sequencing 12 944   221/944 (23)     
Krauth et al (2014) Sequencing 12 139 16/139
9
 (12)       
Guglielmelli et al (2014a) Sequencing 12 166     54/166
2
 (33)   
Damaj et al (2014) Sequencing 12 43     6/43
8
 (14)   
Tefferi et al (2014) Sequencing 12 570     
142/570
2
 
(25) 
  
Patnaik et al (2014) Sequencing 12 420    164/420 (39)    
Guglielmelli et al (2014b) Sequencing 12 797     
203/797
2
 
(26) 
  
  
 
    
1
5
9
 
Table 5.1 continued 
Reference 
Method of 
analysis 
Exons 
analysed 
Number 
of 
samples 
analysed 
Incidence of ASXL1 mutation (%) 
De novo AML 
Secondary 
AML 
MDS CMML MPN CML JMML 
Renneville et al (2014) Sequencing 12 226 21/226 (9)       
TOTAL   10884 
259/2871
5 
(9) 
77/282
5 
(27) 
MDS 
182/1090 
(17) 
CMML 
388/968 
(40) 
MPN 
511/2218 
(23) 
CML 
26/225 
(12) 
JMML 
5/117 
(4) All AML 336/3153 (11) 
1
Refractory anaemia with ringed sideroblasts in transformation. 
2
Primary myelofibrosis. 
3
CML in blast crisis. 
4
AML with preceding CMML. 
5
Breakdown of primary and secondary AML not given, 
excluded from subtotals.
 6
Only first 325 bases of exon 12 examined. 
 7
AML with myelodysplastia-related changes. 
8
Systemic mastocytosis. 
9
t(8;21) AML. 
Abbreviations: aCGH, array comparative genomic hybridisation; AML, acute myeloid leukaemia; BC-CML, chronic myeloid leukaemia in blast crisis; CML, chronic myeloid leukaemia; CMML, chronic 
myelomonocytic leukaemia; HRM, high resolution melting; MDS, myelodysplasia; MPN, myeloproliferative neoplasia; NGS, next generation sequencing; PMF, primary myelofibrosis; SM, systemic 
mastocytosis; SNP, single nucleotide polymorphism. 
  
160 
    
myeloid diseases as well as in 24 of 96 normal bone marrow samples. 
However, the findings from this study have not been replicated, for example, 
Grossmann et al (2012) analysed 491 normal control bone marrow samples and 
only one sample (0.2%) had this mutation, which they thought might be due to 
an undetected early myeloid disease. Other groups have also confirmed the 
validity of this mutation by using different proof-reading polymerases 
(Brecqueville et al, 2012), and analysing serial dilutions of the mutation with 
known wild-type samples to see if the mutant levels are as expected (Chou et 
al, 2010b). Furthermore, the consistency across groups in terms of incidence 
and correlation with other mutations has led most groups to consider the 
c.1934dupG mutation to be genuine (Gelsi-Boyer et al, 2012). 
There is also conflicting evidence as to whether mutations in ASXL1 have an 
effect on RNA expression levels. The gene expression profile from CD34-
positive cells of 23 MDS and 9 CMML samples was investigated, and whilst 
there was variable ASXL1 mRNA expression across the whole cohort, there 
was no difference in levels between the 6 mutated samples and the remaining 
wild-type samples (Gelsi-Boyer et al, 2009). Conversely, analysis of microarray 
results from 162 MDS samples of which 35 had nonsense or frameshift 
mutations, showed a significant reduction in gene expression of ASXL1 in the 
mutant samples compared to the wild-type samples, with mean copy numbers 
of 5.8 and 7.6 respectively (p= 0.025) (Thol et al, 2011b). Furthermore, Western 
blot analysis of protein expression using both N- and C- terminal directed 
anitbodies in 2 primary AML samples with ASXL1 mutations (one nonsense and 
one frameshift) showed reduced or absent expression (Abdel-Wahab et al, 
2012).  
5.1.3 Functional consequences of ASXL1 mutations 
To assess the effect of ASXL1 loss on the chromatin state, Abdel-Wahab et al 
(2012) used short hairpin RNAs, shRNAs, to silence ASXL1 in the leukaemia 
cell line, UKE1. Chromatin immunoprecipitation followed by next generation 
sequencing (ChIP-seq) data revealed a significant decrease in H3K27me3 
transcriptional start site occupancy in ASXL1 knockdown cell lines compared to 
cell lines with an empty vector. Western blot analysis of purified histones from 
these two cell lines confirmed a significant reduction in H3K27me3 marks in the 
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knockdown cell line, but with preserved protein expression of the PRC2 
complex members EZH2, SUZ12 and EED. Knockdown of ASXL1 in primary 
CD34-positive cells, using small interfering RNAs, led to upregulation of 
homeotic genes including HOXA5-9 as analysed by gene expression microarray 
(Abdel-Wahab et al, 2012). Furthermore, ChIP for EZH2 followed by qPCR of 
bound DNA at the HOXA locus in ASXL1 knockdown cells revealed decreased 
HOXA product compared to empty vector cells. The authors concluded that 
these findings were consistent with the loss of ASXL1 causing a loss of PRC2 
recruitment to the HOXA locus. This was confirmed by another group who 
investigated the effects of shRNA ASXL1 knockdown in CD34-positive cells 
(Davies et al, 2013). They noted impaired granulocytic differentiation in these 
cells, along with a significant increase in the number of multipotent mixed 
lineage colony-forming units. Gene expression profiling of these cell lines also 
revealed dysregulated gene expression of PRC2 targets.  
Whilst initial investigations of ASXL1 knock-out in mouse models showed some 
disruption in haematopoiesis, it did not trigger MDS or leukaemia (Fisher et al, 
2010). However in this study, ASXL1 was constitutively ablated by the 
introduction of a neomycin resistance cassette with several premature stop 
codons. This led to a high rate of perinatal lethality in the homozygous mutant 
embryos, which may have masked the haematological effects of knocking down 
ASXL1. Subsequent knock-out mouse models have displayed features of 
myelodysplasia (Abdel-Wahab et al, 2013; Inoue et al, 2013; Wang et al, 2014). 
Wang et al (2014) generated a knock-out model by the introduction of a 
cassette disrupting exon 1. Although they too found 80% embryonic lethality, in 
those mice that survived there were morphological features of myelodysplasia. 
Inoue et al (2013) used a BM transplant model, where cells were transduced 
with a vector containing either c.1934dupG or c.1900_1922del ASXL1 
constructs or mock transduced and these cells were then transplanted into 
sublethally irradiated mice. Morphological abnormalities in myeloid and 
erythroid cell lines were seen 12 months after transplant of the mutant vector, 
and these mice had a reduced median survival of 400 days compared to 2 
years in the mock transduced mice. Abdel-Wahab et al (2013) used conditional 
allele targeting of the ASXL1 gene to delete it specifically in the haematopoietic 
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compartment. Microscopic examination of blood revealed dysplastic myeloid 
and erythroid cells in the 6 month old ASXL1 knock-out mice.  
5.1.4 Incidence and characteristics of AML patients with ASXL1 mutations 
In the 14 studies investigating ASXL1 mutations in AML, the overall incidence is 
11% (Table 5.1). Mutations in this gene are more frequent in older patients. In a 
cohort of 501 patients with de novo AML, Chou et al (2010b) found ASXL1 
mutations in 54 patients (11%). The median age of those with the mutation was 
66 years versus 49 years in the wild type patients (p <0.001).  Similarly, 
Metzeler et al (2011a) found the mutation to be present in 16% of 234 patients 
≥60 years but only in 3% of 189 patients <60 years (p <0.001).  An association 
between ASXL1 mutations and secondary AML has also been noted by several 
groups (Devillier et al, 2012; Fernandez-Mercado et al, 2012; Pratcorona et al, 
2012; Rocquain et al, 2010; Schnittger et al, 2013). The total mutation rate in 
these papers for primary AML was 154 in 1606 patients (10%) compared to 53 
in 185 patients with secondary disease (28%) (including AML with 
myelodysplastic changes, therapy-related, post-MDS and post-CMML AML) (p 
<0.001). 
Initially, ASXL1 mutations were thought to be mutually exclusive with NPM1 
mutations in AML (Carbuccia et al, 2010), however subsequent studies have 
shown that although there is a strong inverse correlation between the two 
mutations, they do rarely co-occur (Chou et al, 2010b; Fernandez-Mercado et 
al, 2012; Metzeler et al, 2011a; Pratcorona et al, 2012; Schnittger et al, 2013).  
The two largest studies found 10 out of a total of 181 ASXL1 mutant samples to 
also have an NPM1 mutation (Chou et al, 2010b; Schnittger et al, 2013). Given 
this strong inverse correlation, it is perhaps unsurprising that an inverse 
correlation has also been seen with FLT3/ITDs, and DNMT3A mutations, both 
of which frequently co-occur with NPM1, with these mutations present in only 3-
10% and 4-15% of ASXL1 mutant samples respectively (Chou et al, 2010b; 
Devillier et al, 2012; Fernandez-Mercado et al, 2012; Metzeler et al, 2011a; 
Pratcorona et al, 2012; Schnittger et al, 2013). Mutations in ASXL1 have been 
associated with RUNX1 mutations, as this mutation was present in 30% of 
ASXL1 mutant samples compared to 10% in the ASXL1 wild type samples 
(Chou et al, 2010b). 
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5.1.5 Impact of ASXL1 mutations on outcome in AML patients 
Some studies have suggested that a mutation in ASXL1 is associated with a 
worse overall prognosis (Metzeler et al, 2011a; Paschka et al, 2011; Pratcorona 
et al, 2012; Schnittger et al, 2013), although this has not been corroborated by 
all groups (Ibanez et al, 2012; Shen et al, 2011). Others have found that, whilst 
presence of an ASXL1 mutation was associated with a shorter overall survival 
in univariate analysis, it was not an independent risk factor in multivariate 
analysis when age, karyotype, NPM1 mutation without FLT3/ITD, biallelic 
CEBPA mutations (Chou et al, 2010b) or age, karyotype, transplantation status 
were taken into account respectively (Patel et al, 2012).  
Given the association of ASXL1 mutations with older age and secondary 
disease, it is not clear whether knowing its status in a patient with newly 
diagnosed AML would provide sufficient additional information to significantly 
alter the expected outcome or mandate consideration of treatment modification. 
This chapter outlines the screening of mutations in ASXL1 exon 12 in 371 
samples from four predefined groups of younger (15-59 years) and older (≥60 
years) patients with primary or secondary AML, and relates genotype to 
outcome. 
5.2 Patients, Materials and Methods 
5.2.1 Patients 
Genomic DNA screened was from diagnostic peripheral blood or bone marrow 
samples of 371 adult patients with AML entered onto the UK Medical Research 
Council (MRC) AML10 (n =178), AML11 (n=145) and AML12 (n=48) trials 
between 1988 and 2002. Patients were selected according to age and type of 
disease but not karyotype except those with acute promyelocytic leukaemia, 
who were excluded. All had known genotype for FLT3, NPM1, IDH1 and IDH2. 
They were analysed in four pre-defined groups: 153 younger patients (15 – 59 
years) with primary AML, 69 younger patients with secondary disease (40 post-
MDS, 29 due to other causes including therapy-related AML), 116 older patients 
(60 or more years) with primary AML and 33 older patients with secondary AML 
(20 post-MDS, 13 other). All younger patients (n=222) were enrolled on the 
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AML10 and AML12 trials. Four of the older patients with secondary disease 
were enrolled on the AML12 trial; the remaining 145 older patients were 
enrolled on the AML11 trial. Ethical approval was obtained from the Multi-
Centre Research Committee of Wales. Informed consent was obtained in 
accordance with the Declaration of Helsinki. 
5.2.2 Screening for ASXL1 exon 12 mutations by dHPLC 
Mutation screening of ASXL1 exon 12 was carried out by denaturing high 
performance liquid chromatography using the WAVE® DNA Fragment Analysis 
System (Transgenomic, Glasgow, UK) (see section 2.1.4). The entire coding 
sequence of ASXL1 exon 12 was amplified by PCR using the proof-reading 
DNA polymerase, Optimase® (Transgenomic, Glasgow, UK) in 8 overlapping 
fragments, A-H (Figure 5.1). A further PCR product (A2) was used to confirm 
the presence or absence of the most commonly documented mutation 
(c.1934dupG). PCRs were performed as outlined in section 2.1.2. Details of all 
PCR primers and annealing temperatures are shown in Appendix 1. The 
presence of PCR products was confirmed on an agarose gel. To ensure that 
mutations associated with loss of heterozygosity due to chromosome (20q) 
deletion or uniparental disomy were not missed, the amplicons were mixed with 
known wild-type amplicons, denatured and cooled slowly to allow the formation 
of heteroduplexes on re-annealing. Resultant products were then analysed on 
the WAVE® at optimal melting temperatures (given in Appendix 1) calculated 
using Transgenomic Navigator software. A temperature was chosen if at least 
part of the amplicon was predicted to be approximately 75% helical. For most 
fragments, more than one temperature was used in order to examine the full 
amplicon, and ASXL1 exon12 fragments A, A2 and E are given as examples in 
Figure 5.3. 
5.2.3 Investigation of abnormal WAVE chromatograms 
All samples with abnormal WAVE chromatograms, except fragment E, were 
sequenced using fresh PCR products. A common synonymous single 
nucleotide polymorphism, SNP rs 4911231, (c.3759T>C, p.S1253S) was 
detected in fragment E; the 1000 Genomes Project (2012) reports the T allele 
frequency to be 58% and C allele 42%. As both alleles are common, PCR 
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Figure 5.3 Representative amplicon melting curve profiles for WAVE® 
analysis. Examples of the melting curve profiles for 3 of the fragments 
analysed on the WAVE® at the selected temperatures. Predicted helical 
proportion is plotted against position in the amplicon. Downward arrows show 
site of the most common mutation, c.1934dupG in fragment A and A2, and the 
frequent synonymous SNP, c.3759T>C in fragment E. Upward arrow shows the 
start of the coding sequence in fragment A amplicon. 
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products for this fragment were initially analysed on the WAVE® unmixed, i.e. 
no wild-type amplicons added.  Characteristic chromatograms were produced if 
samples were heterozygous for this SNP, thus if there was another mutation it 
should not be missed. If the fragment amplicon showed a single peak, it was 
rerun as a 3:1 mix with HL60 DNA (T/T at SNP site) to differentiate homozygous 
T/T from C/C and identify potential homozygous/ hemizygous mutations (Figure 
5.4). To confirm that the abnormal chromatogram was due to the SNP, a PCR 
with a mismatch primer that introduced a restriction enzyme digestion site was 
created that would allow discrimination between the alleles (Figure 5.4C). PCR 
products were obtained using BioTaq DNA polymerase (Bioline, UK ) (see 
section 2.1.2) and digested with Bsr1 (New England Biolabs (UK) Ltd., Hitchin, 
UK) for 2hrs at 65oC, to give bands of 99+27 bp for T-alleles and a single uncut 
band of 126bp for C-alleles (Figure 5.4D).  
Where sequencing of amplicons indicated more than one mutation within the 
same fragment, a repeat PCR was performed using BioTaq DNA polymerase 
(Bioline, UK) and the products were cloned using the TOPO TA cloning kit 
(Invitrogen, Paisley, UK) (section 2.1.9). Approximately 20 clones were 
harvested and grown up overnight and then PCR-amplified. At least four clones 
were then sequenced directly in order to assess whether the mutations were on 
the same allele. 
Where available, follow-up samples for patients with a mutation in their 
presentation sample were analysed to assess whether the mutation persisted, 
using WAVE® analysis, sequencing or enzyme digestion as appropriate. 
Microsatellite analysis of 2 polymorphic markers, D11S554 and FES (primers in 
Appendix 1), was used to verify that the paired samples were from the same 
patient. Regions of the genome known to contain variable number tandem 
repeats were amplified to create PCR products of different fragment lengths 
which could be differentiated using fragment size separation on the CEQ 8000 
Genetic Analysis System (Beckman Coulter, USA) (section 2.1.5). DNA 
samples derived from the same patient would produce the same length 
products. 
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Figure 5.4 Identification and confirmation of the common synonymous 
SNP, c.3759T>C.  Characteristic chromatograms at 58.5°C for samples that are 
homozygous T (black), heterozygous (red) and homozygous C (blue) for the 
SNP in (A) unmixed samples and (B) mixed with known TT product (HL60), to 
differentiate homozygous CC from TT. (C) The principle of the mismatch primer 
PCR and restriction digest to identify the base at the SNP site. The underlined 
base is the location of the mismatch (A>C) introduced in the primer and the 
base in red is the SNP under investigation. (D) An example of the confirmatory 
BsrI digest visualised on a 2% agarose gel stained with ethidium bromide.
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5.2.4 Therapy 
The MRC AML10 trial (Figure 5.5) recruited patients suitable for intensive 
chemotherapy, the majority of whom were under the age of 56, between 
1988and 1995 (Hann et al, 1997). At diagnosis, patients were randomised to 
receive two cycles of either DAT or ADE induction chemotherapy. Both 
regimens included daunorubicin on days 1, 3 and 5 and intravenous cytarabine 
every 12 hours for 10 days in the first cycle, and 8 days in the second. The 
difference between the two arms was that DAT entailed 6-thioguanine given 
orally twice daily for 10 days in the first cycle and 8 days in the second cycle, 
whereas ADE involved intravenous etoposide for 5 days per cycle. After 
induction, if patients had achieved complete remission (CR) they were given 
two further cycles of consolidation chemotherapy consisting of MACE then 
MIDAC. For those patients with no HLA-matched sibling, there was a second 
randomisation between further high dose therapy with autologous stem cell 
transplant (SCT) versus no further therapy.  
The MRC AML12 trial (Burnett et al, 2010) recruited patients from 1994-2002 
who were suitable for intensive chemotherapy (Figure 5.5). Randomisation at 
induction was between ADE (given as in AML10) or MAE chemotherapy (as for 
ADE but with mitoxantrone given on days 1,3 and 5 rather than daunorubicin). 
Halfway through the trial there was a protocol amendment, all patients were 
given DAT chemotherapy for induction with either high dose (200mg/m2) or 
standard dose (100mg/m2) cytarabine. Patients were also randomly assigned to 
receive all trans retinoic acid (ATRA) or not. If CR was reached after induction 
chemotherapy, patients had a cycle of MACE chemotherapy followed by a 
second randomisation to either ICE, MiDAC, SCT (allogeneic if available, 
otherwise autologous) or ICE followed by SCT as a fifth cycle of treatment. 
AML11 was designed for older patients with AML or those not suitable for 
intensive chemotherapy and was open from 1990 to 1998 (Goldstone et al, 
2001) (Figure 5.5). The first randomisation was to either have two cycles of DAT 
(first cycle as in AML10 trial and second consisting of daunorubicin on days 1 
and 3, and cytarabine and 6-thioguanine for 5 days rather than 8), ADE (first 
cycle as in AML10, second cycle also had two doses of daunorubicin and 5 
days of cytarabine) or MAC. Patients in remission after two cycles had a 
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Figure 5.5 Outline of the relevant treatment protocols for patients in 
Medical Research Council trials AML10, AML11 and AML12.   
Abbreviations: DAT, daunorubicin + cytarabine + 6-thioguanine (in AML12, 
patients received either a standard (S) or high (H) dose of cytarabine); ADE, 
cytarabine + daunorubicin + etoposide; MACE, amsacrine + cytarabine + 
etoposide; MidAC, mitoxantrone + cytarabine; MAC, mitoxantrone + cytarabine; 
COAP, cyclophosphamide + vincristine + cytarabine + prednisolone; MAE, 
mitoxantrone + cytarabine + etoposide; ATRA, all trans retinoic acid; ICE, 
idarubicin + cytarabine + etoposide; R, randomisation; SCT, stem cell 
transplantation
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consolidation course of DAT 2+7. There were two further randomisations at this 
stage, firstly either stopping treatment after the third course versus continuing to 
have 6 courses of chemotherapy (COAP, DAT and COAP being the last 3 
cycles). The second randomisation was to have IFN-α maintenance for a year 
or not.  
5.2.5 End points 
CR was defined as a normocellular bone marrow with less than 5% blasts, 
showing evidence of normal maturation, although persistent myelodysplastic 
features did not preclude CR being achieved. Patients who failed to achieve 
remission were either clinically classified as induction death (ID), related to 
treatment and/ or hypoplasia, or resistant disease (RD) due to persistence of 
the leukaemia despite treatment. Overall survival (OS) was measured from the 
point of randomisation until death. Cumulative incidence of relapse (CIR) was 
defined as the incidence of relapse following CR, with death as a competing 
risk.  
5.2.6 Statistical methods 
Patient information and outcome data were analysed by Dr Robert Hills, 
Department of Haematology, University of Cardiff. Samples with missense 
mutations of unknown significance were excluded from outcome analysis. 
Mantel-Haenszel and  2 tests were used to test for differences in demographic 
and clinical data by genotype. Kaplan – Meier curves were constructed for 
survival data and compared by means of the log-rank test, with standard tests 
for heterogeneity between subgroups. Surviving patients were censored at 9 
August 2010, with follow-up complete to this date for 85% of patients. Median 
follow-up for survival was 18.4 years (range 5.2 – 22.3 years). Multivariate 
logistic regression analysis was used to find the factors most closely associated 
with complete remission (CR) rate, and multivariate Cox models were used to 
analyse CIR and OS. Models were fitted using forward selection, with variables 
added to the model if they had a p value, derived using the deviance statistic, of 
less than 0.05. Odds ratios (ORs) or hazard ratios (HRs) and 95% confidence 
intervals (CIs) are quoted for endpoints. In all cases a ratio of <1 indicates 
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benefit for a mutation. All p values are two-tailed and all end points are given at 
5 years. 
5.3 Results 
5.3.1 Detection of sequence alterations by WAVE analysis 
Of the 371 patient samples analysed, abnormal dHPLC chromatograms were 
detected in one or more fragments from 249 (67%) patients. All abnormal 
chromatograms were confirmed and the alteration identified by sequencing or 
restriction digestion of a fresh PCR product. Examples of abnormal 
chromatograms are given in Figure 5.6. There were 230 samples with an 
abnormal chromatogram in fragment E consistent with the genotype CC or CT 
at the common synonymous SNP site, c.3759T>C (p.S1253S). The genotype at 
this site was investigated for all samples by restriction enzyme digest (see 
section 5.2.3), an example of which is given in Figure 5.4. There was 100% 
concordance between the results from the WAVE® and the restriction digest. 
The overall frequency was 38% patients with TT, 16% with CC and 46% with 
CT, consistent with the expected percentages based on the 1000 Genome 
Project of 33%, 18% and 49% respectively.  
Excluding abnormal chromatograms explained by c.3759T>C, there were 59 
samples with at least one abnormal chromatogram and the appropriate 
fragment for each sample was sequenced to identify the abnormality. A single 
synonymous mutation was seen in 6 samples, these SNPs were considered to 
be wild-type (WT). Missense alterations were seen in 22 patient samples, of 
which 1 had two separate alterations, 3 had at least one synonymous 
substitution as well, and 1 also had a frameshift mutation. These changes were 
compared to published data and the SNP database (dbSNP, NCBI, Bethesda, 
USA) and, where available, remission samples or DNA from CD3+ cells were 
analysed for presence of the substitution that had been detected in the 
diagnostic sample. The remission sample for a patient who had the missense 
mutation p.G643V in their diagnostic sample was analysed by sequencing and 
the mutation was shown to persist. Two patients with remission samples 
available had a p.E1102D alteration which had been seen in paired fibroblasts 
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Figure 5.6 Representative analysis of two ASXL1 mutations. In each case, the upper panel 
shows the WAVE
®
 chromatogram for fragment A at the specified temperatures. The patient 
sample (red) is normalised and compared to the wild-type control (black). Fragment A2 
(designed to pick up c.1934dupG) is also shown for example A. The lower panel for each 
example is the sequencing results for the patient, with the abnormality highlighted with an 
arrow.  
(A) The most common mutation seen, c.1934dupG predicted to give rise to p.G646WfsX12. (B) 
The nonsense mutation, c.2077C>T predicted to produce p.R693X. 
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in a previous study (Perez et al, 2010). PCR products for fragment D were 
digested with HaeIII, which cuts the “E” allele twice to create 3 fragments of 60, 
213 and 271 bases, but only cuts the “D” allele once to create fragments of 213 
and 331 bases; the fragments were then separated on agarose gel. In both 
cases, fragments of sizes 213, 271 and 331 bases were seen with the 
remission samples consistent with persistence of both alleles. The alteration 
p.S1231F was also analysed by restriction digest of the PCR product for 
fragment E using HinfI enzyme. If the “S” allele was present, the digest created 
3 fragments of 57, 170 and 206 bases and the “F” allele, 2 fragments of 206 
and 227 bases. The follow-up sample showed persistence of the S1231F 
heterozygosity. This suggested that all three missense alterations (p.G643V, 
p.E1102D, p.S1231F) were germline in origin. Consequently, 17 of the 
missense mutations were either previously reported to be SNPs and/ or shown 
to be present in paired normal tissue and were scored as WT (p.G643V, 
p.G652S, p.G704R, p.P779L, p.E1102D, p.S1231F; M1249V, p.A1312V, 
p.G1397S), (Table 5.2). Four patients without available paired tissue had 
missense mutations of unknown significance (p.A636V, p.C687R, p.E1015G 
plus p.S1099C, p.P1134L). They were scored as WT for mutation incidence, 
and were excluded from the outcome analysis. The PCR product for Fragment 
D for the sample with both p.E1015G and p.S1099C missense alterations was 
cloned and used to transform One Shot DH5α cells (see section 2.1.9). Four 
colonies were picked and sequenced and showed that the alterations were on 
the same allele.  
Of the remaining 32 patient samples with at least one abnormal chromatogram, 
23 had frameshift mutations and 9 had nonsense mutations (Table 5.3) (Figure 
5.7). Thirteen of the 32 patients (41%) had the most commonly reported 
frameshift mutation p.G646WfsX12. One patient had two separate frameshift 
mutations (p.G645VfsX58 and p.G645WfsX12), another had both a frameshift 
(p.G646WfsX12) and a missense mutation (p.E865K). Six of these patients had 
follow-up samples available.  Microsatellite analysis (see section 2.1.5) using 
two polymorphic markers was performed and confirmed that each pair of 
diagnostic and follow-up samples originated from the same patient. Four of the 
six had the most frequent mutation, p.G646WfsX12. Three of these four follow-
up samples were WT by both WAVE® analysis and direct sequencing. In the 
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Table 5.2 ASXL1 missense mutations considered to be SNPs 
DNA Change Predicted AA change 
PCR 
fragment 
Number 
of Cases 
Reason for considering as SNP 
c.1928G>T p.G643V A 1 Point mutation persisted in follow-up remission sample 
c.1954G>A p.G652S A 1 SNP rs3746609 
c.2110G>A p.G704R A 1 Point mutation persisted in follow-up remission sample 
c.2336C>T p.P779L B 1 
SNP rs41289850 
Point mutation persisted in follow-up remission sample 
c.3306G>T p.E1102D D 9 
Point mutation persisted in follow-up remission sample  
Mutation present in paired fibroblasts (Perez et al, 2010) 
c.3692C>T p.S1231F E 1 
SNP rs74638057 
Mutation present in paired CD3 sample (Sugimoto et al, 2010) 
c.3745A>G p.M1249V E 1 Point mutation in paired normal tissue (Abdel-Wahab et al, 2011) 
c.3935C>T p.A1312V F 1 Point mutation in paired normal tissue (Bejar et al, 2011) 
c.4189G>A p.G1397S F 1 Point mutation in paired normal tissue (Bejar et al, 2011) 
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Table 5.3 Frameshift and nonsense mutations detected in ASXL1 exon 12 
DNA Change Predicted AA change 
Number of cases in patients <60 years Number of cases in patients ≥60 years 
Total number 
of cases 
De novo (n=153) Secondary (n= 69) De novo (n=116) Secondary (n=33) (n=371) 
WILD TYPE  147 61 103 28 339 
c.1773C>A p.Y591X 0 0 1 1 2 
c.1873C>T p.R625X 0 0 1 0 1 
c.1900_1922del p.E635RfsX15 1 1 2 0 4 
c.1926delA/ c.1926_7delAG p.G645VfsX58/ p.G645WfsX12 1 0 0 0 1 
c.1934dupG p.G646WfsX12 1 2 7* 2 12 
c.2077C>T p.R693X 0 2 0 1 3 
c.2081delC p.T694NfsX9 0 0 0 1 1 
c.2122C>T p.Q708X 0 0 1 0 1 
c.2179delG p.E727RfsX17 0 0 1 0 1 
c.2205delT p.T736QfsX8 0 1 0 0 1 
c.2291_2300del p.L764PfsX5 0 1 0 0 1 
c.2295_2299del p.S766PfsX6 0 1 0 0 1 
c.2356A>T p.R786X 1 0 0 0 1 
c.2388G>A p.W796X 1 0 0 0 1 
c.2751_2761del p.P920CfsX2 1 0 0 0 1 
TOTAL NUMBER OF 
MUTANT CASES 
 6 (4%) 8 (12%) 13 (11%) 5 (15%) 32 (9%) 
* One patient with c.1934dupG also had c.2593G>A (p.E865K) with a remission follow-up sample that was wild-type for both mutations.
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Figure 5.7 Distribution, incidence and type of truncating ASXL1 exon 12 mutations detected in the 4 patient groups
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remaining sample, although the mutation could be seen on direct sequencing it 
was at a much lower level than the diagnostic sample. One of these patients 
also had a missense mutation p.E865K, which was not present on sequencing 
of the remission sample. One patient with the mutation p.Y591X and another 
with the two frameshift mutations p.G645VfsX58 and p.G645WfsX1 also had 
remission samples, which were WT on sequencing. Hence overall, 32 patients 
(9%) had mutations of likely pathological significance that would lead to loss of 
the PHD finger. 
5.3.2 Patient characteristics according to ASXL1 genotype 
A summary of patient characteristics according to ASXL1 genotype is given in 
Table 5.4. ASXL1-mutated patients (ASXL1MUT) had a trend for a higher 
presenting white cell count than ASXL1 WT patients (ASXL1WT) (median 42.8 
versus 25.9 x109/l respectively, p= 0.08) but were not associated with 
cytogenetic risk groups as defined by the MRC classification (Grimwade et al, 
1998), or FAB subtype. There was a marked difference in the incidence of 
mutations according to age, 6% in the younger and 12% in the older age groups 
(p=0.05), and ASXL1MUT patients were significantly older than ASXL1WT patients 
(median 61.5 versus 51 years, p=0.01). They were also more likely to have 
secondary than primary disease (13% versus 7%), although this did not reach 
statistical significance (p=0.08). In younger patients with primary disease, the 
incidence was 4% compared to 12% in those with secondary disease (p=0.03), 
but in older patients the difference between primary and secondary disease was 
not significant (11% versus 15%, p=0.5).  
Presence of an ASXL1 mutation was inversely correlated with an NPM1 
mutation (p=0.0008), although they were not mutually exclusive (9% of 
ASXL1MUT cases were NPM1MUT), and showed a trend for association with IDH2 
mutations (p=0.05), of which 57% (4 of 7) were IDH2MUT-R140 and 43% (3 of 7) 
IDH2MUT-R172. There was no association with FLT3 or IDH1 mutations (Table 
5.5).  
5.3.3 Clinical outcome according to ASXL1 genotype 
Correlating the outcome data of the whole cohort with ASXL1 status revealed 
no difference in response to chemotherapy between the two groups (Table 5.6). 
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Table 5.4 Patient demographics according to ASXL1 mutant status  
 
 Total No. 
ASXL1-WT 
No. (%) 
ASXL1 mutant 
No. (%) 
p 
     
Patients 367 335 (91%) 32 (9%)  
     
Age, years    0.01* 
15-29 43 42 (13%) 1 (3%) 
 
30-39 36 34 (10%) 2 (6%) 
40-49 82 81 (24%) 1 (3%) 
50-59 58 48 (14%) 10 (31%) 
60-69 101 87 (26%) 14 (43%) 
70+ 47 43 (13%) 4 (13%) 
Median (range) 52 (16-80) 51 (16-80) 61.5 (19-74) 0.01** 
     
Sex    0.11† 
Female 187 175 (52%) 12 (38%) 
 
Male 180 160 (48%) 20 (63%) 
     
Diagnosis    0.08† 
de Novo 266 247 (73%) 19 (59%) 
 
Secondary 101 88 (26%) 13 (41%) 
     
WBC, X 10
9
/L     
Median (range) 27.4 (0.4-528.0) 25.9 (0.4-349.0) 42.75 (3.0-528.0) 0.07** 
     
Cytogenetics    0.7† 
Favourable 11 10 (4%) 1 (3%) 
 
Normal Karyotype 153 139 (54%) 14 (61%) 
Other Intermediate 66 60 (23%) 6 (26%) 
Adverse 49 47 (18%) 2 (9%) 
Unknown 88 79 9  
     
FAB Type    0.2† 
M0 6 6 (2%) 0 
 
M1 75 70 (22%) 5 (18%) 
M2 103 97 (31%) 6 (21%) 
M4 101 91 (29%) 10 (36%) 
M5 37 30 (30%) 7 (25%) 
M6 9 9 (3%) 0 
M7 4 4 (1%) 0 
RAEB-t 7 7 (2%) 0  
Other/Unknown 25 21 4  
*Test for trend; † test for heterogeneity, ** Wilcoxon Rank Sum Test
  
179 
    
 
Table 5.5 Correlation of ASXL1 mutation status with other mutations 
 Total No. 
ASXL1-WT 
No. (%) 
ASXL1 mutant 
No. (%) 
p 
FLT3/ITD     
Wild-type 284 258 (77%) 26 (81%) 
0.6† 
Mutant 82 76 (23%) 6 (19%) 
     
FLT3/TKD     
Wild-type 331 300 (90%) 31 (97%) 
0.18† 
Mutant 36 35 (10%) 1 (3%) 
     
NPM1     
Wild-type 232 203 (61%) 29 (91%) 
0.0008† 
Mutant 135 132 (39%) 3 (9%) 
     
ITD/NPM1     
Wild-type/Wild-type 197 174 (52%) 23 (72%) 
0.005† 
Wild-type/Mutant 87 84 (25%) 3 (9%) 
Mutant/Wild-type 35 29 (9%) 6 (19%) 
Mutant/Mutant 47 47 (14%) 0 
     
IDH1 WT 323 295 (88%) 28 (88%) 
0.9† 
IDH1 Mutant 44 40 (12%) 4 (13%) 
     
IDH2 WT 325 300 (90%) 25 (78%) 
0.05† 
IDH2 Mutant 42 35 (10%) 7 (22%) 
† test for heterogeneity 
  
 
    
1
8
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Table 5.6 Outcome of patients with and without a mutation in ASXL1 exon 12. 
Response to 
therapy 
ASXL1
WT
 ASXL1
MUT
 Univariate OR or HR, CI p Multivariate OR or HR, CI* p 
CR (with 
recovery) 
59% 56% 1.11 (0.53-2.32) 0.8 0.47 (0.16-1.34) 0.15 
CR/Cri 66% 56% 1.53 (0.72-3.28) 0.3 1.06 (0.35-3.20) 0.9 
RD 20% 25% 1.39 (0.56-3.42) 0.5 0.85 (0.28-2.60) 0.8 
ID 14% 19% 1.42 (0.51-3.95) 0.5 0.89 (0.16-5.09) 0.9 
       
Outcome at 5 
years 
      
CIR 56% 83% 2.41 (1.19-4.89) 0.01 1.61 (0.85-3.06) 0.14 
OS 22% 6% 1.66 (1.07-2.59) 0.02 1.27 (0.80-2.02) 0.3 
 
CR, complete remission; CRi, complete remission with incomplete haematological recovery; RD, resistant disease; ID, induction death; CIR, cumulative incidence of relapse; 
OS, overall survival; OR, odds ratio; HR, hazards ratio 
*Adjusted for age, sex, white blood cell count, performance status, cytogenetic risk group, FLT3/ITD, FLT3/TKD, NPM1, IDH1 and IDH2 mutant status  
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CR rate, with or without complete haematological recovery, was 66% versus 
56% in the wild-type and mutant groups respectively (OR 1.53, 95% CI 0.72-
3.28, p= 0.3). However, the ASXL1MUT group had a significantly worse CIR at 5 
years, 89% versus 56% for the ASXL1WT patients (HR 2.41, 95% CI 1.19- 4.89, 
p= 0.01) (Figure 5.8A) and OS at 5 years, 6% versus 22% respectively (HR 
1.66, 95% CI 1.07- 2.59, p= 0.02) (Figure 5.8B).  
Analysing outcome data in subgroups of the cohort was limited by the small 
numbers of patients. However, when considered in the four pre-defined groups, 
in the younger patients, CIR was significantly higher in the ASXL1MUT group with 
secondary disease (100% versus 50%, p= 0.04) but not primary disease (75% 
versus 43%, p= 0.6), although there were only four ASXL1MUT patients in each 
group that achieved remission. OS was lower for patients with ASXL1MUT in 
both younger cohorts but the difference was not significant (secondary disease, 
0% versus 18%, p= 0.2; primary disease, 17% versus 32%, p= 0.7) (Figure 5.9 
A and B). In the older patients, there was no difference according to mutant 
status in the groups for either CIR (secondary disease, 50% versus 92%, p= 
0.4; primary disease, 88% versus 74%, p= 0.1) or OS (secondary disease, 20% 
versus 4%, p= 0.7; primary disease, 0% versus 14%, p= 0.2), although again 
there were only 8 and 6 ASXL1MUT patients respectively in the two groups 
(Figure 5.9 C and D).  
In multivariate analysis adjusted for age, sex, white cell count, performance 
status at diagnosis, cytogenetic risk group, FLT3/ITD, FLT3/TKD, NPM1, IDH1 
and IDH2 genotype, ASXL1 mutations lost any prognostic significance because 
age was a major confounding risk factor (Table 5.6).
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Figure 5.8 Outcome according to ASXL1 mutant status in the total cohort.  
(A) Cumulative Incidence of Relapse, (B) Overall survival.
B 
A 
p=0.01 
p=0.02 
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Figure 5.9 Overall survival in the different patient groups.  Younger patients with (A) primary and (B) secondary disease. Older 
patients with (C) primary and (D) secondary disease.
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5.4 Discussion 
Abnormalities in genes affecting the “epigenome”, including ASXL1, are now 
recognised to be mutated in the spectrum of myeloid disorders. Although a 
number of papers have suggested that presence of an ASXL1 mutation is 
associated with a worse overall survival, not all agree and therefore controversy 
exists as to whether knowledge of the ASXL1 genotype at diagnosis would 
influence management. In order to assess this, the mutation status of four 
defined groups of patients, categorised according to age and primary or 
secondary disease status, was analysed and correlated with outcome data.  
Most studies have used sequencing to detect mutations but the WAVE® was 
used in this study, as it provided a faster method of screening for point 
mutations as well as size changes, with minimal processing of the PCR product 
required. Furthermore, this medium throughput method has a higher sensitivity 
than sequencing for detecting mutations. To ensure that mutations were not 
missed, as deletions in 20q are found in 1% of patients with primary AML and 
8% secondary AML (Grimwade et al, 2010), the amplicons under investigation 
were mixed with known wild-type amplicons to create heteroduplexes. The 
investigation was restricted to exon 12 because those studies that looked at the 
whole gene found mutations in other exons in only 1% of samples. Some 
studies have limited the region analysed further to the first 385 bases of this 
exon (Pratcorona et al, 2012) or just screened for size changes using a more 
rapid technique (Paschka et al, 2011), but in our study this would have missed 
38% and 28%, respectively, of our mutant-positive patients. Despite limiting 
analysis to a single exon, due to its size of 2907 bases, it still required 8 
overlapping PCR fragments to cover the coding region, because the optimal 
amplicon size for WAVE® analysis is 200-450 bases, although amplicons up to 
1000 bases can be assessed.  
The characteristic WAVE® chromatogram in fragment A at 64.2°C for the most 
common mutation c.1934dupG was a very subtle widening of the peak plus a 
slight shoulder, this is because fragment A was a relatively large product of 563 
bases and the duplication occurred in a part of the amplicon predicted to have a 
high helical fraction within an 8 base homopolymer run (Figure 5.6A). Hence to 
avoid missing the abnormality, a smaller amplicon A2 of 232 bases was 
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analysed that displayed a more exaggerated shoulder on the chromatogram in 
samples with the c.1934dupG mutation (Figure 5.6A). Secondly, given the 
concern that this mutation may be a chance PCR artefact as it is a duplicated G 
within an 8 base guanine homopolymer run, a second amplicon confirming the 
duplication gave further support for it being a true mutation. Further confirmation 
that this is a true mutation was sought by analysing follow-up samples. Three of 
the 4 patients with the duplication present in the diagnostic sample no longer 
had it in their remission sample, and in the remaining sample it was at a much 
lower level, consistent with this being a true mutation and not a random error 
during the amplification process. This is in agreement with most other groups 
(Gelsi-Boyer et al, 2012).  
Overall, 249 of the 371 patient samples analysed had abnormal chromatograms 
in at least one fragment.  Most (n=217, 87%) of the abnormalities consisted of 
either synonymous or missense alterations. Synonymous changes were 
considered wild-type as there was no predicted change in amino acid. Of the 23 
missense mutations seen in 22 patient samples, 18 were considered somatic as 
they were seen in normal controls or paired normal tissue by us or other groups. 
Remission samples were not available for 3 samples with missense mutations 
that had not been reported previously, and although considered to be wild-type 
for mutation incidence, we excluded these from outcome analysis. Only one 
missense mutation was detected that was not present in a follow-up remission 
sample, however, this sample also had a frameshift mutation and thus was 
considered mutant. Hence, the overall mutation rate of ASXL1 exon 12 was 9%, 
and this is in keeping with other studies in AML (Table 5.1).  
The mutation rate was significantly higher in patients older than 60 years 
compared to those less than 60 years, 12% versus 6% respectively (p= 0.05). 
In those patients under 60 years, the mutation rate was significantly higher in 
secondary disease compared to primary, 12% versus 4% respectively (p= 0.03). 
Hence in patients younger than 60 years with primary disease, the overall 
mutation rate was 4%. The association of ASXL1 mutations with older age and 
secondary disease seen in our cohort has also been seen by other groups 
(reviewed in Gelsi-Boyer et al, 2012).  
There was no association between karyotype and ASXL1 genotype, although it 
has been reported that ASXL1 mutations are more frequent in intermediate-risk 
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patients with an aberrant karyotype than those with a normal karyotype 
(Schnittger et al, 2013). ASXL1 mutations were inversely correlated with NPM1 
mutations, only 9% of those with an ASXL1 mutation also had an NPM1 
mutation compared to 39% of the ASXL1 WT patients (p <0.001). This strong 
inverse correlation has previously been reported (Carbuccia et al, 2010; 
Paschka et al, 2011; Schnittger et al, 2013). 
In the total cohort, ASXL1MUT patients had a poorer outcome with significantly 
worse OS, which is compatible with the adverse impact seen in most studies 
(Chou et al, 2010b; Metzeler et al, 2011a; Paschka et al, 2011; Patel et al, 
2012; Pratcorona et al, 2012; Schnittger et al, 2013). We could not attribute this 
to a higher primary resistance of ASXL1MUT patients to chemotherapy, as has 
been suggested (Chou et al, 2010b; Pratcorona et al, 2012), as we observed no 
difference in the rates of remission and resistant disease according to ASXL1 
genotype in our patients, but the relapse rate was significantly increased in 
ASXL1MUT patients. However, this analysis included older and secondary 
disease patients, characteristics that are likely to impact on outcome. When 
stratified according to age and type of disease, we found no impact on outcome 
in the younger patients with primary disease, although with small numbers of 
mutant-positive patients some caution is required in the interpretation of these 
data, and no differences in outcome were found in the older patients according 
to type of disease. Furthermore, ASXL1 mutations were not a significant factor 
in multivariate analysis because of the overriding impact of age. Only one other 
study by Schnittger et al. (2013) has reported outcome data specifically in 
younger patients with de novo AML in a similar size cohort of 223 patients ≤ 60 
years of age, although all their patients had intermediate-risk cytogenetics. They 
found that the mutations were a significant adverse factor for OS but not event-
free survival in these patients. The reason(s) for the difference is (are) not clear, 
although it should be noted that the survival rates for their patients were much 
higher for all patient groups than those found in not only our study but also other 
studies. 
In conclusion, the low incidence of ASXL1 mutations in younger patients with 
primary disease and the lack of independent prognostic significance in 
multivariate analysis in our cohort suggests that there is a limited role for 
diagnostic screening of ASXL1 for the purpose of prognostic stratification. 
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CHAPTER 6:CONCLUSIONS AND FUTURE DIRECTIONS 
Acute myeloid leukaemia is a biologically heterogenous disease and this is 
reflected in the differing outcomes seen clinically. Currently, when it is 
diagnosed, patients are stratified into one of three prognostic groups depending 
on their cytogenetic status and mutation status in certain genes. Patients with a 
normal karyotype (40% of all patients with AML) fall into the intermediate 
prognostic group, of which only 35% will survive for greater than 10 years 
(Grimwade et al, 2010). Despite this biological heterogeneity, whole genome 
sequencing of samples from AML patients has identified the fewest number of 
mutations per patient of any malignancy to date, with a median of 13 mutations 
per sample compared to other malignancies, which can have hundreds (2013; 
Kandoth et al, 2013). Recently identified recurrent mutations have been in 
genes known to have epigenetic functions. The aim of the studies presented in 
this thesis was therefore to investigate whether genome-wide methylation 
patterns could provide additional information in predicting response to 
treatment, and in addition to ascertain whether knowledge of the mutation 
status of the epigenetic modifier gene ASXL1 would add prognostic value to 
warrant testing in all patients at diagnosis.  
The methylation profile of samples from 40 well-characterised patients in whom 
the outcome was known was first analysed using the Illumina Methylation 27K 
array (Chapter 3). All patients selected had an NK, and were WT for NPM1 and 
FLT3; half the patients had chemosensitive disease and the others were 
chemoresistant. At the time the methylation profile was analysed, more was 
known about the molecular profile of the samples, in particular their CEBPA, 
DNMT3A, WT1, IDH1, IDH2, GATA2 and TET2 genotype. The results of the 
methylation array were validated using pyrosequencing assays of four of the 
genes that were found to be variably methylated. This demonstrated good 
correlation between the two methods of methylation analysis with r2 ranging 
from 0.76 to 0.93 indicating the reliability of the Illumina Methylation array 
results. 
Although the initial aim was to identify a methylation signature associated with 
prognosis, unsupervised clustering of the samples based on their methylation 
profiles did not correlate with overall outcome (Figure 3.9). However, it was 
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apparent from this analysis that the samples did group according to their 
CEBPA genotype and that CEBPADM samples had a distinct methylation profile 
compared to the other CEBPAWT samples. Ten of the 40 samples in this cohort 
(25%) were CEBPADM, which is higher than the published overall incidence of 
10%, but this was not surprising due to the criteria by which this cohort was 
selected, as this genotype is known to be more frequent in NK, NPM1WT 
samples. This methylation profile was then explored further.  
A methylation signature consisting of the top ranked 25 CpG sites that 
differentiated the eight classic CEBPADM samples with an N terminal out-of-
frame mutation coupled with an in-frame C terminal mutation from the 30 
CEBPAWT samples was created. Two scores were derived for each sample 
dependent on how close they were to the classic CEBPADM and CEBPAWT 
signatures, and the difference between these two scores was plotted against 
the distance from the classic CEBPADM score. The CEBPADM samples and 
CEBPAWT samples formed two distinct groups on this plot. This was validated 
with a further 17 classic CEBPADM and 26 CEBPAWT samples. One classic 
CEBPADM case did not group with the other cases. Although biallelic, it had low 
mutant levels of 24% and 31% compared to the mean mutant level of 44% and, 
as methylation levels are quantitative, it was hypothesised that this was the 
reason that the methylation signature was more similar to CEBPAWT in this 
case. Using scores from all classic CEBPADM cases except this one, a classic 
CEBPADM quadrant for the plot was subsequently defined. 
To assess whether the methylation profiles identified were specific to CEBPADM 
samples or whether they could be seen in other cohorts of samples that are 
associated with good prognosis or reduced C/EBPα, three CpG sites that 
formed part of the signature were analysed in 42 samples with NPM1 mutations 
and 40 CBF leukaemia samples. The methylation levels at these sites were not 
the same as classic CEBPADM samples, indicating that the methylation profile 
was indeed specific to this mutation.  
The methylation signature was then used to explore the significance of a variety 
of non-classic CEBPADM and CEBPASM samples (Chapter 4). Overall, 16 non-
classic CEBPADM samples were assessed. Only one of the six samples that 
were predicted to produce just p30 protein was located in the classic CEBPADM 
quadrant. Two of the three samples that led to C loss of function only and two of 
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the seven CEBPADM samples that had a missense mutation were within the 
classic CEBPADM quadrant. This suggests that C loss of function is necessary, 
but not sufficient, to produce the CEBPADM methylation pattern seen in the 
classic samples. Only one of the 38 CEBPASM samples was located in the 
classic CEBPADM quadrant. This is further evidence that CEBPASM AML is 
biologically distinct from CEBPADM. The results from these studies also suggest 
that non-classic CEBPADM AML should not automatically be considered as part 
of the favourable prognostic group which is of clinical significance as stem cell 
transplants are not recommended in patients with favourable prognostic 
molecular aberrations.  
Methylation of the CEBPA promoter was also investigated in the total cohort of 
135 samples in order to ascertain whether this had an impact on the overall 
methylome. Firstly, CpGs that were interrogated as part of the Illumina 
Methylation arrays were analysed. One site 1919 bases upstream of the TSS 
for CEBPA showed differential methylation between CEBPADM and other 
samples, otherwise there was little variability in the methylation levels at the 
remaining 16 CpG sites related to CEBPA. An estimate of methylation levels in 
the distal and core promoter regions was determined using direct sequencing. 
No methylation was seen in the core promoter region in any of the samples. 
Only a few CEBPADM samples had evidence of methylation in the distal 
promoter region, and nearly all those that did had only low levels of methylation. 
Similarly, most CEBPAWT and CEBPASM samples were also unmethylated in 
this region, however five CEBPASM and four CEBPAWT were considered to be 
“hypermethylated”, defined as >25% and >50% methylation respectively. Only 
one of the hypermethylated CEBPASM samples was located in the classic 
CEBPADM quadrant, theoretically the wild-type allele in this case could have 
been silenced and this would be akin to C-LOF mutant only.  
The aim of chapter 5 was to compare the frequencies of ASXL1 mutations in 
younger and older patients with primary and secondary AML, and to ascertain 
whether knowledge of ASXL1 genotype would significantly alter expected 
outcome. Denaturing HPLC was used to screen for mutations in exon 12 of the 
gene. Analysis was restricted to a single exon, as in those studies that analysed 
the whole gene, only 1% of mutations were located outside exon 12. Overall 32 
out of 371 patients had ASXL1 mutations (9%), which is comparable to 
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previously published data. The rate of mutations in younger patients with 
primary disease was 4% and secondary disease was 12%. In older patients, the 
rate of mutation was 11% in primary disease and 15% in secondary disease. 
Although mutations in ASXL1 were associated with a worse overall survival, this 
was not significant in multivariate analysis due to the strong association with 
older age. Knowledge of ASXL1 genotype at diagnosis thus did not provide 
further information regarding outcome of the patient to necessitate screening at 
diagnosis.  
6.1 Future directions 
The data presented in these studies suggest that different mutations identified 
in the CEBPA gene in patients with AML may affect the normal protein function 
in different ways. The methylation profile of the different types of CEBPA mutant 
samples is just one way of assessing the functional variability associated with 
the different types of mutations, however it does not explain why the 
methylation patterns are different. Attempting to correlate the methylation profile 
of the different types of CEBPA mutations with functional studies may provide a 
potential explanation for the variability. For example, the impact of the different 
CEBPA mutations on the function of the protein could be explored using in vitro 
transactivation assays whereby cells are transfected with CEBPA mutant 
constructs together with luciferase reporter constructs for known downstream 
targets of C/EBP.  
As further recurrent mutations are identified, it would be interesting to assess 
the status of the samples used in this study to ascertain whether any further 
mutations have an impact on the methylation profile seen, for example 
activating NOTCH mutations which have been seen in a minority of AML 
samples and have been shown to lead to gene expression profiles that are 
similar to CEBPADM samples (Wouters et al, 2007).  
From a clinical perspective, any potential prognostic role of using DNA 
methylation analysis to assess the significance of a non-classic CEBPADM 
would be at diagnosis rather than detecting minimal residual disease, as there 
would be too much variability in methylation level in normal bone marrow to pick 
up small clones of disease. However, as previously discussed, although the 
methylation profile of different CEBPADM samples indicates that there are 
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differences between some of the non-classic CEBPADM cases compared to the 
classic CEBPADM cases, this does not necessarily mean that the outcome will 
be different in these two groups, and due to the small numbers of patients it 
would be difficult to confirm or refute this.  
6.2 Conclusions 
In conclusion, the results presented in this thesis show that the aberrant 
methylome in AML can be linked with the underlying molecular and cytogenetic 
status of the samples. In particular, in the cohort of AML samples selected in 
this study that were cytogenetically normal with no NPM1 mutation or FLT3/ITD, 
samples with classic CEBPADM mutations had a characteristic methylome 
distinct from all CEBPAWT and the majority of CEBPASM samples. A classic 
CEBPADM signature could be derived that was used to investigate the impact of 
non-classic CEBPADM mutations on the methylation profile of samples. Not all 
samples with non-classic CEBPADM mutations had the classic signature, 
particularly those lacking a C-LOF mutation. As molecular genotyping is 
increasingly being used as the basis for risk-adapted therapy, it is important to 
understand whether all mutations within a particular gene are associated with 
the same prognosis. Moreover, it is important to assess whether mutations 
detected are associated with other confounding factors that confer a poor 
prognosis. In these studies, the impact of ASXL1 mutations in AML was 
analysed. Although mutations were associated with a worse outcome, they 
were not significant in multivariate analysis due to the low incidence and the 
confounding role of age. Thus, as technological advances continue and allow 
whole genome and exome sequencing to become more frequent in AML, the 
interpretation of the results becomes increasingly complex, particularly as 
clinical trials will not be able to power increasingly small sub-group analysis to 
prove which combination of mutations are good or poor risk. It is in this context, 
that the methylation profile may play a role in demonstrating the global effects of 
multiple genetic abnormalities.    
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APPENDIX 
Appendix Table 1 Primer sequences, annealing temperatures and WAVE analysis temperatures if appropriate 
Appendix Table 1 Continued 
PCR Primer Sequence 
Fragment 
Length (bp) 
Annealing 
temperature 
for PCR (°C) 
Temperatures 
for dHPLC (°C) 
ASXL1ex12 A 
F 5’-CCTAGGTCAGATCACCCAGTC-3’ 
563 63 
59 
60.7 
64.2 R 5’-AGCCCATCTGTGAGTCCAACTGT-3’ 
ASXL1ex12 A2 
F 5’-GGATCATCCCCACCACGGAGT-3’ 
232 63 65.7 
R 5’-CCACAGGCCTCACCACCATC-3’ 
ASXL1ex12 B 
F 5’-AGCTAGGAGAGAGGACCTGC-3’ 
565 62 
59.3 
60.2 
61.5 R 5’-CGATGGGATGGGTATCCAATG-3’ 
ASXL1ex12 C 
F 5’-CTCCTATGAGGGAAAGTGATACT-3’ 
518 62 
57.9 
58.9 
60.6 R 5’-CTTGGACAGTGGGGCAGATTG-3’ 
ASXL1ex12 D 
F 5’-ACAGCAGTGAGGCTGACACTAG-3’ 
544 63 
59.5 
60.3 
61.5 R 5’-GCCTCAATCCTGGCAAGACCAG-3’ 
ASXL1ex12 E 
F 5’-GAGCCATGGCTCGCTACGCAT-3’ 
433 64 
58.5 
60.1 R 5’-CTGCTCTGGACCAAAGGAGATC-3’ 
ASXL1ex12 E(MM) 
F 5’-GAAGGAAGTCCGTGCTATGTCACAGGCCAG-3’ 
126 63  
R 5’-CTGCTCTGGACCAAAGGAGATC-3’ 
ASXL1ex12 F 
F 5’-CTTACTACCTCGAGAACACCTCGT-3’ 
489 64 
58.5 
60.8 
62.2 R 5’-AAGAAGGCTCCAGAGGCTCAC-3’ 
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Appendix Table 1 Continued 
PCR Primer Sequence 
Fragment 
Length (bp) 
Annealing 
temperature 
for PCR (°C) 
Temperatures 
for dHPLC (°C) 
ASXL1ex12 G 
F 5’-GATGCCCTTTGTCATGGACTTGC-3’ 
323 64 
59.2 
60.3 
63.1 R 5’-TGCACGCACACTGGAGCGAGA-3’ 
ASXL1ex12 H 
F 5’-GTGCGAGCCACAGTGCATCAC-3’ 
219 64 
55.6 
59.6 
62.5 R 5’-CTAAATATACAATGTTTCCCATGGCCATA-3’ 
CEBPA/1 
F 5’-TCGCCATGCCGGGAGAACTCTAAC-3’ 
548 62  
R 5’-AGCTGCTTGGCTTCATCCTCCT-3’ 
CEBPA/2 
F 5’-GCTGGTGATCAAGCAGGAGC-3’ 
332 62  
R 5’-CCGCCACTCGCGCGGAGGTCG-3’ 
CEBPA/3 
F 5’-GGCAGCGCGCTCAAGGGGCTG-3’ 
424 64  
R 5’-CACGGCTCGGGCAAGCCTCGAGAT-3’ 
CEBPA/Core 
F 5’-GGTTTGTAGGGTATAAAAGTTGGG-3’ 
168 60  
R 5’-ACTCCATAAAAAAATTAAAATTCTCCC-3’ 
CEBPA/DistFor 
F 5’-GGGTTATTAATTATTGGGATTATGTTGAA-3’ 
314 58  
R 5’-AAAAACCCTCAAATATCTCCTAT-3’ 
CEBPA/DistRev 
F 5’-GAGTTTTGGGAGTTTTTAAGTGTT-3’ 
262 58  
R 5’-ACCCAAATAAAACTACTTCTTTAC-3’ 
HLA-B 
(unconverted) 
F 5’-TTTTAAGTTTTATTTTTGTGGGGTA-3’ 
300 Touchdown  
R 5’-AAATCCCAACTAATAACTATTTTTCAA-3’ 
HLA-B 
(converted) 
F 5’-CCCAAAGTCCACTAACATTAGAA-3’ 
464 Touchdown  
R 5’-GCTGAGAAAATAGCCTCAGAATA-3’ 
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Appendix Table 1 Continued 
PCR Primer Sequence 
Fragment 
Length (bp) 
Annealing 
temperature 
for PCR (°C) 
Temperatures 
for dHPLC (°C) 
KIAA0323 
F 5’-/5Biosg/GGGTTTTTTAGTTGTAGTTAGATGTG-3’ 
192 60  R 5’-ACTAAAAACAACAACCATACCTAC-3’ 
PyroSeqR 5’-ACCCCATATAAAACCCATCTTC-3’ 
LY9 
F 5’-/5Biosg/TGTTTTAGAGGGAGGGTTGTTTATA-3’ 
100 58  R 5’-AATCACAAATAAAACCCTAAATAAACTTA-3’ 
PyroSeqR 5’-TAAAACCTCTACCTACC-3’ 
PRF1A 
F 5’-AGTAGGGTTATTTTTTTGTTTTTGATGT-3’ 
150 60  R 5’-/5Biosg/CCTACCAATCCACACTACTAATACA-3’ 
PyroSeqF 5’-GTTATTTTTTTGTTTTTGATGTATA-3’ 
PRF1B 
F 5’-TAGGAAGTGTTGTGATTTATAAGATAAG-3’ 
163 60  R 5’-/5Biosg/CTTTAATATCAACACTTACAAAACCTTAA-3’ 
PyroSeqF 5’-TAAGATAAGATATTTGGGTTA-3’ 
PRIC285 
F 5’-/5Biosg/GTTTTTTTTTGTGTTATTAGTAGGAGAT-3’ 
313 58  R 5’-CCCCAACAACTAAACCAAATATT -3’ 
PyroSeqR 5’-AAAATACCCCCAAATAAAACTAACAA-3’ 
SOC2 
F 5’-/5Biosg/AGGTGGGAAGTAAAGAATAAGATGGA-3’ 
128 62  R 5’-CCAAACCTAAATCCCTAAAAAACCACTTT-3’ 
PyroSeqR 5’-CCTAAAAAACCACTTTCCT-3’ 
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Appendix Table 1 Continued 
PCR Primer Sequence 
Fragment 
Length (bp) 
Annealing 
temperature 
for PCR (°C) 
Temperatures 
for dHPLC (°C) 
VAMP5 
F 5’-GTGTTYGTTTATTAGGTAGAGGTGTTA-3’ 
281 59  R 5’-/5Biosg/CCCRCCTAAACCCTCACCATC-3’ 
PyroSeqF 5’- GTTTATYGTTTTYGATTTGATTTGG-3’ 
WNT2 
F 5’-GTGTATGAAATGATGGTAAGAGATGTT-3’ 
246 62  R 5’-/5Biosg/ATACATAATAATCTCCTTATCCCCTAACC-3’ 
PyroSeqF 5’-GGGAAGGGGGAATATYGTTGTATG-3’ 
Abbreviations: bp, base pairs; dHPLC, denaturing HPLC; F, forward primer; PCR, polymerase chain reaction; PyroseqF or R, 
sequencing primer for pyrosequencing; R, reverse primer.
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Appendix Table 2 List of samples with CEBPA mutations in all cohorts and classification of samples 
Appendix Table 2 continued 
Cohort 
Patient 
No. 
Mutation 1 
Type of 
mutation 
Location
1 
Mutation 2 
Type of 
mutation 
Location
1 
Classification 
1 1 A66fs FS N E316_L317insR IF ins C Classic DM 
1 2 G114fs FS N Q312dup IF ins C Classic DM 
1 3 L78fs FS N E309_V328dup IF ins C Classic DM 
1 4 K313dup IF ins C R343fs FS C Non-classic DM 
1 5 A91fs FS N S319delinsRL IF indel C Classic DM 
1 6 V314G (HOM) IF ins C    
Homozygous non-
classic C 
1 7 I68fs FS N R306_N307insRR IF ins C Classic DM 
1 8 H84fs FS N K302_K304dup IF ins C Classic DM 
1 9 G54fs FS N Q305_R306insQQ IF ins C Classic DM 
1 10 H24fs FS N Q311_Q312insL IF ins C Classic DM 
2 11 S61fs FS N    Classic N 
2 12 G54fs FS N E167fs FS mid Non-classic DM 
2 13 I341V M C    Non-classic C 
2 14 K313dup IF ins C    Classic C 
2 15 Q215X STOP MID    Non-classic SM 
2 16 K313dup IF ins C    Classic C 
2 17 H24fs FS N K304_Q305insL IF ins C Classic DM 
2 18 N321S (HOM) M C    
Homozygous non-
classic C 
2 19 L253fs FS MID    Non-classic SM 
2 20 H24fs FS N Q209fs FS MID Non-classic DM 
2 21 A40fs FS N E309_L317dup IF ins C Classic DM 
2 22 N356_C357del IF del C    Classic C 
2 23 Y67X STOP N R297_V308dup IF ins C Classic DM 
2 24 Q88fs FS N K304_Q305insL IF ins C Classic DM 
2 25 P23fs FS N N307_E309delinsK IF indel C Classic DM 
2 26 H24fs FS N K313Nins14 IF ins C Classic DM 
2 27 P112fs FS N K304_Q305insL IF ins C Classic DM 
  
 
   
2
3
9
 
Appendix Table 2 continued 
Cohort 
Patient 
No. 
Mutation 1 
Type of 
mutation 
Location
1 
Mutation 2 
Type of 
mutation 
Location
1 
Classification 
2 28 A72fs FS N K302_E309dup IF ins C Classic DM 
2 29 G96fs FS N 
T310_Q311insHKA
KQRNVET 
IF ins C Classic DM 
2 30 E59fs FS N E309dup IF ins C Classic DM 
2 31 A113fs FS N L315_E316insQ IF ins C Classic DM 
2 32 A79fs FS N Q312dup IF ins C Classic DM 
2 33 I55fs FS N K313Sins12 IF ins C Classic DM 
2 34 H24fs FS N    Classic N 
3 35 N292fs FS C    Non-classic C 
3 36 P43fs FS N Q312dup IF ins C Classic DM 
3 37 K275fs FS MID    Non-classic SM 
3 38 L331Q M C    Non-classic C 
3 39 G242S M MID    Non-classic SM 
3 40 E50fs FS N V314_L315ins13 IF ins C Classic DM 
3 41 P180fs FS MID    Non-classic SM 
3 42 
R300_D301delinsQN 
[HOM] 
IF indel C    Homozygous classic C 
3 43 A66fs FS N    Classic N 
3 44 G123fs FS MID    Non-classic SM 
3 45 G122fs FS MID    Non-classic SM 
3 46 Y285S M C    Non-classic C 
3 47 A44fs FS N A295P M C Non-classic DM 
3 48 E166X STOP MID    Non-classic SM 
3 49 G36fs FS N Y181X STOP MID Non-classic DM 
3 50 V296E M C    Non-classic C 
3 51 N307fs FS C    Non-classic C 
3 52 H193_P196del IF del MID    Non-classic SM 
3 53 G38fs FS N K313fs FS C Non-classic DM 
3 54 I68fs FS N    Classic N 
3 55 P233R M MID    Non-classic SM 
3 56 E59X STOP N    Classic N 
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Appendix Table 2 continued 
Cohort 
Patient 
No. 
Mutation 1 
Type of 
mutation 
Location
1 
Mutation 2 
Type of 
mutation 
Location
1 
Classification 
3 57 H24fs,P23fs FS N    Classic N 
3 58 P46fs FS N    Classic N 
3 59 Q83fs FS N    Classic N 
3 60 R300_D301delinsQY IF indel C    Classic C 
3 61 R306_V314dup IF ins C N321S M C Non-classic DM 
3 62 P183Q M MID    Non-classic SM 
3 63 I68fs FS N R297P M C Non-classic DM 
3 64 D107fs FS N S299_T318dup IF ins C Classic DM 
3 65 T60fs FS N    Classic N 
3 66 G242S M MID    Non-classic SM 
3 67 P239_A240del IF del nonMID    Non-classic SM 
3 68 R323del IF del C    Classic C 
3 69 H24fs FS N G233fs FS MID Non-classic DM 
3 70 D168fs FS MID    Non-classic SM 
3 71 P187_P189del IF del MID    Non-classic SM 
3 72 S266fs FS MID    Non-classic SM 
3 73 V95fs FS N A238fs FS MID Non-classic DM 
3 74 K276R M MID    Non-classic SM 
3 75 H24fs FS N Q311_Q312insL IF ins C Classic DM 
3 76 L78fs FS N R300P M C Non-classic DM 
3 77 R289C M C    Non-classic SM 
3 78 
E316_R325dup 
[HOM] 
IF dup C    Homozygous classic C 
3 79 L317Q [HOM] M C    
Homozygous non-
classic C 
Abbreviations: FS, frameshift mutation; IF del, inframe deletion; IF indel, inframe insertion/deletion; IF ins, inframe insertion; M, 
missense mutation. 
1Location: N, N terminus (amino acids 1-119); MID, from second ATG to DBD (amino acids 120-277); C, C terminus (amino acids 
278-358). 
